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v Justification of Research 
 
JUSTIFICATION OF RESEARCH 
Mental disorders are on the rise in the European Union. Major depression is a 
commonly occurring, serious, recurrent disorder linked to a diminished role functioning 
and quality of life, which can even lead to suicide. In a recently survey made by World 
Mental Health Organization, 49.4% of the respondents claim already had a time lasting 
several days when they were sad, depressed, or lost interest in their usual activities 
[1]. Usually, the treatment for these cases is performed with the use of 
antidepressants and antipsychotics [2]. These drugs are often associated with 
deliberate self-poisoning (DSP) and it is one of the most common reasons to visit the 
emergency department. In 2012, 72 out of 312 DSP cases were due to antidepressants 
in Belgium [3].  
Determining the presence of various drugs is an important facet of toxicology, 
to establish their use and possible contribution to the cause of poisoning or even 
death. Liquid Chromatography-Mass Spectrometry (LC-MS) has established itself as the 
clear leader in the quantification of the psychotropic drugs in biological samples. There 
are numerous reports of using LC-MS methods for determination of these compounds 
in biological matrices, such as plasma, serum or whole blood [2, 4, 5, 6, 7, 8, 9,  10, 
11].  The pharmacologic effects of most drugs have a direct correlation with their 
concentrations in plasma, which can serve as a basis for therapeutic monitoring. 
Therefore, the plasma is preferred for quantitative analysis when interpretation of the 
concentrations and effects are required [4].  
So, it was developed developed and validated an ultra-performance liquid 
chromatography-tandem mass spectrometry method for the quantification of 15 
common non-tricyclic antidepressants in serum: citalopram, desmethylcitalopram, 
desmethylfluoxetine, desmethylvenlafaxine, duloxetine, fluoxetine, fluvoxamine, 
melitracen, mianserin, mirtazapine, paroxetine, reboxetine, sertraline, trazodone and 
venlafaxine. The selected pharmaceuticals represent (nor) tramadol (added because of 
the desmethylvenlafaxine interference) and all the non-tricyclic antidepressants 
available in Belgium – table I.  
 Compound Chemical Structure Chemical Name (IUPAC) CAS Molecular 
Formula 
Molecular 
weight 
(g/mol) 
Categories 
1. Citalopram  1-[3-(Dimethylamino)propyl]-1-
(4-fluorophenyl)-1,3-dihydro-2-
benzofuran-5-carbonitrile 
59729-33-8 C20H21FN2O 324.392 Antidepressant 
2. Desmethyl-
Citalopram 
(DM Citalopram) 
 1-(4-Fluorophenyl)-1-[3-
(methylamino)propyl]-1,3-
dihydro-2-benzofuran-5-
carbonitrile 
144010-85-5 C19H19FN2O 310.365 Metabolite 
3. Desmethyl-
Fluoxetine 
(DM Fluoxetine) 
 3-Phenyl-3-[4-
(trifluoromethyl)phenoxy]-1-
propanamine 
83891-03-6 
 
C16H16F3NO 295.299 
 
Metabolite 
4. Desmethyl-
Tramadol 
(O - DM 
Tramadol) 
 
3-{2-[(Dimethylamino)methyl]-1-
hydroxycyclohexyl}phenol 
73986-53-5 C15H23NO2 249.349 Metabolite- 
Analgesic 
Table I - Physico-chemical characteristics of psychotropic drugs studied in this project 
 5. Desmethyl-
Venlafaxine 
(DM 
Venlafaxine) 
 
4-[2-(dimethylamino)-1-(1-
hydroxycyclohexyl)ethyl]phenol 
149289-30-5 C16H25NO2 263.375 Metabolite 
6. Duloxetine 
 
(3S)-N-methyl-3-naphthalen-1-
yloxy-3-thiophen-2-ylpropan-1-
amine  
116539-59-4 C18H19NOS 297.415 Antidepressant 
7. Fluoxetine 
 
N-methyl-3-phenyl-3-[4-
(trifluoromethyl)phenoxy]propan-
1-amine 
 56296-78-7 C17H19ClF3NO 309.326  Antidepressant 
8. Fluvoxamine 
 
2-[(E)-[5-methoxy-1-[4-
(trifluoromethyl)phenyl]pentylide
ne]amino]oxyethanamine 
54739-18-3 C15H21F3N2O2 318.335 Antidepressant 
 9. Melitracene 
 
3-(10,10-dimethylanthracen-9-
ylidene)-N,N-dimethylpropan-1-
amine 
5118-29-6 C21H25N 291.4299 Antidepressant 
10. Mianserine 
 
2-Methyl-1,2,3,4,10,14b-
hexahydrodibenzo[c,f]pyrazino[1,
2-a]azepine 
24219-97-4 C18H20N2 264.365 Antidepressant 
11. Mirtazapine 
 
2-Methyl-1,2,3,4,10,14b-
hexahydropyrazino[2,1-
a]pyrido[2,3-c][2]benzazepine 
85650-52-8 C17H19N3 265.353 Antidepressant 
 12. Paroxetine 
 
 
(3S,4R)-3-[(1,3-Benzodioxol-5-
yloxy)methyl]-4-(4-
fluorophenyl)piperidine 
61869-08-7 C19H20FNO3 329.365 Antidepressant 
13. Reboxetine 
 
(2R)-2-[(R)-(2-
Ethoxyphenoxy)(phenyl)methyl]
morpholine 
98769-81-4 C19H23NO3 313.391 Antidepressant 
14. Sertraline 
 
(1S,4S)-4-(3,4-Dichlorophenyl)-
N-methyl-1,2,3,4-tetrahydro-1-
naphthalenamine 
79617-96-2 C17H17Cl2N 306.230 Antidepressant 
 15. Tramadol 
 
(1R,2R)-2-
[(Dimethylamino)methyl]-1-(3-
methoxyphenyl)cyclohexanol 
73986-53-5 C16H25NO2 263.375 Analgesic 
16. Trazodone  2-{3-[4-(3-Chlorophenyl)-1-
piperazinyl]propyl}[1,2,4]triaz
olo[4,3-a]pyridin-3(2H)-one 
 
19794-93-5 C19H22ClN5O 371.864 Antidepressant 
17. Venlafaxine 
 
1-[2-(Dimethylamino)-1-(4-
methoxyphenyl)ethyl]cycloh
exanol 
93413-69-5 C17H27NO2 277.402 Antidepressant 
 
vi Abbreviations 
 
 
ABBREVIATIONS 
5-HT Serotonin 
ACN  Acetonitrile  
ANOVA  Analysis of variance  
API Atmospheric Pressure Ionization 
CE  Collision Energy  
CNS Central Nervous System 
Conc. Concentration 
CV  Coefficient of Variation (frequency distribution) 
CYP 1A2 Cytochrome P450 1A2 (enzyme from the Cytochrome P450 family) 
CYP 2D6 Cytochrome P450 2D6 (enzyme from the Cytochrome P450 family) 
CYP 3A4 Cytochrome P450 3A4 (enzyme from the Cytochrome P450 family) 
DA Dopamine 
Dev. % Deviation from nominal concentration (in percentage) 
DM Desmethyl 
EMA  European Medicines Agency  
ESI  Electrospray Ionization  
eV  Electronvolt  
FDA  Food and Drug Administration  
HPLC  High-performance liquid chromatography  
IS  Internal standard  
KKGT Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie 
LC  Liquid Chromatography  
LC-MS  Liquid Chromatography - Mass Spectrometry  
LC-MS/MS  Liquid Chromatography - Tandem Mass Spectrometry  
LLE  Liquid–liquid extraction  
LOD  Limit Of Detection  
LOQ  Limit Of Quantification  
m/z  Mass-to-Charge ratio  
MAOI Monoamine Oxidase Inhibitors 
MeOH  Methanol  
ME  Matrix Effects  
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MRM  Multiple Reaction Monitoring  
MS  Mass Spectrometry  
MS/MS  Tandem Mass Spectrometry  
NaSSA Noradrenergic/Specific Serotonergic antidepressants  
NDF Number of degrees of freedom 
NE Norepinephrine 
ntads Non-triclycil antidepressants 
p0H Tabulated value 
PD  Psychotropic drugs  
PP  Protein precipitation  
Q1  First Quadrupole  
q2  Second Quadrupole (Collision Cell)  
Q3  Third Quadrupole  
QC Quality Control 
R  Correlation coefficient (measure the strength of association 
between two variables) 
R2  Coefficient of determination (measure how well data fit a 
statistical model) 
SARI Serotonin Antagonists/Reuptake Inhibitors  
SD Standard deviation  
SE Standard error (uncertainty related with mean estimate) 
SNRI Serotonin Norepinephrine reuptake inhibitors  
SS Sum of squares 
SPE Solid Phase Extraction 
SSRI Selective Serotonin Reuptake Inhibitors  
Std. Standard 
Std. Fit Standard fit 
SWGTOX Scientific working group for forensic toxicology 
T0 Time of origin – when studying stability of processed samples, 
as soon as the batch is prepared, one should be immediately 
analyzed to establish the time zero. 
TCA Tricyclic Antidepressants 
TQD Triple Quadropole Detector 
TV Test values 
viii Abbreviations 
 
VarFit Fitting residual variance. it is obtained by dividing the sum of 
squares by the respective degrees of freedom 
Ym Signal Mean Value 
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RESUMO 
Objectivo: Antidepressivos não-tricíclicos são frequentemente encontrados em 
casos de overdose, e para alguns, a monitorização terapêutica tem de ser 
garantida. Assim sendo, foi desenvolvido e validado um método com 
cromatografia líquida acoplada a espectrometria de massa sequencial para a 
quantificação de 15 antidepressivos não tricíclicos comuns em soro: citalopram, 
desmetilcitalopram, desmetilfluoxetina, desmetilvenlafaxina, duloxetina, 
fluoxetina, fluvoxamina, melitracene, mianserina, mirtazapina, paroxetina, 
reboxetina, sertralina, trazodone e venlafaxina. Os fármacos selecionados 
também contêm (nor) tramadol (adicionado devido à sua interferência com 
desmetilvenlafaxine) e todos os antidepressivos não tricíclicos disponíveis na 
Bélgica.   
Métodos: Amostras de soro (250 µL) foram precipitadas com metanol e 
acetonitrilo que contem 5 ng de cada padrão interno: mirtazapine-d4, 
paroxetine-d5, reboxetine-d6 e venlafaxine-d6. O sobrenadante foi evaporado a 
56ºC sob um fluxo de nitrogénio e reconstituído em 100 µL de 50:50 
metanol:água com 2 mM de acetato de amónio. 5 µL foram injectados e os 
analitos separados numa coluna 100 × 2.1 mm ACQUITY BEH C18 (Waters, 
Zelik, Bélgica), usando o sistema Waters ACQUITY Cromatografia Líquida de 
alta pressão. Os analitos foram eluídos em 7.5 min, usando um gradiente de 
0.2% de acetato de amónio e 0.1% de ácido fórmico em água e metanol a um 
fluxo de 0.4 mL/min. A quantificação foi efectuada usando o equipamento 
Waters quadropolo triplo ACQUITY TQD, com monitorização de reacção  
múltipla em modo positivo (2 MRM’s por analito). Uma curva de calibração de 
seis pontos foi usada, de modo a englobar concentrações de 10 ng/mL a 1000 
ng/mL. O método foi validado baseado no guia do Scientific Working Group for 
Forensic Toxicology (SWGTOX).  
Resultados: Não foram encontradas interferências da matriz, padrões internos 
ou medicamentos antidepressivos tricíclicos e o método provou ser selectivo 
para todos os compostos. Limites de quantificação e de detecção vão desde 10 
a 85 ng/mL e 2.0 a 28 ng/mL, respectivamente. Supressão iónica dos efeitos de 
xi Resumo 
 
matriz variam de 36 a 108% para os compostos e de 47 a 102% para os 
padrões internos. A eficiência do processo varia desde 22 a 106%. A imprecisão 
intra e inter-ensaios varia desde 3.5 a 12.3% e 3.1 a 12.3%, rescpectivamente. 
A inexactidão foi mais baixa que 15% para todos os compostos, excepto para 
as concentrações mais baixas de desmetilcitalopram, tramadol e trazodone 
(exactidão < 20%). Não foram observados fenómenos de arrastamento. 
Conclusão: Uma boa validação foi obtida graças ao uso de padrões internos 
deuterados que se ajustaram a todos os compostos de modo a compensar a 
variabilidade global do método. Este método é então adequado tanto a 
monitorização terapêutica como a quantificação nos casos de suspeita de 
overdose.  
 
Palavras-chave: fármacos psicotrópicos; soro; quantificação; validação; LC-
MS/MS; TQD 
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ABSTRACT 
Objective: Non-tricyclic antidepressants are often encountered in overdose 
cases, and for some of them therapeutic monitoring might be warranted. 
Therefore we developed and validated an ultra-performance liquid 
chromatography-tandem mass spectrometry method for the quantification of 15 
common non-tricyclic antidepressants in serum: citalopram, 
desmethylcitalopram, desmethylfluoxetine, desmethylvenlafaxine, duloxetine, 
fluoxetine, fluvoxamine, melitracene, mianserin, mirtazapine, paroxetine, 
reboxetine, sertraline, trazodone and venlafaxine. The selected pharmaceuticals 
represent (nor) tramadol (added because of the desmethylvenlafaxine 
interference) and all the non-tricyclic antidepressants available in Belgium.  
Methods: Serum samples (250 µL) were precipitated with methanol and 
acetonitrile containing 5 ng of the internal standards: mirtazapine-d4, 
paroxetine-d5, reboxetine-d6 and venlafaxine-d6. The supernatant was 
evaporated at 56ºC under a flow of nitrogen and reconstituted in 100 µL of 
50:50 methanol:water with 2 mM ammonium acetate. Five µL was injected and 
the target analytes were separated on a 100 × 2.1 mm ACQUITY BEH C18 
column (Waters, Zellik, Belgium) using a Waters ACQUITY Ultra-Performance 
Liquid Chromatography system. The analytes were eluted within 7.5 min, using 
a gradient of 0.2% ammonium acetate and 0.1% formic acid in water and in 
methanol at a flow rate of 0.4 mL/min. Quantification was performed on a 
Waters triple quadrupole ACQUITY TQD using multiple reaction monitoring 
(MRM) in positive mode (2 MRMs per analyte). A six point calibration curve was 
used to cover a large concentration range from 10 ng/mL to 1000 ng/mL.  The 
method was validated based on the Scientific Working Group for Forensic 
Toxicology (SWGTOX) guideline. 
Results: No interfering signals from matrix, internal standard or tricyclic 
antidepressant drugs were found. Limits of quantification and limits of detection 
ranged from 10 to 85 ng/mL and 2.0 to 28 ng/mL respectively. Ion suppression 
from matrix effects varied from 36 to 108% for the compounds and 47 to 102% 
for the internal standards. Process efficiency varied from 22 to 106%. Intra-
xv Abstract 
 
and interassay imprecision varied from 3.5 to 12.3% and 3.1 to 12.3%, 
respectively. The bias of the assay was lower than 15% for all the compounds, 
except the lowest concentrations of desmethylcitalopram, tramadol and 
trazodone (bias < 20%). No carryover was observed. 
Conclusion: Good validation performance was obtained thanks to the use of 
selected deuterated internal standards that adjusted for all of the compounds, 
to compensate for the global method variability. This method is therefore 
suitable for both therapeutic drug monitoring and quantification in suspected 
overdose cases. 
 
Keywords: psychotropic drug; serum; quantification; validation; LC-MS/MS; 
TQD
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1. INTRODUCTION 
 
1.1 Psychiatric Drugs 
A psychcotropic drug (PDs) can be defined as any medication capable of affecting 
the mind, emotions, and behavior [12]. Psychotropic Drugs affect the functioning of 
the mind through pharmacological action on the Central Nervous System (CNS) by 
crossing the blood-brain barrier, resulting in alterations in perception, mood or 
behavior [13]. Examples of psychiatric drugs include tricyclic antidepressants, 
phenothiazines antipsychotic drugs, tetracyclic antidepressants, butyrophenones, and 
serotonin reuptake inhibitors [14].  
PDs are divided in six main categories, such as antidepressants, antipsychotics, 
anxiolytics, antiepileptics, lithium and other drugs [15]. In forensic toxicology, 
antidepressants are of considerable interest because of their abuse potential and their 
involvement in intoxications and suicides, which makes the ability to reliably detect this 
type of drugs in human biological specimens a necessity [5, 6]. The detection of a PD 
is crucial in determining whether these drugs played a role in the cause of death [16].  
 
1.1.1 Depression and Antidepressants  
Depression is expected to be the second most serious illness by the year 2020 [18]. 
It is a serious psychiatric illness with a highly variable set of symptoms: feelings of 
helplessness and hopelessness, loss of interest in daily activities, appetite or weight 
changes, sleep changes, anger or irritability, loss of energy and poor concentration. 
The individual’s ability to take care of his everyday responsibilities is affected and at its 
worst can even lead to suicide [8]. World Health Organization considered depression as 
number 1 in causing disability [1]. The World Mental Health made a study about the 
prevalence of depression episodes in the 18 countries participating in its surveys (Table 
1.1). 
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Tabel 1.1. - Prevalence of depression in the 18 
countries participating in the WMH surveys. 
Screen+ -  the proportion of respondents who 
reported ever having a time lasting several days 
when they were sad, depressed, or lost all 
interest in their usual activities;  
SE – Standard Error.  
Adapted from [9]. 
Treatment of depression includes 
various forms of psychotherapy and 
pharmacotherapy with antidepressants 
and even electroconvulsive therapy [8]. 
The antidepressants are currently among 
the most frequently therapeutic agents in 
medicine, mainly because of their efficacy 
(elevation of mood, improved appetite and 
sleep patterns, increases physical activity, 
decreased feelings of guilt, among others 
[19]). This type of drugs can also be used 
to treat anxiety, obsessive-compulsive or 
psychosomatic disorders. However, 
antidepressants in general have some side 
effects, as insomnia, dry mouth, blurred 
vision, constipation, dizziness, agitation, 
irritability [15]. 
Commonly prescribed antidepressants 
are divided into three classes: monoamine 
oxidase inhibitors (MAOI), trycliclic 
antidepressants (TCA) and selective 
serotonin reuptake inhibitors (SSRI). Of 
these three classes, tryciclics and SRRIs 
work by blocking reuptake of neurotransmitters, especially norepinephrine, dopamine, 
and serotonin [4, 7, 10]. Therefore, they produce an increase in the concentration of 
neurotransmitters in the synaptic gap.  
Although the underlying pathophysiology of depression has not been clearly 
defined, preclinical and clinical evidence suggest disturbances in serotonin (5-HT), 
norepinephrine (NE), and dopamine (DA) neurotransmission in the central nervous 
system [20]. When the balance of neurotransmitters like dopamine, norepinephrine 
and serotonin is disturbed, emotional regulation becomes unstable and the syndromes 
of depression and mania may develop. Dopamine and serotonin, for example, is 
popular for be contributor to feelings of well-being and happiness. Also, in the absence 
of serotonin, depression is easily triggered [21]. Norepinephrine affects parts of the 
 Screen + 
 % (SE) 
High income  
Belgium 14.1 0.1 
France 21.0 1.1 
Germany 9.9 0.6 
Israel 10.2 0.5 
Italy 9.9 0.5 
Japan 6.6 0.5 
Netherlands 17.9 1.0 
New Zealand 17.8 0.4 
Spain 10.6 0.5 
United States 19.2 0.5 
Total 14.6 0.2 
Low- to middle-income  
Brazil (São Paulo) 18.4 0.8 
Colombia 13.3 0.6 
India (Pondicherry) 9.0 0.5 
Lebanon 10.9 0.9 
Mexico 8.0 0.5 
PRC (Shenzhen) 6.5 0.4 
South Africa 9.8 0.7 
Ukraine 14.6 0.7 
Total 11.1 0.2 
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brain where attention and responding actions are controlled and plays a determinant 
role in executive functioning regulating cognition, motivation, and intellect, which are 
fundamental in social relationships [20]. 
Although the new-generation antidepressants have a low toxicity profile, analysis of 
forensic and clinical samples is important to investigate cases of violent crime, 
unknown death, drug facilitated sexual assault cases and therapeutic drug monitoring. 
Intoxications with these new-generation antidepressants in healthy individuals are rare 
and require very high concentrations (reflecting intentional overdoses), but may still be 
involved in overdose deaths, particularly when combined with other drugs [8]. 
Antidepressants can be classified according to the chemical structure or 
pharmacological action. The pharmacological action is currently more used [15]. The 
selective serotonin reuptake inhibitors (SSRI) have emerged as a major therapeutic 
advance in psychopharmacology [13], but serotonin norepinephrine reuptake inhibitors 
(SNRI), Noradrenergic/Specific Serotonergic antidepressants (NaSSA) and Serotonin 
Antagonists/Reuptake Inhibitors (SARI) are also used nowadays [4,10].  
1.1.1.1 Selective Serotonin Reuptake Inhibitors  
Serotonin is a neurotransmitter especially relevant in affective disorders, 
compulsive-obsessive disorder and aggressive behavior [15]. It is also linked to 
memory, cognition, mood regulation, sleep, pain, blood vessel regulation, anxiety and 
depression [21].  
SSRI inhibit serotonin reuptake, increasing concentrations of serotonin in the 
synapse gap, which causes enhancing of serotonin neurotransmission and results in 
their antidepressant effects [2, 10, 12, 13]. Some SSRIs also inhibit the reuptake of 
norepinephrine (such as fluoxetine and paroxetine), while others inhibit the reuptake of 
dopamine (sertraline).  
This type of antidepressant is absorbed relatively slowly and it is metabolized 
primarily by liver metabolic enzymes. SSRIs are potent inhibitors of several different 
isozymes of the cytochrome P450 family of enzymes. Cytochrome P450 2D6 (enzyme 
member of the cytochrome P450 mixed-function oxidase system) has received the 
most attention, because all of SSRIs are inhibitors of this particularly enzyme, 
interfering in its task: O-demethylation [23]. Their metabolites are mainly eliminated in 
the urine [19]. 
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When SSRIs are ingested with other medications or in really high doses, it may 
lead to serotonin syndrome – excessive serotonin levels that arise from an overdose of 
serotonin reuptake inhibitor or by co medication of serotonin reuptake inhibitor and 
drugs that interfere with the metabolism of serotonin. This serotonin syndrome leads 
to agitation, mental status change, diaphoresis, myoclonus, diarrhea, fever, 
hyperreflexia, tremor, or incoordination and can eventually lead to death [8]. In 
general, SSRIs have milder adverse effects than older antidepressants, and their 
adverse effects are often dose related [19].   
Citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are some of the 
antidepressants studied in this project that are SSRIs.   
1.1.1.2. Serotonin Norepinephrine reuptake inhibitors  
Norepinephrine is also hypothesized to be involved in depression (due a 
dysfunction of a brain area where norepinephrine is present [20]) and it is synthesized 
from dopamine, another mood neurotransmitter [24]. 
SNRI selectively inhibit the reuptake of norepinephrine, but have little effect on the 
reuptake of serotonin or dopamine. They have little affinity for muscarinic or 
cholinergic receptors and do not interact with serotonergic, dopaminergic or 
histaminergic receptors [15]. 
All SNRI work in a similar way and generally cause similar side effects. However, 
each SNRI varies in chemical makeup, so one may affect you differently than another 
does. Side effects are usually mild and go away after the first few weeks of treatment.  
The most common side effects of SNRI include nausea, dry mouth, dizziness, excessive 
sweating and other side effects may include tiredness, difficulty urinating, constipation, 
insomnia or loss of appetite [19].  
Duloxetine, reboxetine, venlafaxine are examples of this type of antidepressants. 
Duloxetine is mainly metabolized by cytochrome P450 1A2 and 2D6 (enzymes 
members of the cytochrome P450 mixed-function oxidase system)and eliminated by 
urine and feces [25]; reboxetine is metabolized in liver, mainly through the 3A4 
isozyme of cytochrome P450 and it is excreted by kidney; venlafaxine is extensively 
metabolized in the liver via the  CYP 2D6 isoenzyme to desmethylvenlafaxine. The 
primary route of excretion of venlafaxine and its metabolites is via the kidneys [19]. It 
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is a potent inhibitor of the reuptake of serotonin, at higher doses inhibits the reuptake 
of noradrenaline and slightly inhibits the reuptake of dopamine [15]. 
1.1.1.3. Noradrenergic/Specific Serotonergic antidepressants  
NaSSA works by blocking receptors called alpha-2 receptors that are found on 
nerve cells in the brain. This enhances the action of noradrenaline and serotonin in the 
brain [19, 26].  
People who take NaSSA may have side effects like sleepiness and nausea. Other 
common side effects are dizziness, increased appetite high cholesterol or weight gain. 
Less common adverse effects include weakness, rapid heartbeats, dry mouth, tremor, 
confusion or vision disturbances [4, 10]. 
This type of antidepressants is extensively metabolized via CYP 1A2, 2D6 and 3A4 
and it is excreted by the kidneys. Mirtazapine is a compound studied in this project that 
belongs to this category. It is well absorbed from gastrointestinal tract after oral 
administration and eliminated from the body mostly by the kidneys [26]. 
1.1.1.4. Serotonin Antagonists/Reuptake Inhibitors  
SARI are another class used as antidepressants, anxiolytics and hypnotics that 
modulate serotonin activity [27].  They act by blocking the postsynaptic 5-HT2 
receptors and the transporter, inhibiting the reuptake of serotonin [28].  
SARI are completely absorbed from the GI tract and metabolized primarily by the 
liver [19]. Most common side effects are sedation, nausea, postural hypotension or 
priapism (rare, but dangerous) [15].  
Since the SARI have drawn attention for their sleep-improving potential, 
Trazodone is now the second most commonly prescribed drug for insomnia [27]. Its 
mechanism of action is the modulation of serotonergic neurotransmission; it is a 
relatively specific inhibitor of the reuptake of serotonin [15]. Trazodone is metabolized 
by CYP3A4 and eliminated by urine in 72 hours [19].   
The main psychochemical characteristics of the compounds of interest are in table 
I (Section V). 
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 This method was also developed for detection and quantification of two 
analgesics: Tramadol and DM Tramadol. Since Tramadol and DM venlafaxine have the 
same precursor ion and similar product ions (table 1.3), we needed a method that can 
distinguish both. This is important because false positives results for tramadol were 
observed in cases where subjects were being treated with venlafaxine [29]. 
 
 
 Tramadol is a centrally acting analgesic used for the treatment of moderate to 
severe pains. The drug inhibits the reuptake of norepinephrine and serotonin. Side 
effects from tramadol use include seizures and respiratory depression [30]. Its main 
active metabolite is DM Tramadol that retains activity as a norepinephrine reuptake 
inhibitor.  
 
1.1.2. Drugs Intoxication 
One of the most commonly used methods of self-injury worldwide is drug 
overdose [31]. As depression is a serious psychiatric illness, there is a high suicide rate 
among depressed patients, however acute intoxications with these new-generation 
antidepressants in healthy individuals are rare and mostly concern very high 
concentrations. Pharmacological treatment is essential for an adequate management of 
these psychiatric disorders. These highly prescribed antidepressants are frequently 
coadministered with other legal or illegal drugs, in case of large intentional overdoses 
[8, 25]. More, there are clinical studies that question the efficacy and safety of these 
drugs, showing a profile of toxicity that is still not well known [33]. This fact has led to 
the development of reliable analytical methods for their analysis [34]. 
Therefore, the development of more efficient analytical techniques is important in 
clinical toxicology, where they help in monitoring therapy (because it is difficult to 
interpret the relationship between plasma concentration and therapeutic and side 
 Percursor Ion Product Ion 
DM Venlafaxine 263.375 58.000 
107.100 
246.220 
Tramadol 263.375 58.000 
246.200 
DM Tramadol 249.349 44.000 
Table 1.3. Percursor and product ions from DM Venlafaxine, Tramadol and DM Tramadol. 
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effects), and in forensic toxicology, given the correlation between depression and 
premature death [33].  
Forensic science is concerned with determining the cause of death and the results 
of a forensic investigation may have a serious impact on lives [12]. It implies an 
understanding of drug use in the immediate ante mortem setting, analytical 
methodologies and interpretation of results [36]. Post-mortem forensic science involves 
analyzing body fluids and organs from death cases and interpreting that information 
[37].  
One of the more important issues confronting the interpretation of post-mortem 
toxicology results the possibility of changes in drug concentration after death; also, 
there are several biological matrices that can be analyzed to determinate 
concentrations.  Generally, specimens routinely collected at autopsy include fluids such 
as blood from peripheral sites and heart blood, urine, bile, cerebrospinal fluid, vitreous 
humor, gastric contents and organ tissues, particularly liver  [37].  
The substance itself does not make something a drug or a poison but rather the 
amount of it that is ingested. Even common materials and pharmaceuticals can be 
poison if too much is ingested; it is the dose that makes a poison. A drug is a 
substance characterized by having properties that is used to treat or prevent a disease 
or to treat symptoms of a disease or injury. A poison is a substance that is capable of 
causing harm to an organism, whether it is an illness, injury or death. The modern 
definition of term poison is essentially the same as that of a toxic substance. The more 
toxic or poisonous a substance is, the more harm a small amount of it can cause. Only 
the amount and time over which the substance is administered will allow to determine 
how harmful it will be [38].  
It is also important to define therapeutic levels. Those levels are the steady state 
concentrations that need to be reached for the drug to exert a significant clinical 
benefit without causing unacceptable side effects. A therapeutic level implies a 
concentration at which a useful response is obtained free from any toxicity. And toxic 
levels are concentrations above which unacceptable side or toxic effects might appear. 
[31, 34]. A lethal concentration is the concentration that has been reported to cause 
death, or is so far above reported therapeutic or toxic concentrations, that one can 
judge that it might cause death in humans. 
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Table 1.4. shows therapeutic, toxic and lethal concentrations in blood for each 
drug that is subject of study in this project. These concentrations are calculated on 
plasma exposure values. However, all these values are not considered absolute, but 
are to be used as a guide. It’s important to mentioned that these values can be 
affected by route of administration, absorption differences, age and sex, tolerance or 
pathological or disease state [40].  
Table 1.4. Toxic concentrations, lethal concentrations and recommended therapeutic range for psychotropic 
drugs.  
Compound Therapeutic 
Concentration 
(ng/mL) 
Toxic 
Concentration 
(ng/mL) 
Lethal 
Concentration 
(ng/mL) 
Reference 
Citalopram 81 – 160 -- 240 – 1300 [40] 
DM Citalopram 10 – 200 -- 5000 – 6000 [39] 
DM Fluoxetine 180 – 466 -- 900 - 5000 [41] 
DM Tramadol 100 - 1000 1000 2000 [39] 
DM Venlafaxine 200 – 400 1000 – 1500 6600 [39] 
Duloxetine 0 - 30 -- >1000 [39] 
Fluoxetine 90 – 400 1000 1300 - 6800 [40] 
Fluvoxamine 150 – 250 650 2800 [39] 
Melitracene 10 – 100 -- 12000 - 23000 [39] 
Mianserine 10 – 150 500 - 5000 3000 – 19000 [39] 
Mirtazapine 4 - 40 100 - 200 2000 – 4000 [39] 
Paroxetine 31-  62 -- 1400 - 3400 [40] 
Reboxetine Cmax < 300 -- -- [39] 
Sertraline 55 – 250 290 1600 – 3000 [40] 
Tramadol 100 - 600 1000 2000 [39] 
Trazodone 800 – 1600 4000 12000 – 15000 [39] 
Venlafaxine 200 – 400 1000 – 1500 6600 [39] 
 
 
1.1.3. Biological Matrices 
In clinical or forensic toxicology, a specific analytical method may be indicated to 
screen and quantify compounds (in this case, antidepressants) in biological matrices 
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[8]. A drug may be detected in any body fluid or tissue with which it has been in 
contact. The primary choice of biological specimen for drug analysis depends on issues 
like purpose of the sampling, time interval to study, willingness to provide a voluntary 
sample, cost of sample preparation and its analysis, drug concentration and drug 
stability.  Blood, urine, oral fluid and hair are the most common matrices in toxicology 
[42].  
To choose the biological matrix, it is important to know the stability of analytes in 
biological material. This is very important to ensure the reliability of analytical results, 
because there are gaps between sample collection, transportation, sample preparation 
and time of the analysis [43]. Different biological matrices are used to determine 
antidepressants, but blood is the most relevant matrix as it gives a direct link between 
the compound concentration and the effect [8].  
1.1.3.1. Blood 
Blood (including serum and plasma) is the only biological specimen, except for 
cerebrospinal fluid, which reflects the drug concentration in the brain. Blood samples 
must be collected by qualified personnel with vacuum tubes or syringes and usually 5-
10 mL is collected [42]. Blood is use to determinate the presence of drug intoxication, 
inebriation or supra-therapeutic drug use [5, 37, 39].  
The following table contains advantages and disadvantages about blood as 
biological matrix (Table 1.5).  
Table 1.5. Some advantages and disadvantages of using blood as a biological matrix. Adapted from [42] 
 Blood 
Maximum drug detection period 1-2 days* 
Intrusive Sampling Yes 
Adulteration potential None 
Possibility for environmental contamination No 
Potential for negative result after drug use Low 
Analytical costs (Including confirmation testing) Medium 
* There are some exceptions. For example, fluoxetine half-life is 4 to 6 days, so it can be detected for longer 
time [42]. 
The main limitation of blood is its maximum drug detection period: blood samples 
are not suitable to study drug use during a wider time-frame.  
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There are several analytical methods for drugs of abuse in blood [45]. Blood is 
analyzed by gas chromatography with single or tandem mass spectrometric detection 
(GC-MS), and recently liquid chromatography with single or tandem mass 
spectrometric detection (LC-MS and LC-MS/MS) has become the technology of choice 
for identification and quantification of a wide range of compounds [37, 40].  
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1.2. Analytical methodologies for psychotropic drug 
analysis 
 
An important step in the development of an analytical method is the extraction 
of the compounds of interest from the biological matrix as this will have implications on 
the overall sensitivity and selectivity of the method [8]. Sample preparation is, by 
definition, a method to concentrate a component of interest to adequate levels for 
measurement free from interfering matrix elements [46]. 
 
1.2.1. Analytical methodology for sample preparation  
 
The main objective of sample preparation is to convert a real biological matrix 
into a form suitable for analysis by the desired analytical technique [39, 42 - 44]. 
Biological matrices, like plasma, are very complex.  They contain a wide variety of 
matrix components such as proteins, lipids and salts. Typical preparation includes 
dilution, extraction, evaporation and reconstitution [50].  
The point of sample preparation is to remove potential interferences such as 
proteins and peptides, from the sample [43, 44, 46]. Peptides and proteins are 
incompatible with standard chromatographic set-ups since the columns would be block 
and ruined. Furthermore, peptides tend to interfere with atmospheric pressure 
ionization, increasing the baseline and causing noise. Phospholipids have also to be 
removed; otherwise they can cause unspecific signals and ion suppression [48]. 
Another important point of sample preparation is that it can concentrate the 
analyte in order to obtain lower limits of quantification [49]. Concentration is usually 
performed by extraction methods. Removal of salts also minimizes contamination of 
the ion source and is thus relevant for robustness [48]. 
Four main methods of sample extraction are applied in liquid chromatography: 
Protein precipitation (PP) (by addition of organic solvents, inorganic acids and/or 
chaotropic salts); protein filtration; solvent extraction (liquid–liquid extraction, LLE); 
and solid phase extraction (SPE). The method must be chosen considering the 
respective analyte and the MS/MS system [43, 44]. 
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All procedures also requires the addition of an internal standard (IS). Internal 
standards play critical roles in ensuring the accuracy of reported concentrations in LC-
MS/MS analysis. To quantify traces amount of analytes in complex biological samples 
by this technique, those have to be treated. Variable losses of the analytes may occur 
during these sample treatment steps; also, there might be some variations during the 
LC-MS/MS analysis (variations in injection volume or ionization) [45 ,55].  
To reduce the impact of those losses and instrumental variations, an IS is added in 
equal amount to both concentration-known and unknown samples (calibration 
standards and quality controls). IS must have the same or similar physical and 
chemical properties as the analyte [53].  
The IS is employed as a calibrant and the concentration of a unknown sample is 
calculated from the ratio between analyte/IS signal ratio [53].  
An IS should meet the following requirements:  
 It should have the same or very similar physico-chemical properties as the 
analyte, so that it can mimic closely the performance of the analyte in 
every stage of analysis. In this way, any losses during sample preparation 
or variations in can be corrected [45, 55]; 
 It must have adequate purity. The interference of an internal standard to 
other cointernal standards in a multianalyte method is rare, but it should 
be also evaluated. Though there are no reported criteria for this, it should 
be at least less than 15 % of the concentration of a cointernal standard in 
a multianalyte method [54]; 
 It must be stable during sample processing and LC separation. In addition, 
an internal standard should not correspond to any in vivo metabolic 
products of the analyte [55]; 
 Its molecular mass should be distinct from that of the analyte.  
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 There are three main types of IS [56, 58]. The first ones are stable isotope 
labeled (SIL) internal standards. They are compounds in which several atoms in the 
analytes are replaced by their respective stable isotopes, such as deuterium ( 2H, D or 
d), 13C, 15N, or 17O.  
The second type of IS covers structural analogues 
with the same (e.g. an ortho and meta substituted 
compound) or different mass (e.g. compounds with 
similar structure and small differences in functional 
groups) [52]. Finally, there are also compounds from 
the same chemical family. In this project, we used the 
third type and then changed the method to choose the 
first type. 
The IS chosen was Trimipramine-d3 (Fig. 1.1), 3-
(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-
trimethyl-1-propanamine. It’s the non-deuterated 
molecular formula is C20H26N2 and its mass is 294.434 
g/mol. It is also an antidepressant, with sleep-
promoting effects. It is mainly used to treat insomnia 
[56].  
However, we didn’t obtain good results with 
trimipramine-d3. The Results and Discussion below 
explain why. New internal standards were added (and 
trimipramine-d3 excluded) in order to get better 
results: Mirtazapine-d4, Paroxetine-d6, Reboxetine-d5 
and Venlafaxine-d6 (Fig. 1.2 – 1.5). 
 
1.2.2. Sample preparation of plasma – 
Protein precipitation  
Protein precipitation (PP) with miscible organic 
solvents (usually acetonitrile or methanol) is the most 
commonly used plasma sample preparation method 
because of its low cost and minimal method development requirements. This method 
Fig. 1.1. Trimipramine-d3 
 
 
 
Fig. 1.2. Mirtazapine-d4 
Fig. 1.3. Paroxetine-d6 
 
 
Fig. 1.4. Reboxetine-d5 
 
Fig. 1.5. Venlafaxine-d6 
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provides sufficient clean-up for most LC-MS analyses [57]. It is rapid and simple, and 
has a good recovery of non polar and analytes, compared to liquid-liquid extraction 
[43, 46]. However, the precipitated proteins may bind various small molecules and 
remove them from the solution and thus, influence quantification [49].  
PP is based on the interaction between the reagent and the protein [47]. To 
denature the proteins, an organic solvent (typically acetonitrile, methanol or ethanol) 
or an acid (e.g. trichloroacetic) is added to a sample. Organic solvents are the most 
used because of its cost and minimal method development requirements [57].  
With the addition of an IS and a treatment agent (2-5 volumes of a water mixable 
organic solvent such as acetonitrile, methanol, isopropanol or acetone) to the sample, 
the mixture is agitated to increase the aggregation speed of the proteins. The 
supernatant, which contains the analyte, is then separated from the protein aggregate 
by centrifugation [47].   
PP is straightforward, but does not allow concentration of the analytes. Instead, 
typically a dilution of at least 1:2 is obtained [48]. PP may be performed alone or in 
conjunction with another extraction technique. For example, protein precipitation is 
commonly performed prior to (SPE) [58].  
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1.3. Liquid Chromatography coupled to Mass 
Spectrometry 
Over the last two decades, there has been a growing interest in the 
development of methodologies for qualitative and quantitative analysis of several drugs 
in different biological matrices. The most common approach to detecting drugs is the 
analysis  of biological fluids and tissues [59]. Liquid chromatography-mass 
spectrometry (LC-MS) has become a mature technique finding many applications in 
clinical chemistry and forensic toxicology. It is often used for the analysis of most of 
the common drugs in biological matrices [8, 22, 50]. LC-MS is the method of choice 
because the sensitivity, selectivity and the relatively high throughput that can be 
achieved and the determination of multiple groups of compounds can be performed in 
a single method. Some of the advantages of this technique include easier sample 
preparation, avoidance of derivatization procedures and short analysis time [60].  
Chromatography is the concept of separating compounds based on 
physicochemical properties.  The components can be separated by distribution 
between two phases: a phase that is stationary (component of the system with which 
the compounds in the mixture will interact), and a mobile phase that moves in a 
definite direction [61].  
But this step is not sufficient to give us an unequivocal identification. It needs 
further information from an auxiliary technique – Mass spectrometry. This last one 
provides molecular weight of the analyte and structural information from the molecule 
under investigation, which is unique for every molecule [12]. It’s powerful analytical 
features, such as sensitivity, selectivity, speed of analysis, cost and effectiveness, have 
continually improved, resulting in more reliable instruments and easier to use [62]. 
 
1.3.1. Liquid Chromatography (LC) 
In liquid chromatography, the substances are separated based on differential 
solubility’s in the two phases, with identification based on retention times within a 
column. Retention time (RT) is the time required for an analyte to elute from a 
chromatographic column with a particular mobile phase [61].  
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Fig.1.6. Basic Components of HPLC. Adpated from [98].  
High-performance liquid chromatography (HPLC) is the term used to describe 
LC in which the liquid mobile phase is mechanically pumped through a column (with 
stationary phase) with high pressures [12]. 
The interaction of the analyte with the stationary phase may be adsorption, 
partition, size exclusion, affinity and ion exchange. In adsorption chromatography, the 
solute are in contact with both phases and when interacts with the stationary phase, 
the polar solutes will be retained longest by polar stationary phases and the nonpolar 
solutes will be retained best by nonpolar stationary phases [56, 60]. 
Fig. 1.6 illustrates the components of an HPLC system.  A solvent reservoir and 
solvent delivery system or high pressure pump are coupled with a sample injection 
system to provide the flow of the mobile phase through the column and for the 
separation of the sample in the column bed.  A detector detects the bands of the 
sample components as they exit the column.  These are converted into electrical 
signals that can be processed by the data management system or computer associated 
with the system [61].  
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The capacity to precisely regulate pressure provides direct control over solvent 
velocity, which enhances the degree of separation and decreases the level of 
component diffusion into the column. Large molecules can be reliably analyzed and a 
much broader range of polarities can be handled with this technique [61].  
HPLC is divided into two basic procedures: normal-phase HPLC and reverse-
phase HPLC. The main difference is in the composition of column packing material, 
which necessitates the use of different solvents. Normal phase is the less common 
method and it has been replaced by almost exclusive use of reverse phase. In normal 
phase separations, the stationary phase is relatively polar and the mobile phase is 
relatively non-polar. More polar analytes will be retained on the polar stationary phase, 
while less polar analytes elute faster [52, 60].  
Reverse phase is the most common and, typically, more efficient method. It 
uses a non-polar stationary phase and a polar mobile phase. An example stationary 
phase is long chain C18 bonded to silica. Most mobile phases for reverse phase are a 
combination of water and miscible organic solvents, such as acetonitrile or methanol, 
or a mixture with various buffer salts [61]. Thus, the more polar analytes elute more 
rapidly than the less polar ones and a decrease in the polarity of the mobile phase 
results in a decrease in solute retention.  
In LC-MS certain ionic modifiers are often added to the mobile phase to 
influence analyte ionization. A volatile mobile phase must be used to ensure reliable 
analysis. Small organic acids like formic and acetic acid are among the most commonly 
used additives. They improve ionization and resolution of a wide range of molecules 
[59].   
Retetion time can also be controlled by changing the polarity of the mobile 
phase: increasing the polarity of the mobile phase leads to longer retention times and 
vice-versa.  
Chromatography is a purification technique that is generally considered a 
nonspecific form of identification: it doesn’t necessarily provide definitive proof in the 
identification of a substance. Although retention times are characteristic for a given 
compound under a specific set of analytical conditions, one must have a reference for 
comparison and identification. The molecular weight of the analyte together with the 
structural information that may be generated, allows an unequivocal identification – 
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Fig. 1.7. Basic concept of mass spectrometry analysis. The excess energy transferred during an ionization event may break 
the molecule into characteristic fragments. Adapted from [53]. 
the mass spectrometer provides the most definitive identification of all the HPLC 
detectors [12].  
 
1.3.2. Mass Spectrometry 
The mass spectrometer is an analytical instrument that separates and identifies 
ionized analytes or fragments based on their mass/charge ratio by passing them 
through a magnetic field. All the instruments have an ionization source at the inlet, 
followed by mass selective detector that allows for the selection of particular masses 
and the final component is a detector that translates and amplifies the selected ion 
signal into an electronic signal sufficient for data processing [64].  
While compounds may be multiply charged, for most toxicological applications, 
analytes are singly charged. This means that the z in the m/z ratio equals to 1. The 
purpose is to obtain a unique, reproducible fragmentation pattern of a particular 
molecular species [12].  
The first step in the mass spectrometric analysis is the production of gas phase 
ions (ionization) of the sample being tested and to introduce those ions into the high-
vacuum, mass selecting stage of the instrument, so they can be collected and 
recorded. High-vacuum environment ensures that the ions can travel unimpeded to the 
detector. The next step is the separation and mass analysis of the molecular ions and 
their charged fragments on the basis m/z ratio and finally, the ion current is measured 
and the result is in the form of a mass spectrum (Fig. 1.7) [53]. 
 
The inlet system for LC, often termed the “interface” between the two 
component techniques, must therefore remove as much of the unwanted mobile 
phases as possible while still passing the maximum amount of analyte into the mass 
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Fig.1.8. Essential components of a mass spectrometer. The inlet system transfers a sample into the ion source. The ion 
source coverts the neutral sample molecules into gas-phase ions. Then, the mass analyzer separates and analyze the ionic 
species. Here, a magnetic field is used to control the motion of ions. The detector measures and amplifies the ion current of 
mass-resolved ions. Finally, the data system records, processes, stores and displays data. Adapted from [53].   
spectrometer. Fig. 1.8. represents the essential components of a mass spectrometer 
[53].  
 
 
 
 
 
Liquid solutions are difficult to handle by MS vacuum systems and require some 
novel introduction and ionization systems. Ionization of the analyte is a very important 
step in the analysis of any class of compounds by MS.  
 
1.3.3.  Modes of Ionization 
The choice of a particular method is mostly dictated by the nature of the sample 
under investigation and the type of information desired [53]. In this case, toxicology 
analyzes mostly smaller molecules and highly polar compounds. This makes 
Electrospray Ionization (ESI) the most appropriate for our experiment. ESI has been a 
major advancement and essentially is the technology that allows for the existence of 
LC-MS/MS [61]. In particular, it has made an enormous impact in the characterization 
of large biomolecules [53]. Electrospray analysis can be performed in positive, which 
typically results in protonated molecular ions, [M+H]+, and negative ionization modes, 
which means deprotonated molecular ions [M-H]- [55]. Positive ionization mode is 
generally applied, because most toxicologically relevant compounds have basic 
properties. 
There are three stages of ESI: nebulization, evaporation and ionization. 
Nebulization is the formation of very small charged droplets, thanks to the charged 
needle. Evaporation further shrinks the droplets by using a warm or dry gas (such as 
nitrogen) to evaporate the solvent and to increase the surface charge density. 
Ionization happens when the droplet reaches a critical size, at which like charges repel 
each other and fragment the small droplet. As the solvent further evaporates, the 
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Fig. 1.9. Mechanism of ion formation in the positive ESI mode. The analyte is introduced into the ESI source throw a 
needle as an eluent flow from the LC. The Electrospray itself is formed as a result of a large electrostatic potential 
difference between the capillary and a cone electrode. Cations concentrate at the tip of the capillary (Taylor cone) and 
tend to migrate toward the cone electrode. The air, which is passed continuously in the region spraying, helps the 
evaporation of the solvent. As the size of the droplet reduces, the repulsive force between charges on the surface of the 
droplets overcome the cohesive forces of surface tension and causes the droplets to disintegrate (Coulombic explosion). 
The skimmer is used to retain these droplets and guide the ion to the analyzer region of the mass spectrometer. Adapted 
from [53].  
 
droplet reaches a size such that charged molecules can no longer stay in the solution 
phase and are expelled into the gas phase (fig 1.9) [52 , 61]. 
 
ESI is most applicable to larger, more polar compounds, but,  macromolecules 
greater than about 1 kilodalton may experience fragmentation.  ESI only works for 
compounds that are ions in solution. This makes it solvent dependent.  Only those 
solvents that can support the solution ions and help form the ions in solution can be 
used. ESI is also flow dependent. The dynamics of the flow are an integral part of 
droplet formation. Too much or too little flow and droplets do not form properly [53], 
[65]. 
 
1.3.4. Quadrupole Analyzer 
Once the gas-phase ions have been produced, they need to be separated 
according to their masses, which must be determined. The physical property of ions 
that is measured by a mass analyzer is their mass-to-charge ratio (m/z).  
As there are a great variety of sources, several types of mass analyzers have 
been developed. All mass analyzers use static or dynamic electric and magnetic fields 
that can be used alone or combined [55].  
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Fig. 1.10. Schematic representation of a quadropole analyzer. The quadrupole mass analyzer uses combined DC (direct current) and 
RF (radio frequency) potentials applied to a set of four rods. It uses a central cavity created by four rods to filter ion fragments. The 
potentials at each rod can be independently regulated to direct ions of a specific mass-to-charge (mass) toward the detector. Ions 
that do not have a stable trajectory through the quadrupole configuration will collide with the rods (are filtered) and never reach the 
detector [12].  
A quadrupole analyzer is the type of mass analyzer used in this project and is 
probably the most used type of mass analyser. It is an ideal detector for 
chromatography as it is capable of fast scanning [53].  
The quadrupole analyser is a device which uses the stability of the trajectories 
in oscillating electric fields to separate ions according to their m/z ratios. This field is 
made up of four circular rods that must be perfectly parallel [53]. This allows for ions 
of a given mass to charge ratio to pass while others are not stable through the length 
of the field (fig 1.10). 
In this method, ions of a specific mass to charge ratio are able to traverse the 
path established by the electromagnetic fields applied to the poles.  Those ions that 
are too heavy or too light are unable to travel the entire distance to the detector and 
are thus not detected.  So the electromagnetic conditions can be varied very rapidly to 
select the desired masses in the analysis [65]. 
 
 
 
 
 
 
 
 
 
 
Two opposite rods have the same voltage, while the perpendicular ones have a 
voltage with opposite signs (+ and -, respectively). The oscillating field applied to the 
rods alternately attracts and repels ions passing through the mass filter, inducing an 
ion motion that is exploited to differentiate ions on the basis of their mass. The 
detector will count the mass and relative abundance of each fragment and show the 
information in peaks [56, 60, 61].   
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Fig. 1.11. Differences between single stage MS and tandem MS/MS. The reason MS/MS is required is 
because many compounds have the same intact mass. The combination of the specific parent mass and the 
unique fragment ion is used to selectively monitor for the compound to be quantified.Adapted from [99]. 
 Some things to consider with a quadrupole is that they are often the lowest 
cost mass selective device, especially as a single quadrupole. They typically have good 
sensitivity, precision, accuracy, and linearity for many forensic applications. 
Unfortunately, quads cannot produce exact or accurate mass information and scan 
speeds can limit sensitivity, and with rapid chromatography the trade of rapid scans to 
accommodate narrow peaks may compromise sensitivity [64]. 
 
1.3.4.1.  MS vs. MS/MS 
  There are differences between MS mode and tandem MS/MS mode. In the MS 
mode, ions formed in the ionization source are separated by a single-stage mass 
analyzer. In tandem in space MS/MS there are three main steps in tandem mass 
spectrometry (Fig. 1.11): (i) ion selection, (ii) ion activation (fragmentation), and (iii) 
analysis of the fragments of the selected ion [55].  
 
 
 
 
 
Tandem mass spectrometry is used to determine ion structure and to detect 
and quantify compounds in complex mixtures [12]. In this project, we used tandem 
MS/MS, so any individual ion can be selected and then activated to generate fragments 
characteristic of the selected ion. The fragments originating exclusively from the 
precursor ion can then be analyzed separately with another mass analyzer.  
Figure 1.12 shows the general diagram of an instrument with three 
quadrupoles, used for MS/MS experiments. Quadrupole mass spectrometers are 
symbolized by upper case Q, and RF-only quadrupoles with a lower case q.  
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Fig. 1.12. Diagram of a triple quadrupole instrument. The first and the last (Q1 and Q3) are m/z selectors. 
The centre quadrupole, q2, is a collision cell made up of a quadrupole using RF only. Adapted from [55]. 
Fig. 1.13. Schematic representation of MRM. A specific m/z value is selected in Q1 and is fragment in q2. Q3 
is set to transmit only ions of a selected m/z rather. Adapted from http://www.mrmproteomics.com/ 
 
 
 
 
 
 
 The first quadropole (Q1), selects a “precursor” ion with a desired mass to 
charge ratio from the ESI source. The second quadropole (q2) is the collision cell, 
where collisions with a neutral gas such as N2 or Ar causes the ions to fragment. Ions 
are confined to the collision cell by a quadropole, operated with a radiofrequency 
voltage between the poles. The resulting fragment ions are transmitted to third 
quadropole (Q3). In here, only fragment ions of the desired mass to charge ratio are 
allowed to pass and reach the detector [64].  
Typically the mass spectrometer is set to scan a specific mass range.  This mass 
scan can be wide as in the full scan analysis or can be very narrow as in selected ion 
monitoring. There are many ways to acquire LC/MS/MS data, but in this experiment, 
we used multiple reaction monitoring. 
 
1.3.5.  Multiple Reaction Monitoring (MRM) 
Liquid chromatography coupled with tandem quadropole mass spectrometry 
using triple quadropode mass spectrometry in multiple reaction monitoring mode is 
often the analytical method of choice for determination and quantification of drugs and 
their metabolites in biological samples [64]. So, we combined the MRM experiment 
with the chromatographic separations and thus, we can achieve high levels of 
sensitivity and specificity, by being more selective. 
MRM combines three sectors (fig 1.13): 
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Fig 1.14.  System configuration for infusing a standard into the LC-MS for  tuning. This step is crucial to make sure that the 
instrument is working well for a particular component. The essence of making these infusions is that we want the 
instrument to give the maximum signal possible for our analyte. Because LC-MS relies on chemical ionization, the chemical 
environment in the LC-MS interface influences how ions are generated. So not only are the interface settings important 
(voltages, flow rates, temperatures, vacuum, etc.), but also the chemical composition of the mobile phase from the HPLC 
influences the analyte ionization. Adapted from http://www.sepscience.com/Techniques/LC/Articles/695-/HPLC-Solutions-5-
LC-MS-Calibration-vs-Tuning 
 
The first sector is normally a quadropole, such as the second sector, but the 
third sector is the variable quad: can be a quad, TOF or Trap.  
One typically use MRM to quantify known analytes in complex samples: 
- Drug metabolite and pharmacokinetic studies; 
- Pesticides and herbicides analysis; 
- Screening for target drugs in toxicology and forensic studies [66]. 
In this project, the first step was assure that all of the antidepressants have the 
correct MRM’s, by infusing them. An infusion pump is used to deliver a constant flow to 
analyte into the LC eluent at a point after the chromatographic column and before the 
mass spectrometer ionization source (Fig. 1.15). The analyte is injected under the 
desired chromatographic conditions and the response from the infused analyte 
recorded [64]. The results form a mass spectrum fragmentation.  An example is shown 
in figure 1.14.  
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1.4. Analytical Method Validation 
Method validation is the process by which it is established through laboratory 
studies, that the performance characteristics of the method meet the requirements for 
its intend purpose [67]. The role and progress of LC-MS/MS in toxicology is becoming 
increasingly important in routine analysis. These procedures must be validated before 
use to ensure their reliability and applicability for the intend purpose [64].  
Bioanalysis is one of the branches of analytical science that requires method 
validation: for example, without proving that the results are based on a validated 
method, that study is nowadays meaningless and will not be recognized [68]. The 
international scientific community need published research results that are valid, 
reproducible and comparable [53, 64, 65].  
Method validation is usually considered to be very closely tied to method 
development. Many of the method performance characteristics that are associated with 
method validation are usually evaluated, at least approximately, as part of method 
development. Indeed it is often not possible to determine exactly where method 
development finishes and validation begins [70].  
There are legal, technical and commercial reasons for the need of 
implementation of validation methods [69].  Millions of tests, measurements and 
examinations are made every day in thousands of laboratories around the world. The 
cost of carrying out there measurements is high, but still it is clearly important to make 
a correct measurement and be able to show that the result is correct [70]. In routine 
daily work in clinical and forensic toxicology, unreliable analytical data might not only 
be contested in court, but could also lead to unjustified legal consequences for the 
defendant or to wrong treatment of the patient [65, 67, 68]. 
Organizations like International Union of Pure and Applied Chemistry (IUPAC), 
International Organization of Standardization (ISO), Association of Official Analytical 
Chemist (AOAC), EURACHEM, European Medicines Agency (EMA), Food and Drug 
Administration (FDA) and International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use developed several 
quality guides [53, 66, 68–71]. In several countries, judicial authorities impose 
proficiency testing and/or accreditation according to the International Organization for 
Standardization (ISO) - norms on laboratories performing analysis of certain samples in 
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a forensic or clinical setting. However, all these guidelines seldom provide a practical 
approach to how validation should occur in a particular laboratory setting. Laboratories 
sometimes struggle with the experimental set up, differences in guidelines, choice of 
appropriate decision criteria and statistics [69].  
Due to the importance of method validation, a number of guidance documents 
on this subject have been issued by various international organizations or conferences 
[64]. In these guidelines, definitions, procedures and parameters of validation are 
established. However, there is no consensus on the extent of validation experiments 
and no acceptance criteria for validation parameters of bioanalytical methods in 
forensic an clinical toxicology [69]. Most analytical chemists are aware of the 
importance of validation, but why it should be done and when, and exactly what needs 
to be done, is not always clear [70]. 
Validation is also required when it is necessary to demonstrate the equivalence 
of results obtained by two methods, e.g. a newly developed method and an existing 
standard/regulatory method [73]. Any modification of an analytical method would 
require revalidation of the procedures [72, 73]. 
The developed method will then be validated for the “fitness for use” [65, 74]. 
The validation procedure includes first the validation of the analytical method:  
selectivity, linearity, precision (repeatability, intermediate precision), accuracy, 
recovery, limit of quantification (LOQ) and limit of detection (LOD); and second the 
validation of the stability in the biological matrix. This validation procedure needs to be 
performed prior to the routine use of the analytical procedure [79].  In this project, the 
Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for 
Method Validation in Forensic Toxicology will be followed [80]
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2. RESULTS AND DISCUSSION 
All the results shown in this part concern to citalopram and paroxetine, both 
antidepressives included in this method and commonly found in patient samples.  The 
results regarding the others compounds can be found in appendices (section 6). 
 
A. Trimipramine d3 as Internal Standard 
 
A. 2.1.  Method Development 
This section presents the results obtained during method development, more 
precisely, which parameters to use in the spectrometric conditions . 
 The first step was to prepare the solutions to make the infusions. This allows 
the optimization of some parameters, to establish optimal conditions for each of the 
molecules as the collision energy and cone voltage.  
After these parameters are optimized, fragmentation mass spectra for each 
analyte of interest can be observed with all fragments of the analyte. With the 
fragmentation spectra, it is possible to choose what transitions to monitor. 
For many reasons product ions of ‘low mass’ can be problematic for MRM 
detection. One of these reasons is due to the observation that ‘chemical noise’ 
(background) is considerably more intense at lower m/z values. The ideal product ion 
to use in MRM method would be the one that can be observed at good relative 
abundance in the spectrum. 
The following table (table 2.1) shows the fragmentations of each compound 
that was monitored in this project. The mass spectras were sorted from mzCloud® 
database. The highest fragment was chosen to be monitored, although both fragments 
were written in the method. 
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Table 2.1. Fragmentations of all compounds 
Compound Chemical Structure, Monitored Fragmentations and 
Mass Spectrum 
 
 
Citalopram 
 
 
 
DM Citalopram 
 
 
 
DM Fluoxetine 
 
2 Results and Discussion 
 
30 
 
 
 
DM Tramadol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DM Venlafaxine 
 
 
 
Duloxetine 
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Fluoxetine 
 
 
 
Fluvoxamine 
 
 
 
Melitracene 
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Mianserine 
 
 
 
Mirtazapine 
 
 
 
Paroxetine 
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Reboxetine 
 
 
 
Sertraline 
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Tramadol 
 
 
 
Trazodone 
 
 
 
Venlafaxine 
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A.2.2. Compound Identification 
As was mentioned before, the compounds can be identified by the retention 
time and ionic fragments (m/z) to be monitored in MRM mode. Not all of the 
transitions were monitored, just one – the transition that produces the higher 
fragment. Table 2.2 shows the compounds sorted by retention time and the transitions 
monitored.   
 
Table 2.2. MRM’s monitored and retention time for all compounds. 
Compound Retention Time (min) Transitions (m/z) 
 Q1 Q3 
DM Venlafaxine 2.04 264.20 246.10 
Tramadol 2.36 264.20 58.20 
Mirtazapine 2.73 266.10 72.20 
DM Tramadol 2.93 250.13 44.00 
Trazodone 3.70 373.72 176.05 
Venlafaxine 4.03 278.10 58.00 
Citalopram 4.25 325.19 109.00 
DM Citalopram 4.27 311.20 109.10 
Mianserine 4.31 265.25 208.00 
Reboxetine 4.61 314.10 176.10 
Paroxetine 4.73 330.10 70.20 
Duloxetine 4.86  298.12 154.10 
Trimipramine d3 4.94 298.00 103.00 
Fluvoxamine 4.97 319.19 71.00 
Fluoxetine 5.02 310.19 44.30 
DM Fluoxetine 5.03 296.00 134.10 
Melitracene 5.10 292.20 247.20 
Sertraline 5.15 306.13 159.00 
 
A.2.3. Preliminary studies  
In order to do a preliminary study, the calibration points with non-tricyclic 
antidepressants (ntads) at different concentrations – 1000, 800, 600, 400, 200, 100, 
50, 20 and 10 ng/mL in serum were prepared and analyzed them in the LC-MS/MS 
with the method. It is important to mention that to achieve these results, several runs 
were made and the MRM’s transitions, the gradient and the extraction procedure were 
changed in order to optimize the process.  
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The following results show citalopram and paroxetine’s values and calibration 
curves (table 2.3 and fig 2.1, and table 2.2 and figure 2.3, respectively), from 1000 
ng/mL calibrator to the 10 ng/mL, including a table where the peak areas are shown, 
internal standard area, signal/noise, response, concentration calculated and deviation 
from the standard concentration, and also the calibration curve type (linear).  
Table 2.3. Preliminary study 1 results – citalopram 
# Name Std. Conc. 
(ng/mL) 
Response Conc. %Dev 
1   ntads 100%  782 2.7471 686.6 -12.2 
2   ntads 80%   626 2.2167 592.4 -5.4 
3   ntads 60%   469 1.6829 499.2 6.4 
4   ntads 40%   313 1.1525 408.0 30.3 
5   ntads 20%   199 0.4929 185.3 -6.9 
6   ntads 10%   78 0.3535 95.1 22.0 
7   ntads 5%   39 0.2209 41.5 6.5 
8   ntads 2%   16 0.1427 16.1 0.3 
9   ntads 1%  8 0.1155 5.8 -27.0 
 
 
 
Fig.2.1. Calibration curve from preliminary study results – citalopram 
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Table 2.4. Preliminary study 1 results – paroxetine 
# Name Std. Conc. 
(ng/mL) 
Response Conc. %Dev 
1 ntads 100% A 996 4.9421 939.8 -5.6 
2 ntads 80% A 797 3.8680 735.2 -7.8 
3 ntads 60% A 597 3.5163 668.2 11.9 
4 ntads 40% A 398 2.1141 401.4 0.9 
5 ntads 20% A 199 1.2110 229.6 15.4 
6 ntads 10% A 100 0.5484 103.4 3.4 
7 ntads 5% A 50 0.2980 55.7 11.5 
8 ntads 2% A 20 0.1695 31.3 56.5 
9 ntads 1% A 10 0.0176 2.3 -76.7 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.2. Calibration curve from preliminary study results – paroxetine. 
 
As we can see, in the lowest calibrator, it should have been detected 10 ng/mL 
and the method only detected 2.3 ng/mL, which is far too different. The following 
figure (fig. 2.3) shows paroxetine at 10 ng/mL. The small area of the peak shows a low 
sensitivity of the method, explaining why such a low concentration was detected. 
 
Fig. 2.3. Paroxetine at 10 ng/mL. 
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Taking a look at both calibration curves and their equations, it is clear that the 
regression model can’t meet our objectives. The closer the R2 value is to 1, the better 
the data fits the curve however, R2 can’t determine whether the coefficient estimates 
and predictions are biased, which is why you must assess the residual plot (Fig. 2.4 
and 2.5). Residuals are the deviations of the observed values from the values predicted 
by the applied calibration model [64]. The residuals should not be either systematically 
high or low and should be centered on zero throughout the range of fitted values. In 
other words, the residuals should fall in a symmetrical pattern and have a constant 
spread throughout the range.  
 
 
 
 
 
 
 
Fig. 2.4. Residuals plot of citalopram 
 
 
 
 
 
 
 
Fig. 2.5. Residuals plot for paroxetine 
The residual plot in fig. 2.4 showed a non-random pattern that could indicate 
that the deterministic portion (predictor variables) of the model is not capturing some 
explanatory information that is “leaking” into the residuals.  The residuals plot in fig. 
2.5 shows a more-or-less random distribution, compared to fig. 2.4, who presents an 
inverted-u shape. However, there seems to be an uneven spreading of residuals across 
fitted values and an asymmetrical pattern, suggesting a non-constant variance.  
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Since the calibration models failed and sensitivity was an issue, it was decided to 
change the sample preparation. The sample preparation used (described in 4.6 
Extraction Procedure) only diluted the sample, making decreasing the amount of drug 
injected in the system. After re-searching the literature, it was decided to test a new 
sample preparation, adapted from [81]. This sample preparation was choose because 
of its good results with a similar equipment and method.  
This sample preparation (sample preparation B) consisted in precipitation of 
serum samples (250 µL) with methanol and acetonitrile containing 5 ng of the internal 
standard, trimipramine-d3. The supernatant (900 µL) was evaporated to dryness at 
56ºC under a flow of nitrogen and reconstituted in 100 µL of 50:50 methanol:water 
with 2 mM ammonium acetate.  
Another preliminary study was made (preliminary study 2), considering sample 
preparation B, preparing seven calibrators. Table 2.5 shows the values for citalopram 
fig 2.6 shows its calibration curve. As for paroxetine, the results are in table 2.6 and 
the fig. 2.7 shows the calibration curve. 
Table 2.5. Preliminary study 2 results with sample preparation B – citalopram 
# Name Std. Conc. 
(ng/mL) 
Response Conc. %Dev 
1  ntads 80%  626 12.631 580.7 -7.2 
2  ntads 40%  313 6.6064 298.4 -4.7 
3  ntads 30%  235 5.8343 262.2 11.6 
6  ntads 20% 156 4.1559 183.6 17.7 
4  ntads 10% 78 2.0306 84.0 7.6 
5  ntads 5%  39 1.0544 38.2 -2.0 
7  ntads 1% 8 0.2863 2.2 -22.0 
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Table 2.6. Preliminary study 2 results with sample preparation B – paroxetine 
# Name Std. Conc. (ng/mL) Response Conc. %Dev 
1   ntads 80%  797 5.3613 713.5 -10.5 
2   ntads 40%  398 2.9526 385.0 -3.3 
3   ntads 30%  299 2.5417 329.0 10.0 
6   ntads 20% 199 2.0804 266.0 33.7 
4   ntads 10% 100 0.8974 104.7 4.7 
5   ntads 5%  50 0.4583 44.8 -10.3 
7   ntads 1% 10 0.1698 5.5 -55.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.7. Calibration curve from preliminary study 2 results with sample preparation B – paroxetine. 
 
Fig.2.6. Calibration curve from preliminary study 2 results with sample preparation B – citalopram. 
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For citalopram, the linearity of curves had an improvement and, as we can see 
for fig. 2.8 (paroxetine at 10 ng/mL), sensitivity of the method is no longer an issue 
with this sample preparation. 
Fig.2.8. Paroxetine at 10 ng/mL, with sample preparation B. 
 
Paroxetine’s peak shape at 10 ng/mL improved significantly and the same 
happened to all compounds. Looking at the residuals of both compounds at fig. 2.9 
and 2.10, we can see that sample preparation B proved to be better than the previous 
one, but the results were not good enough to start a validation procedure. Both 
residuals plots show an asymmetrical distribution along the x-axis. Also, the same 
inverted u-shaped is now in both compounds, suggesting that both calibration models 
failed. 
 
Fig. 2.9 Residual plot for citalopram 
 
Fig. 2.10. Residual plot for paroxetine 
-0,5 
0 
0,5 
1 
0 200 400 600 800 
R
e
si
d
u
al
s 
Std. Concentration (ng/mL) 
Citalopram 
-0,4 
-0,2 
0 
0,2 
0,4 
0,6 
0 200 400 600 800 1000 R
e
si
d
u
al
s 
Std. Concentration (ng/mL) 
Paroxetine 
2 Results and Discussion 
 
42 
 
  Trimipramine-d3 is a deuterated internal standard, based on trimipramine, a 
tryciclic antidepressant (and we are working with non-tryciclic and analgesics), so the 
physical-chemical properties are not so similar between internal standard and analytes. 
It was decided to test others internal standards, deuterated compounds that were 
present in our list of compounds: mirtazapine-d4, paroxetine-d6, reboxetine-d5 and 
venlafaxine-d6. 
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B. Mirtazapine-d4, paroxetine-d6, reboxetine-d5 and venlafaxine-d6 as 
Internal Standards 
 
B.2.1. Method Development 
 The first step was infusions, which were made to establish optimal conditions 
for each of the molecules as the collision energy and cone voltage. The results from 
the infusions are given in table 2.7. 
Table 2.7: MRM transitions used collision energies and cone voltages. 
Compound Transitions (m/z) Collision 
Energy (V) 
Cone 
Voltage (V) 
Dwell time 
(s) Precursor Ion Product Ion 
Mirtazapine-d4 270.1 76 24 30  
 
0.01 
Paroxetine-d5 336.1 76.2 30 29 
Reboxetine-d6 319.2 176.1 12 22 
Venlafaxine-d6 284.2 64.0 20 28 
 
To find out which concentration should be used all the internal standards were 
injected in different concentrations (1 µg/mL, 100 ng/mL and 20 ng/mL). The agreed 
concentration to all of the compounds was 100 ng/mL, so a new precipitation fluid (PF 
II) was made (100 ng/mL of all the internal standards in 50:50 methanol:acetonitrile).  
B.2.2. Preliminary study  
 Preliminary study 3 consists in sample preparation B but, with the internal 
standards mentioned before. The results for citalopram are in table 2.8 and fig. 2.11, 
while the results for paroxetine are given in table 2.9 and figure 2.12. 
Table 2.8. Results from the preliminary study 3 with sample preparation B and new internal standards – 
citalopram 
# Name Std. Conc. 
(ng/mL) 
Response Conc. %Dev 
1   ntads 80%  626 9.2997 650.2 3.9 
2   ntads 60%  469 7.1697 501.6 7.0 
3   ntads 30%  235 3.2158 225.9 -3.9 
6   ntads 20% 199 2.5995 180.4 -9.3 
5   ntads 5%  39 0.5351 38.9 -0.3 
5   ntads 2%  16 0.2148 16.6 3.5 
7   ntads 1% 8 0.1180 9.8 -1.9 
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Fig.2.11. Calibration curve – citalopram 
 
 
Table 2.9. Results from the preliminary study 3 with sample preparation B and new internal standards – 
paroxetine 
# Name Std. Conc. 
(ng/mL) 
Response Conc. %Dev 
1   ntads 80%  797 51.688 826.2 3.7 
2   ntads 60%  597 37.251 595.3 -0.3 
3   ntads 30%  299 17.613 281.4 -6.2 
6   ntads 20% 199 11.750 187.6 -5.7 
5   ntads 5%  50 3.232 51.5 2.9 
5   ntads 2%  20 1.303 20.5 2.6 
7   ntads 1% 10 0.671 10.5 5.2 
 
 
Fig.2.12. Calibration curve - paroxetine 
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The preliminary study 3 with the new internal standards was successful – 
linearity was achieved and the deviations’-issue was solved (all deviations were 
significantly reduced). The fact that paroxetine-d6 was used as internal standard for 
paroxetine explain the excellent results, better than for citalopram. Taking a look at the 
residuals plots (Fig. 2.13 and 2.14), both residuals plots showed a random distribution 
and a more or less symmetrical pattern.  
 
Fig. 2.13. Residuals plot – citalopram 
 
 
Fig. 2.14. Residuals plot – paroxetine 
 
The following table (table 2.10) shows only the R2 for the compounds achieved 
with this preliminary study and the internal standard chosen, based on this last 
parameter.  
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Table 2.10. Internal standards used for every compound and R2 achieved on this last preliminary study  
Compound IS R2 
Citalopram Reboxetine-d5 0.992 
DM Citalopram Paroxetine-d6 0.994 
DM Fluoxetine Reboxetine-d5 0.997 
DM Tramadol Venlafaxine-d6 0.992 
DM Venlafaxine Venlafaxine-d6 0.998 
Duloxetine Reboxetine-d5 0.999 
Fluoxetine Paroxetine-d6 0.998 
Fluvoxamine Venlafaxine-d6 0.998 
Melitracene Paroxetine-d6 0.993 
Mianserine Reboxetine-d5 0.998 
Mirtazapine Mirtazapine-d4 0.999 
Paroxetine Paroxetine-d6 0.999 
Reboxetine Reboxetine-d5 0.998 
Sertraline Venlafaxine-d6 0.998 
Tramadol Venlafaxine-d6 0.992 
Trazodone Paroxetine-d6 0.992 
Venlafaxine Venlafaxine-d6 0.999 
 
Since the results from the preliminary study were good enough, it was decided 
to proceed for the validation of the method, following the Scientific Working Group for 
Forensic Toxicology (SWGTOX) guideline. 
 
B.2.3. Analytical method validation 
 
B.2.3.1. Selectivity 
It is very important to obtain a signal free from the influence of other species 
contained in the sample and this signal should be unequivocally assigned to the 
analyte of interest. Potential interfering substances in a biological matrix include 
endogenous matrix components, metabolites, decomposition products, medication and 
other exogenous compounds [74].  
Ten independent sources of blank whole blood were chosen, from previously 
analyzed cases in the Toxicology Lab of Ghent Universitary Hospital, to evaluate matrix 
interferences. The blank matrix samples were extracted without the addition of internal 
standard and analyzed using the new developed method. No interferences were noted 
after analysis of the blank plasma samples. An example is shown in the next figure (fig. 
2.15). The 3rd MRM represents mirtazapine-d4, the 6
th, venlafaxine-d6, the 8
th, 
reboxetine-d5  and the 11
th, paroxetine-d6. 
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Fig. 2.15. Random patient sample taken from the Toxicology Lab, previously analyzed and the results were negative 
regarding non-tricyclic antidepressants. As we can see from the chromatograms, none of the compounds were found, 
as it was expected. There is a peak for trazodone, however, the peak area is only 1737.924, while the peak area for 
the lowest calibrator, at 38 ng/mL has the area of 34463.969. This peak is not considered as interference, because is 
less that 20% of the lowest calibrator.  
One of the blank matrix samples was selected and IS was added (5 ng/mL). 
This was to demonstrate that the internal standard would not interfere with the signal 
for the other compounds. As we can see for fig. 2.16, all detected peaks represent the 
internal standards, which mean that there is no interference with the other compounds 
or their non-deuterated forms. 
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Fig. 2.16. Chromatograms of a blank sample matrix with only internal standards. The results show peaks 
for the deuterated forms, but all the others chromatograms were clean. 
Another blank matrix sample was fortified with antidepressants (200 ng/mL) 
and analyzed without IS. This was to evaluate whether the unlabeled analyte ions 
interfere with the signal for the other compounds. The results demonstrated no 
interferences between the analyte and the internal standard. All analytes were 
detected; however, it is necessary to confirm if mirtazapine, paroxetine, reboxetine and 
venlafaxine are in the sample or if the signal is due to their deuterated forms (fig. 
2.17). 
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Fig. 2.17. Chromatograms of a blank sample matrix with only antidepressants. The results don’t show 
peaks for the deuterated forms, so we can conclude that there are no interferences between IS and ntads. 
Interference from possible co-administrated medications is also a very important 
test – many patients don’t only take non-tricyclic antidepressants, they can also be 
taking tricyclic ones. To evaluate the interferences between these two similar 
categories, a solution was injected with tryciclic antidepressants diluted in serum to a 
concentration of 200 ng/mL for all the compounds. The tryciclic antidepressants 
present in the sample are described in table 2.11 and the results are in fig. 2.18. 
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Table 2.11. Name, molecular formula and weight (MW in g/mol) of tricyclic antidepressants used for 
checking interference.  
  
 
  
 
Amitriptyline 
MW: 277.403 
Clomipramine 
MW: 314.900 
Desipramine 
MW: 266.381 
Dosulepine 
MW: 295.450 
Doxepin 
MW: 279.376 
Imipramine 
MW: 280.407 
  
 
 
  
Maprotiline 
MW: 277.403 
Norclomipramine 
MW: 337.290 
Nordosulepine 
MW: 282.450 
Normaprotiline 
MW: 264.403 
Nortriptyline 
MW: 263.380 
Trimipramine 
MW: 294.434 
 
 Fig. 2.18.  Chromatograms from the tricyclic antidepressants sample. Again, trazodone shows a peak, however, like before, 
this peak doesn’t have enough area to be considered interference. All other chromatograms were considered noise. 
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All interference studies were successful, which means the method only detects the 
seventeen analytes it is supposed to. Although the figures don’t show, both transitions 
were always used to make sure about the compound detected, except for the internal 
standards, where only one transition was used. Since the selectivity part was 
completed with success, the calibration model comes next in the validation plan.  
 
B.2.3.2. Calibration Model 
It is important to know the response of the instrument with regard to the 
concentration of analyte over a specified concentration range. The calibration range is 
defined as “the region between the limits within which a quantity is measured, 
received or transmitted, expressed by stating the lower and upper range values”[82]. 
This can be performed by the analysis of spiked calibration samples and plotting the 
resulting responses versus the corresponding concentrations [83]. 
All calibration curves had a R2 = 0.99 or higher, except for fluoxetine and 
tramadol. The calibrations curves for citalopram and paroxetine are represented in the 
following figures (fig. 2.19 (a) and 2.20 (a)).   
However, the calibration model cannot be evaluated simply via its correlation 
coefficient (R2). Indeed, a significant proportion of errors at the lower end of the 
calibration curve can coexist with acceptable R and R2 values. Therefore, other 
parameters, such as visual inspection of plots of residuals versus concentration allows 
us to determine if the variances appear to be equal across the calibration range with a 
similar degree of scatter at each concentration - fig. 2.19 (b) and 2.20 (b).   
Fig. 2.19. Calibration curve (a) and plot of residuals vs. concentration (b) for citalopram  
(b)  
(a)  
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B. 2.3.2.1. Grubbs Test 
Grubbs test was used to detect outliers in a data set that follows 
an approximately normal distribution. More than two outliers in a complete data-set of 
a calibration model experiment may indicate serious problems with the method, which 
requires further investigation [64]. In following statistical tests, we only present the 
results for citalopram, but the same calculations were made for all compounds.  In 
table 2.12, the results for citalopram show an outlier, because Gmax in calibrator 5% is 
higher than 1.71, the critical value. For future analysis, the highest response (1.51) 
was eliminated, and without this value, Gmax = 1.28, below the critical value. 
 
Table 2.12. Grubbs test for citalopram values 
Name Response G Min G Max 
  ntads 30%  9.11 10.20 9.86 9.79 9.98 1.65 1.02 
  ntads 20%  6.37 6.60 6.28 6.69 5.67 1.63 0.91 
  ntads 10%  3.09 3.17 2.95 3.02 3.16 1.35 0.99 
  ntads 5% 1.39 1.36 1.37 1.51 1.34 0.72 1.74 
  ntads 2%  0.57 0.68 0.59 0.68 0.62 1.08 1.05 
  ntads 1%  0.32 0.29 0.30 0.23 0.32 1.67 0.76 
B.  2.3.2.2. Fisher Test 
The next step is to test for homogeneity of variances (Fisher-Snedecor 
Distribution). This test is used to compare two variances and to see if the distribution is 
similar in lowest and highest concentration.  
Fig. 2.20. Calibration curve (a) and plot of residuals vs. concentration (b) for paroxetine  
(a)  
(b)  
(a)  
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Table 2.13 shows the standard concentrations, the mean, standard deviation 
and coefficient of variance of responses obtained (responses are already shown in 
table 2.12). With this data, it’s possible to calculate TV and if it’s higher than pH0,there 
is inhomogeneous variances (heteroscedasticity) over the calibration range.  
Table 2.13. Results obtained in the test of homogeneity of variances for citalopram 
Std. Concentration (ng/mL) Ym SD %CV 
8 0.29 0.04 12.5 
16 0.63 0.05 8.10 
39 1.40 0.06 4.60 
78 3.08 0.10 3.20 
156 6.32 0.40 6.40 
235 9.79 0.41 4.20 
 
According to table 2.13,     
     
     
        , while     = 0. The H1 hypothesis in 
section 4.7.2.2 is accepted and data suggest inhomogeneous variances. The next step 
is to do a Linearity test to check if linear is the best model to fit the data. 
B.  2.3.2.3. Mandel test 
There are no outliers and inhomogeneous was proven in the section before; 
one must evaluate the linearity and check which model (linear or quadratic) fitted 
better in the calibration data.  
The possibility of both models have similar performance is 64% (pH0 = 0.064). 
Thus, we decided to choose the linear adjustment, since it has more degrees of 
freedom (table 2.14). 
Table 2.14. Results obtained with linearity test 
Linear 
 
 Quadratic  
SS 0.043  SS 0.011 
ndf 4  ndf 3 
VarFit 0.011  VarFit 0.004 
StdFit 0.103  StdFit 0.060 
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B.  2.3.2.4. Weighted Least Squares 
In case of heteroscedasticity data set, weighted least squares should be 
applied. Slops and intercepts of the calibration lines were calculated using weighted 
linear regression: 
 
 
, 
 
  
, 
 
 
 and  
 
  
 [83]. The best weighting factor is the one which 
presents the lowest value of the sum of the relative errors         ) in the working 
range.  
To test Weighted Least Squares (WLS), six calibrators were analyzed, repeating 
the same experiment for three different days. Evaluation of response variability was 
checked and it was shown that statistical dispersion is in direct proportion to the 
concentration (fig. 2.21) and %CV is more or less constant throughout the working 
range (fig. 2.22), giving more emphasis to WLS analysis.  
 
 
 
As a measure to choose the weighting factor, it was used the percentage of 
relative error (%RE), which compares the estimated concentration, from the regression 
equation obtained for each   , with nominal standard concentration in the sample. The 
        of the different weighting factors were compared, and in citalopram case, the 
model chosen is 
 
  
, since the error associated with this model is the lowest (table 
2.15). Plots of %RE versus concentration for the four models of citalopram obtained in 
the study are shown in figure 2.23. For all the other compounds, the analysis is 
presented in appendices 6.1 and 6.2 and a summary of calibration model is in table 
2.16. 
 
Fig. 2.21. Evaluation of dispersion and standard 
concentration 
Fig. 2.22. Evaluation of %CV and standard 
concentration 
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Table 2.15. Relative errors (%RE) and the respective sum generated by the use 
of simple linear regression and weighted linear regression for each weighting 
factor    for the intra-assay data 
 
Citalopram nominal 
concentration (ng/mL) 
Model 
 
 
 
 
  
 
 
 
 
 
  
 
782 12.1 14.1 12.2 12 
469 18.6 12.1 19.8 16.2 
235 28.9 35.4 28 30.9 
156 15.9 12.3 16.4 14.8 
39 11.2 9.1 9.1 10.7 
8 22.8 26.4 22.7 27.3 
        109.5 109.4 108.2 111.9 
 
Fig. 2.23. Percentage of relative error (%RE) versus standard concentration obtained for models 
 
 
, 
 
  
, 
 
 
 
and  
 
  
. All models seem to behave equally but 
 
  
 has the lowest        .  
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Table 2.16. Summary of calibration model for all compounds 
Compound Working range 
(ng/mL) 
Calibration curve and 
errors 
R2 Regression Interval of confidence Weighting 
factor 
     Lower limit 
(95%) 
Upper limit 
(95%) 
 
Citalopram 8-235 Y=0.04 (0.2).X - 0.14 
(2.5) 
0.995 Linear -0.257 0.007  
  
 
DM 
Citalopram 
20-400 Y=-9e-5X2 (0.7) + 0.14X 
– 1.10 (3.7) 
0.994 Quadratic -0.163 1.924  
 
 
DM 
Fluoxetine 
50-600 Y=0.01 (0.0).X + 0.19 
(0.7) 
0.991 Linear 0.287 0.101  
 
 
DM 
Tramadol 
10-300 Y=0.02 (0.4).X - 0.04 
(2.2) 
0.993 Linear -0.151 0.073  
  
 
DM 
Venlafaxine 
39-469 Y=0.002 (0.0).X + 0.02 
(0.4) 
0.991 Linear -0.007 0.050  
  
 
Duloxetine 20-400 Y=0.02 (0.2).X+0.12 
(1.5) 
0.994 Linear -0.012 0.249  
  
 
Fluoxetine 50-600 Y=0.01 (0.0) X - 0.33 
(0.9) 
0.982 Linear -0.461 0.193  
  
 
Fluvoxamine 50-600 Y=0.01 (0.1) X + 0.17 
(2.0) 
0.993 Linear -0.033 0.306  
 
 
Melitracene 10-800 Y=0.05 (0.5) X - 1.64 
(1.6) 
0.994 Linear -2.381 0.907  
  
 
Mianserine 10-300 Y=0.01 (0.0) X - 0.02 
(0.5) 
0.995 Linear -0.047 0.001  
  
 
Mirtazapine 10-300 Y=0.10(0.5)X-0.40(2.7) 0.996 Linear -0.782 0.023  
  
 
Paroxetine 20-400 Y=0.06 (0.6).X – 0.14 
(2.1) 
0.995 Linear -0.461 0.277  
  
 
Reboxetine 20-400 Y=0.02 (0.1).X + 0.03 
(1.8) 
0.991 Linear -0.175 0.236  
  
 
Sertraline 50-600 Y=0.01 (0.1) X + 0.05 
(0.3) 
0.992 Linear -0.019 0.112  
 
 
Tramadol 10-800 y = -1e-7X2 (0.0) + 
0,002X - 0.04 (0.5) 
0.985 Quadratic -0.059 0.004  
  
 
Trazodone 213-2560 y = -3e-6 (0.1).X2 + 
0.02X + 0.69 (3.1) 
0.994 Quadratic -0.015 0.012  
  
 
Venlafaxine 50-600 Y=0.01 (0.2).X - 0.04 
(2.5) 
0.990 Linear -0.020 0.125  
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B.2.3.3. Imprecision and accuracy (Bias) 
To establish the method’s bias and precision, three pools of fortified matrix 
samples were prepared at the following concentrations:  low (50 ng/mL for all 
compounds, except citalopram and desmethylvenlafaxine, 39 ng/mL and trazodone, 
213 ng/mL), medium (400  ng/mL for all, citalopram and desmethylvenlafaxine, 313 
ng/mL and trazodone, 1707 ng/mL) and high (1000 ng/mL for all, citalopram and 
desmethylvenlafaxine, 782 ng/mL and trazodone, 4267 ng/mL). Each concentration 
pool of fortified samples was analyzed in triplicate (A, B and C) on five separate days 
along with a freshly prepared calibration curve (6 calibrators).  
The bias was calculated by first determining the mean for each concentration. 
An example (citalopram) of how it was calculated for the lowest concentration is given 
in table 2.17. 
Table 2.17. Results for citlopram at low concentration (39 ng/mL) 
  Run 1 Run 2 Run 3 Run 4 Run 5 
A 41.6 42.7 34.1 45.7 44.3 
B 42.9 45.1 34.2 42.6 43.8 
C 41.8 36.8 34.7 45.2 43.4 
Mean 42.1 44.9 34.3 44.5 43.8 
SD 0.7 4.3 0.3 1.7 0.5 
CV 1.7% 10.3% 0.9% 3.7% 1.0% 
%Bias 2.04% 0.66% -16.79% 7.85% 6.24% 
 
B. 2.3.3.1. Cochran Test 
One of the assumptions for the usage of ANOVA is the homogeneity of 
variances. Following section 4.7.3.1., if Ccal is higher than the Ccrit, we concluded that 
the differences between the variances are statically significant (table 2.18). 
Table 2.18. Results obtained with Cochran test. 
Compound Concentration (ng/mL) Ccal Ccrit 
Citalopram 39 0.836 0.789 
In table 2.17, the higher bias belongs to day 3. If removed from the analysis 
and eliminate the outlier from run 2 (36.8 ng/mL), Ccal = 0.447 and there is no 
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statistical significance between variances. To calculate if there is a significant 
difference between days with ANOVA analysis: 
   
    
    
      and           
There is a possibility of 40.8% of no difference between the concentrations of 
the four runs and the dispersion estimates are: 
                                  
                                
Using the same procedure for all the compounds, by checking first if there is 
homogeneity of variances with Cochran test and, if there’s not, removing the day with 
the higher bias, results in table 2.19 and 2.20 were achieved. 
Table 2.19. Results for BIAS and imprecision for citalopram, desmethylcitalopram, desmethylfluoxetine, 
desmethylvenlafaxine, duloxetine, fluoxetine, fluvoxamine and melitracen 
     
% BIAS 
% Imprecision 
  
Compound Conc. level   Within Run CV  Between Run CV  
1. Citalopram 
  
  
Low 5.8  5.8  3.2  
Medium 1.4  4.2  4.3  
High 5.7  4.2  3.4  
2. DM Citalopram 
  
Low 10  14.3  7.1  
Medium 9.9  5.1  5.6  
High -3.4  5.4  4.9  
3. DM Fluoxetine 
  
  
Low 12.3  5.2  9.3  
Medium 8.5  5.4  5.2  
High -9.0  5.6  4.2  
4. DM Tramadol 
  
  
Low 2.2  10.6  9.4  
Medium 0.0  4.8  5.4  
High 4.0  7.1  4.6  
5. DM  Venlafaxine 
  
Low 9.6  7.3  12.3  
Medium 4.1  3.9  8.2  
High 11.4  5.2  5.0  
6. Duloxetine 
  
  
Low 8.1  8.7  5.8  
Medium 6.9  5.6  5.3  
High 3.7  4.8  4.4  
7. Fluoxetine 
  
  
Low 0.9  9.3  4.8  
Medium 10.7  11.8  7.2  
High -2.2  8.9  7.1  
8. Fluvoxamine 
  
  
Low 11.9  6.3  10.2  
Medium 10.2  5.1  5.5  
High -2.4  5.0  4.9  
9. Melitracene 
  
  
Low 1.4  8.7  8.1  
Medium -2.2  9.8  4.8  
High 7.8  8.0  5.9  
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Table 2.20. Results for BIAS and imprecision for mianserin, mirtazapine, paroxetine, reboxetine, sertraline, 
trazodone and venlafaxine 
     
% BIAS 
% Imprecision 
  
Compound Conc. level    Within Run CV  Between Run CV  
10. Mianserine 
  
  
Low 9.8  7.9  6.5  
Medium 6.2  3.5  4.7  
High 0.4  5.1  3.6  
11. Mirtazapine 
  
  
Low 4.9  8.1  4.9  
Medium -1.3  4.6  7.8  
High 0.2  6.5  7.1  
12. Paroxetine 
  
  
Low 1.0  10.1  8.0  
Medium 3.2  7.1  8.2  
High 1.4  6.7  5.2  
13. Reboxetine 
  
  
Low -0.9  3.5  7.0  
Medium 1.8  3.3  4.7  
High 4.5  4.8  3.6  
14. Sertraline 
  
  
Low 8.8  7.9  10.8  
Medium 6.7  6.5  4.5  
High -0.1  5.5  6.3  
15. Tramadol 
  
  
Low 7.5  12.3  7.0  
Medium 15.7  8.7  5.8  
High 4.7  9.2  7.5  
16. Trazodone 
  
  
Low 18.4  5.8  6.3  
Medium 7.2  5.0  4.9  
High -6.9  4.4  3.1  
17. Venlafaxine 
  
  
Low 10.1  6.1  5.1  
Medium 3.1  2.9  5.1  
High 5.4  5.2  4.4  
 
The Scientific working group for forensic toxicology (SWGTOX) says that both 
imprecision and bias shouldn’t exceed 20%, and, as we can see, all of the compounds 
fit in that criterion.  
B.2.3.4. Carry-Over 
As mentioned above, carry-over is the amount of the analyte retained in an LC 
system from a preceding sample that carries over into the next injected sample; also, 
there are certain compounds with mutual affinity and lead to the formation of 
dimmers. These dimmers can manage variations and abnormal results [84]. Carry-over 
phenomenon can be measured by the response of the blank sample or the lowest 
calibrator after the injection of a preceding sample at high concentration. 
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Following section 4.7.5,  if the Δlow is calculated and if it exceeds 2 × SD low 
unaffected, carry-over is present. Table 2.21 shows the results for all compounds: 
Table 2.21. Results for carry-over 
Compound Δlow 2 x SD low 
Citalopram 1.4 1.8 
DM Citalopram 4.2 4.8 
DM Fluoxetine 8.7 8.8 
DM Tramadol 0.8 1.0 
DM Venlafaxine 0.8 1.1 
Duloxetine 6.3 7.3 
Fluoxetine 4.0 4.5 
Fluvoxamine 4.9 5.1 
Melitracene 1.9 2.4 
Mianserine 2.5 2.6 
Mirtazapine 0.2 1.2 
Paroxetine 4.6 5.8 
Reboxetine 1.0 1.6 
Sertraline 4.3 5.7 
Tramadol 0.9 1.3 
Trazodone 17.9 22.7 
Venlafaxine 0.8 1.3 
 
Sample carry-over is a major problem that can influence the accuracy and 
precision of the method, with the consequences being more pronounced at lower 
concentrations. As we can see in table 2.21, carry-over is absent in all compounds (the 
criterion fits).  
 
B.2.3.5. Matrix Effects 
Matrix effect (ME) causes a compound’s response to differ when analyzed in a 
biological matrix compared to a standard solution. Molecules originating from the 
sample matrix that coelute with the compounds of interest can interfere with the 
ionization process in the mass spectrometer, causing ionization suppression or 
enhancement [85]. As a result, depending on the environment in which the ionization 
and ion evaporation processes takes place, there is a decrease in analyte ionization 
(ion suppression) or an increase in this ionization (ion enhancement) [86].  
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The origin and mechanism of matrix effects are still not fully understood. It is 
generally accepted that matrix effect evaluation should be a mandatory part of the 
validation procedure of all LC–MS based methods. Consensus on how these matrix 
effects should be evaluated is obviously needed. [85]. Ionization 
suppression/enhancement was evaluated using the description in section 4.7.6 
Extraction efficiency (RE) and process efficiency (PE) were also calculated. 
Ion suppression may adversely affect both the sensitivity and the reproducibility 
of a particular assay [87]. All the data are described in appendix 6.5. and final results 
for low and high concentrations are in table 2.22 and 2.23, respectively. 
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Table 2.22. Results for matrix effects at low concentrations 
 Low Concentration 
 % Matrix effects % Extraction efficiency % Process efficiency 
Citalopram  82 85 70 
DM Citalopram  78 81 63 
DM Fluoxetine  45 71 32 
DM Tramadol  99 99 95 
DM Venlafaxine  97 109 106 
Duloxetine  42 59 25 
Fluoxetine  49 46 22 
Fluvoxamine  77 72 56 
Melitracene  36 64 23 
Mianserine  54 64 35 
Mirtazapine  95 96 91 
Paroxetine  45 62 28 
Reboxetine  87 87 76 
Sertraline  27 83 22 
Tramadol  93 82 77 
Trazodone  88 84 73 
Venlafaxine  100 96 96 
Internal Standards    
Mirtazapine-d4 91 98 89 
Paroxetine-d6 47 73 34 
Reboxetine-d5 89 92 81 
Venlafaxine-d6 96 100 96 
 
For example, in citalopram’s case, the matrix effect was 82%, which means 
there was 18% of ion suppression. However, some of the results were really low, 
considered table 2.22. Fluoxetine, melitracene and paroxetine have low values in ME 
and PE. The internal standard used to measure these compounds is paroxetine-d6, 
which also has low percentages in ME and PE. So, the internal standard is 
compensating for the low percentages. 
As for DM fluoxetine, duloxetine and mianserine, both have reboxetine-d5 as an 
internal standard, which doesn’t compensate much for the low values. For example, for 
DM fluoxetine, if the process efficiency is 32%, this means that 68% of the signal is 
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lost. One of the possible explanations is that the extraction procedure is not 
appropriate for this specific compound (extraction efficiency equal to 71%). This is also 
the case for duloxetine and mianserine, due to its very low process efficiency (25 and 
35%, respectively).  
Sertraline has the biggest loss in signal, with 78% lost. Not much is lost due to 
ion suppression (only 27%) and the extraction efficiency is quite high (83%). Sertraline 
is the last compound to be eluted, with the highest retention time. Many compounds 
are eluted at the same time, causing interference with each other and affecting the 
ionization. 
Table 2.23. Results for matrix effects at high concentrations 
 High Concentration 
 % Matrix effects % Extraction efficiency % Process efficiency 
Citalopram  99 78 78 
DM Citalopram  93 80 74 
DM Fluoxetine  70 51 36 
DM Tramadol  94 92 87 
DM Venlafaxine  94 102 96 
Duloxetine  64 42 27 
Fluoxetine  63 36 23 
Fluvoxamine  90 64 58 
Melitracene  49 45 22 
Mianserine  66 52 70 
Mirtazapine  97 84 81 
Paroxetine  68 45 31 
Reboxetine  98 78 77 
Sertraline  43 50 22 
Tramadol  98 84 82 
Trazodone  97 81 78 
Venlafaxine  108 87 93 
Internal Standards    
Mirtazapine-d4 97 80 77 
Paroxetine-d6 72 48 34 
Reboxetine-d5 95 78 74 
Venlafaxine-d6 102 91 93 
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For high concentrations, we have the same compounds giving low percentages. 
Fluoxetine, melitracene and paroxetine have low values regarding for process and 
extraction efficiency, just like paroxetine-d6. So, once again, the internal standard is 
compensating the low percentages. 
The same happens to DM fluoxetine and duloxetine, with low values to process 
and extraction efficiency. The high value in matrix effects suggests that the loss of the 
signal is due to ion suppression.  Sertraline has low values in the three parameters, 
which can indicate that the loss of the signal is caused both by ion suppression and 
extraction procedure.  
The ion suppression that both low and high concentrations show can be caused 
by the co-elution of several compounds, causing interference in ionization and so, 
losing the signal of the analytes. In figure 2.24., it is possible to see that there is a 
significant decrease of matrix effects from 4 min. This corresponds to the co-elution of 
paroxetine, duloxetine, fluvoxamine, fluoxetine, DM fluoxetine, melitracene and 
sertraline (in this order), the compounds that presented the highest lost of signals. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.24. Matrix effects vs. retention time of the analytes at high concentrations.  
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B.2.3.6. Limits 
B.2.3.6.1 Limit of Detection 
There are different approaches for the determination of LOD: the precision and 
accuracy of the data, the signal to noise ratio (S/N), and the parameters of the 
analytical curve. The estimation method based on parameters of the analytical curve 
shows greater statistical reliability and is useful for any quantitative method that 
follows a linear calibration model. So, the LOD was estimated based on the equations 
in Section 4.7.7.  
B.2.3.6.2. Limit of Quantification 
As for the LOQ, three runs were made (Run 1, 2 and 3) with six calibrators 
(1000, 600, 300, 200, 50 and 10 ng/mL) and three quality controls (QC) in duplicate 
(with 50, 20 and 10 ng/mL). From these QC’s, LOQ is chosen. It is important to check 
that the lowest concentration should be able to achieve acceptable detection, 
identification and also, the bias and imprecision should not be more that ± 20%. The 
following table (table 2.24) shows the results and all the data. 
Table 2.24: Results for LOD and LOQ in ng/mL 
Compound LOD (ng/mL) LOQ (ng/mL) 
Citalopram 3 10 
DM Citalopram 1 20 
DM Fluoxetine 3 10 
DM Tramadol 4 20 
DM Venlafaxine 4 10 
Duloxetine 2 20 
Fluoxetine 7 20 
Fluvoxamine 5 10 
Melitracene 1 20 
Mianserine 4 20 
Mirtazapine 1 10 
Paroxetine 1 20 
Reboxetine 3 20 
Sertraline 2 20 
Tramadol 8 20 
Trazodone 6 85 
Venlafaxine 2 20 
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B.2.3.7. Stability 
As the samples may not always be analyzed immediately after extraction due to 
large batches or unforeseen delay, it is important to evaluate the impact of room 
temperature storage of processed samples sitting on the autosampler.  
 
B.2.3.7.1. Processed Samples 
To analyze stability in processes samples, twelve aliquots of fortified matrix 
samples at two concentrations were extracted (20 and 800 ng/mL). The concentration 
pool was then divided into 12 autosampler vials and placed in the autosampler. The 
first vials of each level was injected three times to represent the time zero (T0). The 
remaining vials of each concentration were analyzed in triplicate every six hours up to 
66 hours. Analyte signals from the triplicate analyses were averaged and compared to 
the T0 signals.  
By plotting the average peak areas for each compound and internal standards, 
it is possible to evaluate the processed samples while they were stored on the 
autosampler. As the required bias is  20%, two lines were made, the red one which 
correspond to an increase of 20% in signal, compared to T0, and a green one which 
correspond to a 20% decrease in signal.  
These data appear to suggest all the compounds are not stable after 6h in the 
autosampler (Fig. 2.25 – 2.28). It was noted that at the 6-hour mark, stability seemed 
to have dropped very close to the “instability” point, except for DM Tramadol in the 
highest concentration. The same happens for the internal standards, showing some 
instability after 12h (in appendice 6.6). 
If the areas of compounds and internal standards are decreasing throughout 
time, a compensation is very clear, since what makes the calibration curve is the ration 
between these areas. In fig. 2.29, area ratio between citalopram and reboxetine-d5 at 
20 ng/mL vs. time is shown and, if both area decrease, the response will have more or 
less the same values. However, there’s instability 18h after extraction, so based on this 
study, it was decided that samples remaining in the autosampler more than 18h should 
be re-extracted. 
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Figure 2.30 shows the calculated concentration of Citalopram at 20 ng/mL vs. 
time. As one can see, the calculated concentration never exceeds or is inferior 20% of 
the calculated concentration in T0. The same happens with the other compounds at 
low and high concentrations, but the laboratory maintains the decision mentioned 
before, of not analyzing samples after 18h of extraction. 
 
 
Fig. 2.25. Citalopram at 20 ng/mL. The green line represents the decrease of the peak 
areas, while the red line represents 20% peak area increase, compared to T0 and the 
blue line represents 20% peak area decrease. 
 
Fig. 2.26. Citalopram at 800 ng/mL 
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Fig. 2.27. Paroxetine at 20 ng/mL 
 
Fig. 2.28. Paroxetine at 800 ng/mL 
 
 
 
 
 
 
Fig. 2.29. Area ratio was calculated with citalopram and reboxetine-d5 results. The blue line represents the 
response, while the red line represents 20% response increase, compared to T0 and the green line 
represents 20% response decrease. Since both compounds show a decrease on areas, the response seems 
to show more stability and so, the samples can remain in the autosampler until 18h after extraction. 
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Fig. 2.30. Calculated concentration in ng/mL vs time in citalopram’s case at 20 ng/mL. 
B.2.4. Application of the developed analytical method to real samples 
An analytical method was developed and validated for the determination of 15 
antidepressants and 2 analgesics in serum by LC-MS/MS. To complete this study even 
more, it is important to use the method developed in patients’ samples where these 
drugs are indeed present.  
B.2.4.1. Association for Quality Assessment in Therapeutic Drug 
Monitoring and Clinical Toxicology (KKGT) Samples 
The first analyzed samples were provided by Association for Quality Assessment 
in Therapeutic Drug Monitoring and Clinical Toxicology (KKGT). The objective of the 
association is to stimulate the quality of Therapeutic Drug Monitoring, Clinical 
Toxicology and the analysis of other substances in laboratories. Every year, KKGT 
releases a quality control samples for psychotherapeutic drugs (table 2.25). According 
to the report from 2015 [88], psychotherapeutic drugs III, IV and V are indicated the 
test with the new method. 
Table 2.25. KKGT 2015 – compounds and concentrations presented in psychopharmaceuticals samples 
Compound Concentration (µg/l) 
Psychopharmaceuticals III 
Fluoxetine 299.1 
DM Fluoxetine 353.6 
Fluvoxamine 151 
Mirtazapine 75.85 
Paroxetine 46.59 
Psychopharmaceuticals IV 
Citalopram 90.70 
DM Citalopram 36.27 
Psychopharmaceuticals V 
Sertraline 59.12 
Venlafaxine 61.40 
DM Venlafaxine 204.7 
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Fluoxetine, DM Fluoxetine, Fluvoxamine, Mirtazapine, Paroxetine, Citalopram, 
DM Citalopram, Sertraline, Venlafaxine and DM Venlafaxine were analyzed by doing a 
five point’s calibration curve (100%, 60%, 20%, 10% and 0%). The results for the 
compounds of interest are given in the following tables (table 2.26). 
Table 2.26. Psychotherapeutic drugs results 
Name Type Std. Conc  Conc. %Dev 
  ntads 100% Standard     
  ntads 60% Standard     
  ntads 20% Standard     
  ntads 10% Standard     
  Blank 0% Standard     
Psychotherapeutic Drugs III 
  DM Fluoxetine QC 353.6  303.5 -14.2 
  Fluoxetine QC 299.1  218.0 -27.1 
  Fluvoxamine QC 151.0  197.2 30.6 
  Mirtazapine QC 75.9  74.8 -1.4 
  Paroxetine QC 46.6  38.8 -16.7 
Psychotherapeutic Drugs IV 
  Citalopram QC 90.7  75.0 -17.3 
  DM Citalopram QC 36.3  32.9 -9.3 
Psychotherapeutic Drugs V 
  Sertraline QC 59.1  54.9 -7.1 
  DM Venlafaxine QC 204.7  244.8 19.6 
  Venlafaxine QC 61.4  58.7 -4.4 
 As we can see, all the compounds have deviation above 20%, except for 
fluoxetine (-27.1%) and fluvoxamine (30.6%). This could be due the degradation or 
instability of some compounds when one is working with frequently used samples. 
Also, a previsouly studiy proved that fluoxetine is not stable after 8 weeks [89], while 
KKGT samples used for the study were analyzed in the end of March and arrived in the 
Toxicology Lab in the beginning of January.  
 
 
B.4.2.2. Patients’ samples from the Toxicology Laboratory  
Patients’ samples, provided by the Toxicology Laboratory in Ghent Hospital 
University, were previously analyzed with API 2000 LC-MS/MS Turbo Ion Spray from 
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ABSCIEX. This instrument has been analyzing non-tricycles antidepressants since 2003. 
So, positive samples already analyzed, were processed according to the protocol 
defined before. A five point’s calibration curve was made, including the blank sample 
and the quality control samples from the KKGT were also analyzed (in this case, the 
quality control samples analyzed were from 2015).  
February and March 
Ten patients’ samples, from February and March 2015 were analyzed and 
compared to the results (reported concentrantion in ng/mL) from LC-MS/MS API 2000 
– C264, C313, C367, C403, C048, C034, B996, B796, B793 and B708. The results are 
in the following table (table 2.27) for the compounds that were found in the samples. 
It was also calculated the Bias, having as a nominal concentration, the value found 
with the API 2000, except for the quality controls, where nominal concentration is in 
table 2.25. 
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Table 2.27. Patients’ samples analyzed with the new method and the method in API 2000 equipment. Concentrations 
achieved with both methods are shown, as the bias.  
Sample Type Compound Concentration 
LC-MS/MS TQD  
Concentration LC-
MS/MS API 2000 
% Bias 
  ntads 100% Standard     
  ntads 60% Standard     
  ntads 20% Standard     
  ntads 10% Standard     
  ntads 0% Standard     
  KKGT III QC Citalopram 77.9  -14.1 
  C264 Analyte Citalopram 276.7 400 -30.8 
  C313 Analyte Citalopram 22.8 24 -5.0 
  C367 Analyte Citalopram 141.9 155.9 -9.0 
  C403 Analyte Citalopram 43.9 55 -20.2 
  KKGT IV QC DM Citalopram 34.970  -18.4 
  C264 Analyte DM Citalopram 33.8 40 -15.5 
  C313 Analyte DM Citalopram 7.2 6.1 -18.3 
  C367 Analyte DM Citalopram 30.5 33 -7.6 
  C403 Analyte DM Citalopram 8.1 8.6 -5.8 
  KKGT V QC DM Venlafaxine 348.5  11.4 
  C034 Analyte DM Venlafaxine 68.5 108 -37 
  KKGT V QC Sertraline 54.7  -10.9 
  C403 Analyte Sertraline 17.6 15.5 13.5 
  C367 Analyte Trazodone 5586.7 5893 -5.2 
  C403 Analyte Trazodone 974.5 1190 -18.1 
  C048 Analyte Trazodone 109.2 156 -30.0 
  C034 Analyte Trazodone 424.3 428 -0.9 
  B796 Analyte Trazodone 299 189 58.2 
  B793 Analyte Trazodone 1448.3 1460 -0.8 
  KKGT V QC Venlafaxine 57.0  -6.3 
  C034 Analyte Venlafaxine 13 28 -53.6 
All the values from the analysis with the new method seem to be close to the 
values from the API 2000, except for sample number C034, with DM Venlafaxine. 
However, the API 2000 doesn’t have a quality control sample for DM Venlafaxine, so 
this result may not be right and the same applied to venlafaxine case (%bias = -53.6).  
Sample number B796 also has a difference between the concentration found 
and the reported one. However, these concentrations are not in the expected range 
and trazodone doesn’t have either a quality control in neither the methods, which is 
difficult to prove if this value is correct.  
 73 
 
  3 Conclusions and future perspectives 
 
74 
 
 
3. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
In this project, a method was developed for the identification and quantification 
of 15 non-tricyclic drugs in serum with LC-MS/MS. 
Chromatographic conditions were created and optimized, with an efficient 
separation and a running time for 7.5 min. The mass spectrometer was operated in 
MRM mode, allowing the selection of the transitions to be monitored for each 
antidepressant and also the internal standard used. Each compound had 2 MRM’s to 
allow a more reliable identification.  
Since no method is complete without validation, after the preliminary studies, 
the method was validated according to the Scientific Working Group for Forensic 
Toxicology (SWGTOX) guideline. The analytical parameters studied included selectivity, 
calibration model (linearity), precision and accuracy, carry-over, matrix effects, limits 
and stability of processed samples. 
The method was selective for all the compounds and no interferences were 
found with tricyclic antidepressants.  
 Calibration model test proved that the methodology was linear for most of 
compounds over the concentration range studied, with R2 > 0.99 (except for fluoxetine 
and tramadol) and the residuals were also evaluated. However, it was observed a 
heteroscedastic distribution of the residuals, so it was used a weighted linear 
regression, with empirical weighting factors of 
 
 
, 
 
  
, 
 
 
 and 
 
  
.  
 Limits of detection ranged from 1.0 to 8 ng/mL and limits of quantification were 
lower than 20 ng/mL (except for trazodone). 
 Precision and accuracy were studied throw five runs in five different days. Intra 
and interassay imprecsion varied from 3.5 to 12.3% and 3.2 and 10.8%, respectively. 
Bias was also lower than 15%, except for the lowest values of desmethylcitalopram, 
tramadol and trazodone, where bias was lower than 20%. Also, some compounds at 
specific concentrations (mostly the lowest concentration) don’t show homogeneity of 
variances when statistical test are performed.  
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Carry-over was also evaluated and all the compounds do not show any 
significant values for this parameter. Nevertheless, it advice to introduced wash 
injections (blanks with methanol 100%) in order to avoid possible contamination from 
the previous run performed with the equipment.  
 Matrix effects were evaluated, showing very different values, from 36 to 108% 
for the compounds and 47 to 102% for the internal standards. The low values could 
possibly be explained by the close retention time that paroxetine, duloxetine, 
fluoxetine, melitracene and sertraline had. Since ion suppression demonstrated a high 
value, process efficiency varied from 22 to 106%, clarifying a problem with signal loss. 
However, the internal standards also showed a low value, from 36 to 93% or process 
efficiency. This can compensate in terms of response the previous problem. 
 Compounds proved not stable 18h after the extraction. The temperature of the 
autosampler where the samples were reserved was 15ºC. In the future, it is proposed 
to re-study this parameter with the autosampler at 4ºC and see how the temperature 
affects the stability of these non-tricyclic antidepressants. 
 The developed method was applied to Quality Controls from KKGT and patient 
samples from the Toxicology Lab, previously analyzed with the equipment responsible 
for non-tricyclic antidepressants analysis. KKGT results proved to be acceptable, except 
for fluoxetine and fluvoxamine. These two compounds are not found very often in 
patient samples. However, patient samples proved to be good, with the concentration 
found with this methodology closed to the concentration reported.  
 This method can thus replace the method existing in the laboratory so far, since 
the volume of serum samples were optimized (from 500 to 250 µL) and the distinction 
between desmethylvenlafaxine and tramadol is clear now. Due to the increased use of 
antidepressants and their involvement in intoxications, the ability to reliably detect this 
class in biological specimens is very important, being serum a relevant biological 
matrix. This method is therefore suitable for both therapeutic drug monitoring and 
quantification in suspected overdose cases.  
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4.  MATERIALS AND METHODS 
 
4.1. Equipment 
 Liquid Chromatography system coupled to mass spectrometer, with the 
following components: 
- Liquid Chromatography, Waters Acquity ® Ultra Performance LC ; 
- ESI source, Zpray® and Multi-Mode ESCi; 
- Hybrid triple quadropole/linear ion trap mass spectrometer, Waters TQD 
Detector; 
- Software MassLynx® for MS System; 
- Sofwtare Acquity® UPLC Console; 
 Thermomixer comfort Eppendorf®; 
 Vortex Genie 2 Scientific Industries; 
 Centrifuge Microfuge® 16 Beckman Coutler; 
 Bransonic Ultrasonic cleaner (Branson); 
 Roller mixer (Greiner labortechnik). 
4.2. Material 
 Acquity UPLC BEH C18 1.7 µm 2.1 x 100mm Column (from Waters); 
 Micropipettes® Research Plus (Eppendorf®); 
 Transfer pipettes (SARSTEDT®); 
 Test-tubes heavy-walled, 40 x 8 mm (NOVOLAB); 
 Vials 1mL  from Waters Acquity ®; 
 Protein LoBind Tube 1,5 mL from Eppendorf®. 
 
4.3. Standards  
 nTads solution containing: 
- Citalopram.HBr, from Cerilliant®; 
- DM Citalopram.HCl, from Cerilliant®; 
- DM Venlafaxine.HCl, from Cerilliant®; 
- Duloxetine.HCL, from Cerilliant®; 
- Fluoxetine.HCl, from Cerilliant®; 
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- Fluvoxamine, from Cerilliant®; 
- Melitracene.HCl, from Lipomed®; 
- Mianserine.HCl, from Cerilliant®; 
- Mirtazapine, from Cerilliant®; 
- DM Tramadol.HCl, from Cerilliant®; 
- Norfluoxetine, from Cerilliant®; 
- Paroxetine, from Cerilliant®; 
- Reboxetine, from Cerilliant®; 
- Sertraline.HCl, from Cerilliant®; 
- Tramadol.HCl, from Cerilliant®; 
- Trazodone.HCl, from Cerilliant®; 
- Venlafaxine.HCl, from Cerilliant®. 
 
 Internal Standard:  
- Mirtazapine-d4, powder  from Alsachim ®; 
- Paroxetine-d6, solution in methanol from Cerilliant ®; 
- Reboxetine-d6, powder from SantaCruz Biotech ®; 
- Trimipramine-d3, solution in methanol from Cerilliant ®; 
- Venlafaxine-d6, solution in methanol from Cerilliant ®. 
4.4. Reagents 
 Acetonitrile (LC Grade, Biosolve) - ACN;  
 Dichloromethane (Sigma ≥ 99.9%);  
 Formic Acid (LC Grade, Sigma Aldrich) - FA;  
 Methanol (LC Grade, Biosolve) – MeOH;  
 Water (LC Grade, Veolia Water) 
 
 
4.5. Method Development 
The development of a LC-MS method requires the optimization of several 
parameters. This optimization refers to an adjustment of instrumental parameters in 
order to optimize performance characteristics of each compound. 
To set the conditions, an infusion of every standard solution was performed 
with a syringe pump with a concentration of 1 µg/mL in 50:50 mobile phase A and B 
for all analytes. Each solution was injected one by one with a flow rate of 5 µL/min. 
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With this procedure, the conditions to the ESI source to apply to every 
substance, including the ideal collision energy (CE) for the fragmentation were 
optimized.  
 
4.5.1. Instrumental Conditions 
4.5.1.1. Liquid Chromatography 
The separation in the chromatography was achieved with Acquity® UPLC BEH 
C18 1.7 µm 2.1 x 100mm Column (from Waters).  
A gradient was developed (Table 4.1.) with a flow rate of  0.4 mL/min and 7.5 
min of running time for each sample to have an efficient separation, with the 
description of mobile phase A and B.  
The volume that was injected for each sample was 5 µL.  
 
Table 4.1. Gradient used in this method 
 
 
 
 
 
 
 
 
 
4.5.2. Mass Spectrometry 
The mass spectrometer is equipped with an ESI source, which was operated in 
positive ion mode. All values of the source dependent parameters were optimized and 
described in table 4.2.: 
 
 
 
 Mobile phase (%v/v) 
Time 
(min) 
% A 
Water + 0.1% 
Formic Acid + 2 mM 
Ammonium Acid 
% B 
Methanol + 0.1% 
Formic Acid + 2 mM 
Ammonium Acid 
2 75 25 
5 20 80 
6 20 80 
6.5 10 90 
7 10 90 
7.5 75 25 
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Table 4.2. Values of the ESI source 
Parameter Value 
Voltages 
- Capillary (kV) 
- Cone (V) 
- Extractor (V) 
- RF Lens (V) 
 
3 
35 
1 
1.0 
Temperatures 
- Source Temperature (ºC) 
- Desolvation Temperature (ºC) 
 
120 
400 
 
All values of the analyzer are described in table 4.3: 
Table 4.3. Values for the analyzer 
Parameter Value 
LM Resolution 1 14 
HM Resolution 1 14.1 
Ion Energy 0.3 
Collision 10 
LM2 Resolution 2 14 
HM Resolution 2 14.4 
Ion energy 2 1.8 
Gain 1 
Collision Gas Flow (mL/min) 0.15 
 
To monitor the precursor and product ions of each analyte, the mass 
spectrometer was operated in MRM mode. To establish the appropriate MRM 
conditions for the individual compounds, the different compounds, in mobile phase 
(50:50 A:B, vol/vol), were infused into the mass spectrometer and the cone voltage 
was optimized to maximize the intensity of the protonated molecular species [M+H]+. 
Collision-induced dissociation of each protonated molecule was performed. The 
collision energy was adjusted to optimize the signal for the most abundant product 
ions, which were subsequently used for MRM analysis. The transitions monitored are 
given in table 4.4. Every compound has two product ions to increase specificity.  
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 Tabel 4.4. Transitions monitored, with collision energies and cone voltages.  
Compound Transitions (m/z) Collision 
Energy (V) 
Cone Voltage 
Precursor Ion Product Ion  
Citalopram 325.2 109 
262.1 
30 
20 
30 
30 
DM Citalopram 311.2 109.1 
262.2 
30 
25 
30 
30 
DM Fluoxetine 296.0 134.1 5 15 
DM Tramadol 250.1 44.0 20 30 
DM Venlafaxine 264.2 107.1 
121.0 
246.1 
20 
20 
10 
30 
30 
37 
Duloxetine 298.1 43.9 
154.1 
5 
5 
10 
10 
Fluoxetine 310.2 44.3 
148.1 
12 
10 
20 
20 
Fluvoxamine 319.2 
 
71.0 
87.2 
15 
15 
25 
30 
Melitracene 292.2 84.05 
247.20 
50 
50 
15 
36 
Mianserine 265.3 117.8 
208.0 
35 
25 
39 
39 
Mirtazapine 266.1 72.2 
195.4 
25 
25 
35 
40 
Paroxetine 330.1 70.2 
192.2 
28 
20 
40 
40 
Reboxetine 314.1 131.2 
176.1 
20 
5 
22 
21 
Sertraline 306.1 159.0 
275.0 
30 
15 
20 
20 
Tramadol 264.2 58.2 
121.0 
5 
40 
30 
30 
Trazodone 373.7 176.05 15 30 
Venlafaxine 278.1 58 
121.02 
10 
15 
25 
25 
Trimipramine-d3 298.0 103.0 30 35 
Mirtazapine-d4 270.1 72.2 35 30 
Paroxetine-d5 336.1 76.2 29 29 
Reboxetine-d6 319.2 176.1 20 22 
Venlafaxine-d6 284.2 266.2 25 28 
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4.6. Extraction Procedure 
4.6.1. Protein Precipitation 
First, a solution with all the analytes (called ntads) was prepared. The 
concentrations and volumes of each compound to make the ntads solutions are given 
in table 4.5. Citalopram and DM venlafaxine have a different initial concentration from 
the others and trazodone has the highest final concentration because of its expected 
range. 
Table 4.5. Volumes and final concentrations of compounds in the stock solution used for the calibrators 
 
Inicial 
Concentration 
(µg/mL) 
Inicial 
Volume (µL) 
Final 
Concentration 
(µg/mL) 
Final Volume 
(µL) 
Citalopram  100 200 7.824 
 DM Citalopram  1000 104 9.957 
 DM Fluoxetine  1000 104 9.957 
 DM Tramadol  1000 104 9.957 
 DM Venlafaxine  100 200 7.824 
 Duloxetine  1000 104 9.957 
 Fluoxetine  1000 104 9.957 
 Fluvoxamine  1000 104 9.957 1406 
Melitracene  1000 104 9.957 
 Mianserine  1000 104 9.957 
 Mirtazapine  1000 104 9.957 
 Paroxetine  1000 104 9.957 
 Reboxetine  1000 104 9.957 
 Sertraline  1000 104 9.957 
 Tramadol  1000 105 9.957 
 Trazodone  1000 150 42.674 
 Venlafaxine  1000 104 9.957 
   
The calibration points – 100%, 80%, 60%, 40%, 20%, 10%, 5%, 2% and 1% 
were made in serum. The volume information of what was added are in table 4.6.  
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Table 4.6. Calibrators’ concentration, volume of stock solution used and volume of serum and water added 
to achieve the final volume of 1 mL. 
Calibrator Concentration (ng/mL) Volume of 
the stock 
solution 
(µL) 
Volume of 
Serum (µL) 
Volume 
of water 
(µL) 
 
 
Most of the 
compounds 
Citalopram and 
DM venlafaxine  
Trazodone 
100% 996 782 4267  100  100 
80% 797 626 3414  80  120 
60% 597 469 2560  60  140 
40% 398 313 1707  40  160 
30% 299 265 1280  30 800 170 
20% 199 156 853  20  180 
10% 100 78 427  10  190 
5% 50 39 213  5  195 
2% 20 16 85  2  198 
1% 10 8 43  1  199 
 
After preparing the calibration points, 50 µL of each one of them were added to 
50 µL of water and 200 µL of precipitation fluid (containing 20 ng/mL of Trimipramine 
in MeOH) in an Eppendorf cup. The samples were mixed by vortex and by continuous 
agitation for 5 minutes at 1000rpm in the thermomixer. To help the proteins to 
aggregate, they were centrifuged at 14,000×g for 5 minutes. 50 µL of each 
supernatant were collected to a vial and 50 µL of water were added (to make a dilution 
1:2).  
The previous sample preparation was not satisfactory, so a second sample 
preparation was designed – serum samples (250 µL) were precipitated with methanol 
and acetonitrile containing 5 ng of the internal standards: mirtazapine-d4, paroxetine-
d5, reboxetine-d6 and venlafaxine-d6. The supernatant was evaporated at 56ºC under a 
flow of nitrogen and reconstituted in 100 µL of 50:50 methanol:water with 2 mM 
ammonium acetate. Five µL of each vial was injected. 
 
4.7. Analytical Method Validation 
 Validation is required for any new method; for a particular type of material and 
a particular operating range of concentrations, the method must be able to solve a 
particular analytical problem [78].  The following steps ensure that the minimum 
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standards of practice for validating analytical methods in forensic toxicology have been 
performed. 
4.7.1. Selectivity 
 Selectivity is the ability of the bioanalytical method to measure unequivocally 
and to differentiate the analytes in the presence of components, which may be 
expected to be present [77]. In other words, is the ability to determine the analyte in 
presence of other compounds [68].  
 To evaluate selectivity, 10 different sources of each matrix without IS, 1 blank 
sample with IS and 1 fortified sample with high analyte concentration and without IS 
were selected, along with samples containing potentially interfering compounds or 
metabolites but no analyte. Normally, absence of interfering components is accepted 
where the response is less than 20% of the lower limit of quantification for the analysis 
and 5% for the internal standard [73].  
4.7.2. Calibration Model (Linearity) 
 The choice of an appropriate calibration model is necessary for reliable 
quantification. Therefore, the relationship between the concentration of analyte in the 
sample and the corresponding response must be investigated [64]. It is the ability of 
the method to obtain test results which are proportional to the concentration in the 
sample [68]. It is necessary to use a sufficient number of calibrators to define 
adequately the relationship between concentration and response [79]. The Scientific 
Working Group for Forensic Toxicology recommends 6 calibrators at 6 concentration 
levels, with 5 replicates each [80]. At least, a minimum of five concentrations is 
recommended [67].  
 It is necessary to determinate the range of analyte concentrations over which 
the method shall be used, sometimes called the working range. Within this range, 
there will be a correlation between signal response and analyte concentration in the 
sample [80].   
The choice of an appropriate calibration model (linear, quadratic…) is necessary 
for accurate and reliable quantitative results. The most often used calibration model is 
the simple linear regression model using least squares method [80]. This model 
represented the relationship between two variables by a straight line, mathematically 
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expressed by the equation 4.1, where y is the instrumental response and x is the 
concentration of the compound [83].  
          
Where, y (response) and x (concentration) are independent and dependent 
variable, b and m are the calibration parameters, the y-intercept and the slope, 
respectively.  
Although it has become widespread practice, it is emphasized that a calibration 
model cannot be evaluated simply via its correlation coefficient (R) and coefficient of 
determination (R2) [80], that should be above 0.99 in both cases [90]. So, statistic 
provides a fundamental tool in the qualitative and quantitative analysis of a specific 
analyte. Statistic distribution, like Grubbs, Fisher or Mandel tests are related with 
testing hypothesis, since they can provide a basis for comparison between the test 
values (TV) and the critical values.   
4.7.2.1. Grubbs Test 
The initial step of studying the calibration function is to check for outliers [64]. 
This can be checked by appropriate statistical procedures like the Grubbs test and 
eliminated if found to be significant.  
Grubbs test is defined by the hypothesis: 
- H0 = There is no outliers in the data set; 
- H1 = There is outliers in the data set. 
There are two sides of the test: the test whether checks if the minimum value is 
an outlier, or the maximum value is an outlier, following this two equations (Eq. 4.2 
and 4.3): 
      
          
 
 
      
          
 
 
Eq. [4.1] 
Eq. 4.2 
 
 
Eq. 4.3 
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So, Grubbs’ test can be used to answer the following questions: is the 
maximum value an outlier? Or the minimum value is an outlier? For the two-sided test, 
the hypothesis of no outliers is rejected if (Eq. 4.4): 
   
     
  
  
 
  
       
  
     
  
       
  
 
With tα/(2N),N−2 denoting the critical value of the t-distribution with (N-2) 
degrees of freedom and a significance level of α/(2N). 
The critical value for α=0.05 is 1.71. If any value from Gmin and Gmax is superior, 
it will be considered an outlier and H1 is accepted. More than two outliers in a complete 
data-set of a calibration model indicate problems with the method.  
 
4.7.2.2. Fisher Test 
The next step is to check for homogeneity of variances (homoscedasticity). 
Again, this can first be done visually using residuals plots. The plots of residuals versus 
concentration appear to show residuals randomly distributed around the x-axis.  In 
fact, the variances tend to increase as the concentration increases, which usually 
points to the hypothesis of others models of calibration beyond the simple linear 
regression. In such cases, homoscedasticity should be tested by an appropriate 
statistical procedure. 
To compare de variances of a normal distribution, the Fisher test should be used. 
This test follows the equation 4.5: 
    
  
 
  
  
Where   
  stands for the standard deviation at the highest calibrator and   
  stands 
for the standard deviation at the lowest calibrator. Then, it is compared the value with 
the tabulated value (pH0) of the F distribution at a confidence level of 95% and 5 
degrees of freedom, given by the equation 4.6: 
                   
The criteria of these results are: 
Eq. 4.4 
Eq. 4.5 
Eq. 4.6 
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- Ho =      H0 – the difference in variances is not statistically significant 
and thus, there is homoscedasticity, so the ordinary least squares 
regression models are applicable. 
- H1 =        – scatter of the replicates increases with concentration 
indicating inhomogeneous variances (heteroscedasticity) over the calibration 
range, so weighted least squares regression models are applicable. 
The evaluation of the behavior of variance is very important for the choice of the 
correct regression model.  
 
4.7.2.3. Mandel Test 
 
The test is based on the assumption that relatively large deviations of measured 
values from a straight line are caused by nonlinearity and may be reduced through the 
selection of a “better” regression model, in this case, a quadratic model. The first step 
is to adjust a first degree polynomial (P1) and a second degree polynomial (P2) and 
calculate for each the sum of squares. Six calibrators and the mean of response were 
used to calculate the variance (Var) of linear correlation and quadratic correlation (eq. 
4.7 and 4.8): 
           
                        
 
   
 
              
                        
 
   
 
 
N is the number of calibration standards used to construct the curve. From this, 
it is possible to calculate the fit standard error with equation 4.9: 
 
                    or                          
 
From this, is possible to calculate the significance of this variance (Fcal) through 
the equation 4.10:  
      
   
    
  
 
   
   
    
 
Then, Fcrit (F 0.01 (  ;   )) is calculated, where    represents the 
difference between degrees of freedom (in this case, one). If Fcrit presents a good 
Eq. 4.7 
 
 
Eq. 4.8 
Eq. 4.9 
 
 
Eq. 4.10 
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possibility of both models have similar performance (for example, more than 50% 
chances), one should choose P1. If it presents a very low value, P2 should be chosen.  
 
4.7.2.4. Weighted Least Squares  
The constant variance over the whole range is not always observed. Large 
deviations at larger concentrations tend to influence (weight) the regression line. Thus, 
if the data are heteroscedastic (Fcal > Fcrit), the use of weighted least squares (WLS) is 
the simplest and the most effective way to harmonize the differences of variances of 
the line points [83].  
For this study, calibration curves for all the analytes were prepared with six 
calibrators each - 100%, 60%, 30%, 20%, 5%, 1%, with 5 ng of IS. This procedure 
was repeated in three different days.  
Since there are evidences of the heteroscedastic, the following step should be 
the choice of the weighting factores (wi). As it is not suitable to calculate the inverse of 
variance in laboratory routine, taking the account the fact that it requires several 
determinations for each calibration point and a fresh calibration line each time the 
method is used, so other empirical weights should be studied: 
 
 
, 
 
  
, 
 
 
 and 
 
  
 [83].  
The best weighting factor is chosen according to a percentage relative erros 
(%RE), which compares the regressed concentration (      ) computed from the 
regression equation obtained for each wi, with the nominal standard concentration, 
     (eq. 4.11). 
     
            
    
      
Plots of %RE versus concentration were performed for the analytes in order to 
choose the best weighing factor, along with the sum of %RE (    ) The     more 
adequate will be the one which gives rise to a slight horizontal band of randomly 
distributed %RE around the x-axis and presents the smallest value of across the whole 
concentration range [83].  
In the simple linear regression model, the relationship between variables is 
established by a straight line, mathematically expressed by the equation (4.1). But, 
Eq. 4.11 
Eq. 4.11 
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Eq. 4.12 
 
 
 
Eq. 4.13 
since it is used a WLSLR, the model parameters (b1 and b0) of the weighted straight 
line equation need to be estimated using the term according to the following equations 
(eq. 4.12 and 4.13), before being calculate the Ccalculated [83]. 
    
                           
          
             
 
    
      
                              
            
              
 
Where    and    is the i
th data pair of n total data pairs and wi is the weighting 
factor chose. Finally, the correlation coefficient (R) of the weighted straight line 
equation can be obtained with equation 4.14.  
   
                                 
             
                            
               
 
 
4.7.3. Precision 
Precision is the degree of agreement among individual test results when an 
analytical method is used repeatedly to multiple samplings of a homogeneous sample, 
under the prescribed conditions [64], [67], [68]. Precision may be considered in three 
levels: repeatability, intermediate precision and reproducibility.  
Precision can be expressed as coefficient of variation (CV), variance (S2), 
standard deviation (S) [75]. In this project, it will be expressed as coefficient of 
variation.  
Repeatability is a measure of the variability in results when a measurement is 
performed by a single analyst using the same equipment over a short timescale. 
Intermediate precision expresses within laboratories variations (different analysts, 
different equipment, etc) [64], [70]. Reproducibility is a measure of the variability in 
results between laboratories. It has to be studied only if a method is supposed to be 
used in different laboratories [64]. In this project, the reproducibility of the method 
was not studied. 
Eq. 4.14 
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The study of intermediate precision and the repeatability consisted of analyzing 
a test sample in several different runs. Within each run, the sample was analyzed 5 
times under repeatability conditions [64], [70], [91]. Three pools of fortified matrix 
samples at the concentrations 50 ng/mL, 400 ng/mL and 1000 ng/mL were prepared. 
Each concentration pool of fortified samples was analyzed in triplicate on five separate 
days along with a freshly prepared calibration curve (6 calibrators). The precision is 
first calculated by determining the mean for each concentration. From these values, it 
was calculated the within-run and between-run using the one-way ANOVA approach, 
expressed in terms of % CV, through the following equations (eq. 4.15 and 4.16) [80]: 
                   
     
                                
      
 
                    
 
                
 
                                
      
The % CV shall not exceed 20% at each concentration [80].  
 
4.7.3.1. Cochran Test 
One of the assumptions for the usage of ANOVA is the homogeneity of 
variances. Cochran test is used in this case, so one can decide if a single estimate of 
variance is significantly larger than a group of variances. This test follows the equation 
(eq 4.17), where C detects one exceptionally large variance value. 
      
    
 
   
  
   
 
Where     
  is the maximum variance and    
  
    is the sum of all variances. 
The value of Ccal is compared with tabled value, Ccrit, (α=0.01) for the Cochran test, 
where the number of replicas is 3 and the number of runs is 5. The criteria used for 
these results are: 
- If C   Ccrit, there is homogeneity of variances and thus, ANOVA can be 
used; 
Eq. 4.15 
Eq. 4.16 
Eq.  4.17 
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- If C > Ccrit, the differences between the variances are statistically significant, 
and therefore, ANOVA can’t be used.  
 
4.8.4. Accuracy (bias) 
Accuracy is the difference between the expectation of the test results and an 
accepted reference value [92]. It can be measured as a percentage deviation from the 
accepted reference value [64].  
A practical determination of bias relies on comparison of the mean of the 
results from the candidate method with a suitable reference value [70]. It shall be 
measured in pooled fortified matrix samples using a minimum of three separate 
samples per concentration at three different concentration pools (low, medium, and 
high) over five different runs. The following equation should be used (eq. 4.18) [80]: 
                         
 
                                                           
                     
       
 
The maximum acceptable bias is 20% at each concentration [73], [74], [80]. 
  
4.7.5. Carry-Over  
Carryover is the contamination of a sample by the analyte of interest coming 
from a previous sample injection. The autosampler is often assumed to be the main 
source of carryover due to the high concentration of analyte exposed to a large variety 
of surface materials and large number of interrupted flow paths [93]. To evaluate 
carryover as part of the method validation, it is recommended that following an 
injection of a high concentration sample, it should be injected the lowest calibrator. 
Eight samples were prepared: three with 1000 ng/mL and five with 10 ng/mL (Fig 4.1) 
and concentration analyzed with equation 4.19. 
 
 
 
Eq. 4.18 
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Then, the Δlow is calculated and if it exceeds 2 × SD low unaffected, the carry-
over is present. This concentration shall be confirmed using triplicate analyses [80].  
 
4.7.6. Matrix Effects  
Matrix effect is the effect on an analytical method caused by all other 
components of the sample except the specific compound to be quantified [94]. Matrix 
effects result from co-eluting matrix components that affect the ionization of the target 
analyte, resulting either in ion suppression, or, in some cases, ion enhancement. Matrix 
effects can be highly variable and can be difficult to control or predict [95]. It is a well-
known phenomenon in LC-MS/MS analysis, mainly depending on the sample matrix, 
sample preparation procedure, quality of chromatography separation, mobile-phase 
additives and ionization type [64], [86].  
There are two common methods to assess matrix effects: the post-column 
infusion method and the post-extraction spike method [95]. In this project, post-
extraction was used. The post-extraction spike method quantitatively assesses matrix 
effects by comparing the response of an analyte in neat solution to the response of the 
analyte spiked into a blank matrix sample that has been carried through the sample 
preparation process [95].  
In this case, three different sets of samples are prepared: one, consisting on 
neat standards (set A), one prepared in blank matrix extracts from different sources 
and spiked before extraction (set B) and one prepared in blank matrix from the same 
sources but spiked after extraction (set C).  
Fig.4.1. Illustration of how carry-over was studied. This batch was repeated three times. 
Eq. 4.19 
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From these data, one can calculate the ME (ion suppression/enhancement) RE 
(extraction efficiency) and PE (process efficiency), according to the equations 4.20, 
4.21 and 4.22. Two ionization suppression or enhancement percentages will be 
established – one at low concentration (50 ng/mL) and one at the high concentration 
(500 ng/mL).  
 
        
                               
                              
         
 
        
                               
                              
         
 
        
                               
                              
        
 
 
4.7.7. Limits 
4.7.7.1. Limit of Detection (LOD) 
The LOD must be differentiated from the LOQ. LOD is the smallest 
concentration that can be distinguished from the noise level. The LOQ should be at 
least twice the response of the LOD. The LOQ should serve as the lowest concentration 
on the calibration curve [79].  
Five calibrations curves are constructed across the working range of the 
analytical method over different runs. The LOD can be estimated from the standard 
error of the y intercept (s(b0)) and the average slope (Avgb1) with equation 4.23 [80]: 
     
         
   
  
 
 
 
 
Eq. 4.20 
Eq. 4.21 
Eq. 4.22 
Eq. 4.23 
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4.7.7.2. Limit of quantification (LOQ) 
Limit of quantification is the lowest sample concentration that can be quantified 
with suitable accuracy  and precision [64], [72], [96], [97]. There are a number of 
different approaches for determining a method’s LOQ. A method’s LOQ incorporates 
instrumental performance, as well as the sample matrix and inherent procedural 
limitations [80]. 
In this project, LOQ was determined with three quality control samples at 10, 
20 and 50 ng/mL are analyzed in duplicate (two separate samples) over a minimum of 
five runs. The concentrations used for this approach must remain within the previously 
established calibration curve.  
The lowest concentration that was capable of reproducibly providing 
symmetrical peaks and the minimum mass spectral identification ratios, while 
maintaining a bias of ±20% and a % CV of <20%, is considered the estimated LOQ 
[80].  
 
4.7.8. Stability 
Stability is the absence of an influence of time on the concentration of the 
analyte in a sample [72]. It is the chemical stability of an analyte in a given matrix 
under specific conditions for given time intervals [47]. Stability of an analyte during the 
whole analytical procedure is a prerequisite for reliable quantification [64].   
Analyte stability may be affected by a number of variables, including storage 
conditions and sample processing.  All stability determinations shall include a set of 
samples prepared from reference materials. The reference materials are used to 
prepare fortified samples of the analyte(s) at both low and high concentrations (20 and 
800 ng/mL) in each matrix that will be analyzed in the method. 
 
4.7.8.1. Processed samples 
Sometimes, it may be necessary to run the samples the following day or later. 
In these instances, it is important to evaluate the length of time a processed sample 
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can be maintained before it undergoes unacceptable changes, preventing reliable 
analyte detection, identification and quantification. Typically processed fortified 
samples are combined per concentration and then divided into different autosampler 
vials. The first vials of each concentration are immediately analyzed in triplicate to 
establish the time zero responses (T0). All remaining vials are stored in a manner that 
they would typically be stored during routine analysis (in our case, the autosampler). 
The remaining vials are then analyzed in triplicate at different times intervals. Average 
responses at each time interval are compared to the time zero responses. The 
processed samples in different autosampler vials are analyzed repeatedly up to 
72hours.  [80]. 
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6. APPENDIX 
 
Appendix 6.1: Calibration Model 
Calibration curves (a) and residuals plots (b) for desmethylcitalopram, desmethylfluoxetine, 
desmethyltramadol, desmethylvenlafaxine, duloxetine, fluoxetine, fluvoxamine, melitracene, 
mianserin, mirtazapine, reboxetine, sertraline, trazodone and venlafaxine. 
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Appendix 6.2: Data of the study of weighted least squares linear 
regression
DM Citalopram 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 23.6 25.9 25.9 23.9 
597 20.9 18.6 18.6 22.3 
300 36.1 47 47 39.5 
199 19.3 7.1 7.1 14.8 
50 24.7 23.8 23.8 24.3 
10 35.3 33.8 33.8 38.8 
     159.9 156.2 156.2 163.6 
 
DM Fluoxetine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 26.9 66.6 23.6 50 
597 15.9 29.5 17.5 14.9 
300 14.9 32.6 15.2 14.6 
199 60.9 16.9 63.4 37.4 
50 93.9 66 90.5 87.4 
10 56.7 63 84.9 71.2 
     269.2 274.6 295.1 275.5 
 
DM Tramadol 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 9.2 6.1 10.2 10 
597 12.9 12.6 13 13 
300 42.1 47 40.9 41.3 
199 10.4 10.3 10.4 10.4 
50 29 23.3 31.2 30 
10 38.5 36.2 42.5 39.8 
     142.1 135.5 148.2 144.5 
 
DM Venlafaxine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 19.3 29.7 21.1 30.8 
597 17.9 18.4 18 20.8 
300 47.1 39.7 45.3 26.1 
199 22.6 17 20.3 23.7 
50 24 24.5 24 31 
10 65.9 28.4 79.7 4.8 
     196.8 157.7 208.4 137.2 
 
 
 
 
 
Duloxetine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 20.1 44.1 18.4 35.8 
597 21.6 6 23.4 9.7 
300 10 27.3 9.3 18.8 
199 30.6 10.1 31.9 15.8 
50 50.3 35.9 49.2 45.5 
10 44.7 39.3 52.4 43.1 
     177.3 162.7 184.6 168.7 
 
Fluoxetine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 16 25.5 16.9 29 
597 20.2 15.8 19.2 14.2 
300 9.1 9.2 9.1 9.7 
199 16 15.5 15.3 15.7 
50 40.4 41 37.7 36.9 
10 57.6 34.4 67.9 34.7 
     159.3 141.4 166.1 140.2 
 
Fluvoxamine 
 
 
 
 
 
 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 9.7 31.6 9.1 16.3 
597 9.5 24.3 10.4 9 
300 34.9 58.5 33.5 37.7 
199 44.7 16.8 46.3 32.8 
50 75.4 57 75.3 67.5 
10 43.4 41.7 48.8 60.3 
     217.6 229.9 223.4 223.6 
 
 
Melitracene 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 22.9 28.7 17.4 28.9 
597 18.2 29 26.6 34.7 
300 49.7 41.7 39.8 35.1 
199 19.1 11.2 20.5 11.6 
50 16.1 16.3 11.9 10.1 
10 60.2 22.4 55.7 21.7 
     186.2 149.3 171.9 142.1 
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Mianserine 
Std. Conc.. 1/x 1/x
2
 1/y 1/y
2
 
996 8.3 16.7 16.7 16.7 
597 22.8 13.6 13.6 13.6 
300 27.8 35.6 35.6 35.6 
199 12.6 11.1 11.1 11.1 
50 17 14.1 14.1 14.1 
10 47.4 49 49 49 
     135.9 140.1 140.1 140.1 
 
Mirtazapine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 16.8 16.7 16.9 16.8 
597 12.4 10.4 12.9 12.8 
299 28.6 32.2 27.5 27.8 
199 20.5 20.5 20.6 20.6 
50 16.4 14.2 17.3 16.6 
10 30.9 25.1 35.3 28.8 
     125.6 119.1 130.5 123.4 
 
Paroxetine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 16.4 16.3 17.3 20.2 
597 15 14.9 15.9 18.7 
300 51.1 51.7 49.5 45.6 
199 7.9 8.4 7.3 7.4 
50 16.2 15.8 18.2 18.2 
10 51.1 41.1 62.7 45.9 
     157.7 148.2 170.9 156.0 
 
Reboxetine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 11.4 11.4 11.8 11.8 
597 9.6 8.9 10.6 10.6 
300 46.4 47.8 45.1 45.1 
199 8.1 7.2 8.9 8.9 
50 9.8 12 9.6 9.6 
10 51.8 36.2 62.3 62.3 
     137.1 123.5 148.3 148.3 
 
Sertraline 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 21.2 34.7 9.7 14.9 
597 13.9 32.4 16.9 25.3 
300 12 30.1 15 17.2 
199 36.8 20.1 28.3 27.6 
50 96.3 62.9 67.8 55.8 
10 56.5 44.3 62 71.7 
     236.7 224.5 199.7 212.5 
 
 
 
 
Tramadol 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 5.9 4.2 5.9 5.9 
597 13.6 13.8 17.7 17.7 
299 21 24.3 22 22 
199 14.7 14.6 16.4 16.4 
50 30 21.1 16.4 16.4 
10 39.3 32.5 32.1 32.1 
     124.5 110.5 110.5 110.5 
 
Trazodone 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
4267 19.3 19.3 18.9 18.2 
2560 27 27 24.4 24 
1280 34.3 34.3 69.9 25.9 
853 12.3 12.3 30.9 37.8 
213 74.4 74.4 30.3 67.7 
43 33.2 33.2 35.4 21.4 
     200.5 200.5 209.8 195 
 
Venlafaxine 
Std. Conc. 1/x 1/x
2
 1/y 1/y
2
 
996 16.3 16.3 18.2 25.8 
597 20.5 20.5 22.4 27 
300 58 58 55.8 48.8 
199 13 13 12 11.9 
50 26.5 26.5 25.3 29.9 
10 61 61 38.2 43.1 
     195.3 195.3 171.9 186.5 
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Appendix 6.3: Imprecision and accuracy (bias) 
Concentrations of the five runs made in five different days. All the samples were made in 
triplicate (A, B and C) at low, medium and high concentrations. 
 
DM Citalopram 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 57.3 50.7 55.8 68.2 69.4 
B 55.0 65.9 48.7 64.2 66.8 
C 62.6 47.6 51.6 68.3 65.3 
        
Medium       
A 458.3 432.3 452.5 493.9 398.1 
B 471.8 412.8 432.6 504.2 402.3 
C 426.8 357.4 416 488.2 416.5 
        
High       
A 844.0 967 948.8 962.5 980.8 
B 863.7 857.6 1001.6 956.8 1038.2 
C 873.6 1002.7 1016.8 990.9 1131.3 
  Low Medium High 
Mean 59.8 437.5 962.4 
SD 7.7 40.4 77.6 
CV 13.0% 9.2% 8.1% 
Final Bias 19.7% 9.9% -3.4% 
 
DM Fluoxetine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 49.5 61.9 43.3 58.8 67.5 
B 53.9 59.1 46.4 53.4 69.5 
C 52.7 52.4 42.9 57.2 67.1 
        
Medium       
A 436.3 419.6 454.6 454.4 478.9 
B 419.1 357.9 413.7 461.3 476 
C 405.5 366.4 428 478.3 428.7 
        
High       
A 870.3 1015.1 837.6 847.5 935.7 
B 858.4 858.6 927.7 876.6 1010.6 
C 906.9 877.6 878.7 867.7 1029.8 
  Low Medium High 
Mean 55.7 431.9 906.5 
SD 8.4 37.1 63.9 
CV 15.1% 8.6% 7.1% 
Final Bias 11.4% 8.5% -9.0% 
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DM Tramadol 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 46.5 47 42.8 47.5 54.5 
B 48.6 45.7 44 49.7 55.2 
C 52.9 50.2 42.3 50.4 62.7 
        
Medium       
A 429.4 356.5 457.2 370.9 422.9 
B 444.9 341 407.1 366.4 427.4 
C 395.6 372.2 402.7 361.2 417.3 
        
High       
A 924.1 1194.6 987.1 1022.2 1037.3 
B 961.1 977.1 1033.2 1039.8 1218.2 
C 1004.2 1069.7 1059.4 950.4 1060.5 
  Low Medium High 
Mean 49.3 398.2 1035.9 
SD 5.3 35.2 81.5 
CV 10.9% 8.8% 7.9% 
Final Bias -1.3% 0.0% 4.0% 
 
 DM Venlafaxine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 45.5 41.1 33 58.6 47.2 
B 38.3 42.6 33.4 53.6 41.8 
C 37.2 40.9 34.2 56.7 43 
       
Medium       
A 304.3 275.9 319 396.7 307.7 
B 292.5 301.4 324.5 397.3 302.2 
C 302.5 307.3 305.3 420 328.6 
        
High       
A 767.6 938 784.7 862 884.6 
B 765.4 856.7 810.4 880.3 967.8 
C 815.5 989.4 874 921.3 948.3 
  Low Medium High 
Mean 43.1 325.6 871.0 
SD 8.0 43.0 72.2 
CV 18.6% 13.2% 8.3% 
Final Bias 10.6% 4.1% 11.4% 
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Duloxetine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 48.9 55.6 37.9 54 61.3 
B 56.3 56.5 40.9 51.1 60.3 
C 48.4 43.3 38.7 52.6 60.1 
        
Medium       
A 416.7 451.5 419.5 459.4 468.3 
B 391.6 391 387.1 475 446.6 
C 389.8 378.2 395 491.1 420.5 
        
High       
A 949.2 1059.6 956.8 979 1069 
B 920.2 1006.6 1078 1042 1168.1 
C 1001.5 1090.5 989 995.7 1180.2 
  Low Medium High 
Mean 51.1 425.4 1032.3 
SD 7.8 37.1 75.9 
CV 15.4% 8.7% 7.4% 
Final Bias 2.1% 6.9% 3.7% 
 
Fluoxetine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 49.4 55.2 50.9 49.4 65.7 
B 51.4 59.8 48.3 47.1 60.4 
C 49.8 43.9 53.4 47 61.6 
        
Medium       
A 444.4 464.9 518.2 479.9 508.3 
B 432.9 318.6 429 462 520.8 
C 398.1 390 411.6 412.9 419 
        
High       
A 793.1 1036.8 987.4 875.7 1006.7 
B 969 877.6 1090.3 985.4 1133.9 
C 896.8 820.8 1002.8 922.5 1213.3 
  Low Medium High 
Mean 52.9 440.7 974.1 
SD 6.3 54.2 115.3 
CV 11.8% 12.3% 11.8% 
Final Bias 5.8% 10.7% -2.2% 
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Fluvoxamine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 57.1 57.1 43 57.8 68.6 
B 51.6 49.6 44.3 51.9 68.9 
C 48.7 57.9 43 60.6 70.4 
      
Medium       
A 409.9 384.7 466.3 481.9 428.5 
B 432.2 391.1 435.1 499.1 484.5 
C 374.9 414 432.1 474.4 472.2 
        
High       
A 911.3 1103.5 915.1 875.3 1018 
B 872.3 973.9 1000.7 991.2 1080.6 
C 897.4 1041.6 952.7 883 1068.3 
  Low Medium High 
Mean 55.3 438.7 972.3 
SD 9.1 39.3 78.6 
CV 16.5% 9.0% 8.1% 
Final Bias 10.7% 10.2% -2.4% 
 
Melitracene 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 55.7 47.5 41.8 61.8 61.3 
B 54 55 41.9 58.1 57.4 
C 55.1 40.7 42.8 53.9 60.4 
        
Medium       
A 401 441.8 423.3 465.5 380 
B 400.5 362.9 377.1 468 399.4 
C 381.5 320.7 368.5 490.7 412.1 
        
High       
A 916.4 1157.1 1025.8 1066.9 1011.6 
B 965.3 946.7 1090.9 1097.7 1250.2 
C 942.9 1101.6 1137 1138.7 1263 
  Low Medium High 
Mean 52.4 406.2 1074.1 
SD 7.5 45.5 106.8 
CV 14.3% 11.2% 9.9% 
Final Bias 5.0% 2.1% 7.8% 
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Mianserine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 48.9 57.3 48 66.8 63.2 
B 52.6 63.4 47.9 61.7 63.5 
C 54.6 49.1 50.3 62.5 59.8 
        
Medium       
A 431.7 405.2 410.6 469.2 436.5 
B 431.7 375.8 418.8 483 422.9 
C 398.4 362.7 413.8 463.2 415.2 
        
High       
A 900.4 1059.4 972.9 984.4 999.7 
B 949.2 912.1 1053.9 980.2 1072.5 
C 964.1 1011.1 994.4 1028 1123.9 
  Low Medium High 
Mean 56.6 422.6 1000.4 
SD 6.7 32.5 60.2 
CV 11.9% 7.7% 6.0% 
Final Bias 13.3% 6.2% 0.4% 
 
Mirtazapine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 48.7 49.3 41.2 63.4 54 
B 51.3 52.7 41.7 54.9 52.7 
C 48.4 47.9 44.1 49.4 56.7 
        
Medium       
A 417.3 372.1 316.9 445.6 374.8 
B 432.3 354.6 347.6 492.7 411.4 
C 423.5 364.6 322.1 440.3 376.1 
        
High       
A 1017.6 1215.5 811.3 1034.5 1021.9 
B 947.7 1025.9 864.8 903.2 1089.2 
C 995.8 1084.9 798.8 1023.3 1142.1 
  Low Medium High 
Mean 50.4 392.8 998.4 
SD 5.8 49.6 116.9 
CV 11.4% 12.6% 11.7% 
Final Bias 0.9% -1.3% 0.2% 
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Reboxetine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Super Low      
A 44.7 48.8 41.5 55.1 55.1 
B 47.8 51.7 42.5 52.1 55.9 
C 46.1 46.9 41.9 57.1 56.4 
        
Medium       
A 408.9 373.5 418.1 424.4 429.6 
B 409.6 350.7 400.5 447.7 408.5 
C 395.8 349.5 393.3 460.4 407.1 
        
High       
A 953.3 1154.2 1013 1028.9 1069.8 
B 963.1 978.2 1066.5 1005.1 1092.6 
C 1016.1 1053.7 1028.2 1016.8 1166.5 
  Low Medium High 
Mean 49.5 405.1 1040.4 
SD 5.6 30.9 62.2 
CV 11.3% 7.6% 6.0% 
Final Bias -0.9% 1.8% 4.5% 
 
Paroxetine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 52.3 44.7 44.5 56.5 58.2 
B 52.8 55.5 40.8 53.3 62.2 
C 55.6 38.4 41.4 58 59.5 
        
        
Medium       
A 421.3 408.9 424.1 486.9 372.6 
B 433.3 361.2 383.9 509.7 397.1 
C 378.4 312 370.9 506.1 394.6 
        
High       
A 907 981.4 920.9 1032.9 1018 
B 932.9 894.9 1010.5 1014.2 1118.2 
C 946.6 1080.6 1003.6 1066.3 1224.6 
  Low Medium High 
Mean 51.6 410.1 1010.2 
SD 7.6 55.4 88.3 
CV 14.8% 13.5% 8.7% 
Final Bias 3.2% 3.2% 1.4% 
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Sertraline 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 48.7 62.9 35.4 66.2 63.2 
B 55.1 56 41.5 54.8 61.0 
C 47.3 53.8 40.9 58.4 65.9 
        
Medium       
A 411 422.4 431.9 514.8 415.1 
B 401 383.6 403.2 534.2 484.0 
C 405.8 415.1 425.6 545.4 498.9 
        
High       
A 902.0 1039.9 923.3 930.1 1069.7 
B 857.4 972.9 932.4 999.2 1261.1 
C 913.4 1063.2 975.6 973.6 1113.8 
  Low Medium High 
Mean 54.1 446.1 995.2 
SD 9.5 53.7 102.2 
CV 17.7% 12.0% 10.3% 
Final Bias 8.1% 12.1% -0.1% 
 
Tramadol 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 47.2 50.6 49.4 46.5 50.7 
B 45.1 47.3 49.4 49.8 59.4 
C 66.1 54.4 46.7 53.5 63.3 
        
Medium       
A 450.6 441.4 512.4 476.3 454.4 
B 441.1 392.4 469.4 549.6 486.7 
C 359 490.2 465 473.6 443.5 
        
High       
A 851.4 1186.7 1139.4 1016.1 1003.5 
B 871.3 962.3 1098.1 950 1344.6 
C 933.4 1109.8 1086.8 965.7 1130.4 
  Low Medium High 
Mean 52.0 460.3 1043.3 
SD 6.3 45.3 130.8 
CV 12.2% 9.9% 12.5% 
Final Bias 3.9% 15.7% 4.7% 
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Trazodone 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 237.1 258.4 219.4 271.8 289.7 
B 267.1 257.9 221 258.1 263.3 
C 255.3 245 214.2 260.5 265 
        
Medium       
A 1967.9 1694.4 1791.3 1887.6 1936.6 
B 1862.7 1717.2 1784.1 2112.8 1786.4 
C 1849.5 1512.4 1779.9 2041.3 1727.5 
        
High       
A 3942.1 3987.3 3811.9 3767.7 4026.2 
B 3850.7 3655.4 4161.5 3649 4264.7 
C 3956.8 4068.5 4063.9 4001.4 4388.9 
  Low Medium High 
Mean 252.2 1830.1 3973.1 
SD 21.1 148.9 207.9 
CV 8.3% 8.1% 5.2% 
Final Bias 18.4% 7.2% -6.9% 
 
Venlafaxine 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Low      
A 58.7 52.5 40.5 54.8 61.9 
B 48.8 50.5 41.3 49.5 61.2 
C 58 50.6 40 52.5 61.3 
        
Medium       
A 395.3 367.1 426 469.7 401.8 
B 401.8 380.8 416.8 456.7 388.7 
C 383.2 376.4 395.1 475.5 419.8 
        
High       
A 962.9 1177.7 1006.7 1011.8 1080.9 
B 948.2 999 1033.8 1003.1 1197.6 
C 1017 1134.3 1069.9 985.4 1124.8 
  Low Medium High 
Mean 52.1 410.3 1050.2 
SD 7.4 33.8 77.3 
CV 13.7% 8.2% 7.4% 
Final Bias 4.3% 3.1% 5.4% 
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Appendix 6.4: Carry-over 
To perform carry-over study, three samples in high concentrations (1000 ng/mL) , followed 
by five samples in very low concentrations (10 ng/mL) were analyzed in three runs (1st, 2nd 
and 3rd) . The results for all the compounds are on the tables below. Std. Conc. stands for the 
nominal concentration and Conc. is the value calculated by the method. %Dev. shows the 
deviation from the nominal and the calculated concentration.  
Citalopram 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 782 775 .8 -0 .8 
  Cal 100%  B 1st 782 860 .9 10 .1 
  Cal 100%  C 1st 782 778 .9 -0 .4 
  Cal 1%  A   1st  8 9 .7 21 .5 
  Cal 1%  B   1st 8 8 .1 0 .6 
  Cal 1%  C   1st 8 7 .6 -5 .3 
  Cal 1%  D   1st 8 7 .9 -1 .6 
  Cal 1%  E   1st 8 8 -0 .3 
  Cal 100%  A 2nd 782 775 -0 .9 
  Cal 100%  B 2nd 782 812 .6 3 .9 
  Cal 100%  C 2nd 782 736 .6 -5 .8 
  Cal 1%  A   2nd 8 10 .4 30 .3 
  Cal 1%  B   2nd 8 8 .7 9 .1 
  Cal 1%  C   2nd 8 7 .6 -5 .4 
  Cal 1%  D   2nd 8 8 .1 1 .2 
  Cal 1%  E   2nd 8 7 .7 -3 .9 
  Cal 100%  A 3rd 782 743 .8 -4 .9 
  Cal 100%  B 3rd 782 794 .5 1 .6 
  Cal 100%  C 3rd 782 759 -2 .9 
  Cal 1%  A   3rd 8 7 .7 -3 .5 
  Cal 1%  B   3rd 8 7 .4 -8 
  Cal 1%  C   3rd 8 6 .9 -13 .7 
  Cal 1%  D   3rd 8 7 .3 -8 .7 
  Cal 1%  E   3rd 8 7 .8 -2 .1 
 
DM Citalopram 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 1012 1 .6 
  Cal 100%  B 1st 996 1108 .6 11 .3 
  Cal 100%  C 1st 996 1001 .2 0 .5 
  Cal 1%  A   1st  10 15 .5 54 .5 
  Cal 1%  B   1st 10 10 .4 4 .5 
  Cal 1%  C   1st 10 9 .3 -6 .8 
  Cal 1%  D   1st 10 9 .3 -7 
  Cal 1%  E   1st 10 10 -0 .2 
  Cal 100%  A 2nd 996 893 .2 -10 .3 
  Cal 100%  B 2nd 996 910 .4 -8 .6 
  Cal 100%  C 2nd 996 840 .1 -15 .7 
  Cal 1%  A   2nd 10 16 .9 69 .4 
  Cal 1%  B   2nd 10 11 .7 17 .5 
  Cal 1%  C   2nd 10 9 .1 -8 .7 
  Cal 1%  D   2nd 10 9 .6 -3 .9 
  Cal 1%  E   2nd 10 10 .2 2 .5 
  Cal 100%  A 3rd 996 1033 .9 3 .8 
  Cal 100%  B 3rd 996 1080 .5 8 .5 
  Cal 100%  C 3rd 996 1075 .6 8 
  Cal 1%  A   3rd 10 10 0 .2 
  Cal 1%  B   3rd 10 9 .5 -5 .3 
  Cal 1%  C   3rd 10 8 .6 -14 .2 
  Cal 1%  D   3rd 10 8 .8 -12 
  Cal 1%  E   3rd 10 9 .6 -4 .1 
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DM Fluoxetine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 985 -1 .1 
  Cal 100%  B 1st 996 1074 .9 7 .9 
  Cal 100%  C 1st 996 1000 .9 0 .5 
  Cal 1%  A   1st  10 16 .8 68 .3 
  Cal 1%  B   1st 10 10 .8 7 .6 
  Cal 1%  C   1st 10 10 .8 7 .6 
  Cal 1%  D   1st 10 8 .1 -18 .6 
  Cal 1%  E   1st 10 8 -20 .4 
  Cal 100%  A 2nd 996 914 .9 -8 .1 
  Cal 100%  B 2nd 996 1000 .6 0 .5 
  Cal 100%  C 2nd 996 923 .7 -7 .3 
  Cal 1%  A   2nd 10 23 .1 131 .3 
  Cal 1%  B   2nd 10 12 .7 27 .1 
  Cal 1%  C   2nd 10 10 .7 6 .6 
  Cal 1%  D   2nd 10 9 .9 -1 .1 
  Cal 1%  E   2nd 10 9 .2 -8 .4 
  Cal 100%  A 3rd 996 980 .9 -1 .5 
  Cal 100%  B 3rd 996 1057 .2 6 .1 
  Cal 100%  C 3rd 996 1018 .7 2 .3 
  Cal 1%  A   3rd 10 9 .8 -2 .1 
  Cal 1%  B   3rd 10 7 .4 -26 .3 
  Cal 1%  C   3rd 10 7 -30 .2 
  Cal 1%  D   3rd 10 6 .5 -35 .1 
  Cal 1%  E   3rd 10 6 .5 -35 
 
DM Tramadol 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 848 .2 -14 .8 
  Cal 100%  B 1st 996 889 .4 -10 .7 
  Cal 100%  C 1st 996 840 .6 -15 .6 
  Cal 1%  A   1st  10 10 .9 8 .6 
  Cal 1%  B   1st 10 9 .9 -1 .5 
  Cal 1%  C   1st 10 9 .3 -6 .8 
  Cal 1%  D   1st 10 9 .6 -3 .8 
  Cal 1%  E   1st 10 9 .7 -2 .6 
  Cal 100%  A 2nd 996 1035 .2 3 .9 
  Cal 100%  B 2nd 996 1260 .8 26 .6 
  Cal 100%  C 2nd 996 1237 .4 24 .2 
  Cal 1%  A   2nd 10 10 .6 5 .7 
  Cal 1%  B   2nd 10 9 .8 -1 .8 
  Cal 1%  C   2nd 10 9 .1 -8 .5 
  Cal 1%  D   2nd 10 9 .6 -4 .1 
  Cal 1%  E   2nd 10 9 .5 -4 .7 
  Cal 100%  A 3rd 996 851 .2 -14 .5 
  Cal 100%  B 3rd 996 1018 .9 2 .3 
  Cal 100%  C 3rd 996 984 .2 -1 .2 
  Cal 1%  A   3rd 10 10 .3 2 .5 
  Cal 1%  B   3rd 10 9 .4 -5 .6 
  Cal 1%  C   3rd 10 9 .8 -2 
  Cal 1%  D   3rd 10 10 .4 4 .3 
  Cal 1%  E   3rd 10 10 .2 2 .4 
 
 
DM Venlafaxine 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 782 755 .3 -3 .4 
  Cal 100%  B 1st 782 728 .5 -6 .8 
  Cal 100%  C 1st 782 737 .1 -5 .7 
  Cal 1%  A   1st  8 8 .4 4 .9 
  Cal 1%  B   1st 8 7 .2 -9 .8 
  Cal 1%  C   1st 8 8 0 .5 
  Cal 1%  D   1st 8 7 .7 -3 .5 
  Cal 1%  E   1st 8 8 .2 3 .1 
  Cal 100%  A 2nd 782 793 .8 1 .5 
  Cal 100%  B 2nd 782 854 .7 9 .3 
  Cal 100%  C 2nd 782 848 .2 8 .5 
  Cal 1%  A   2nd 8 9 .6 20 .1 
  Cal 1%  B   2nd 8 7 .9 -1 .8 
  Cal 1%  C   2nd 8 7 .6 -4 .4 
  Cal 1%  D   2nd 8 7 .8 -3 
  Cal 1%  E   2nd 8 7 .8 -2 .8 
  Cal 100%  A 3rd 782 748 .1 -4 .3 
  Cal 100%  B 3rd 782 809 .8 3 .6 
  Cal 100%  C 3rd 782 762 .9 -2 .4 
  Cal 1%  A   3rd 8 8 .3 3 .5 
  Cal 1%  B   3rd 8 7 .6 -5 
  Cal 1%  C   3rd 8 7 .9 -0 .8 
  Cal 1%  D   3rd 8 7 .6 -4 .5 
  Cal 1%  E   3rd 8 7 .9 -1 .5 
 
 
Duloxetine 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 943 .7 -5 .2 
  Cal 100%  B 1st 996 1123 .1 12 .8 
  Cal 100%  C 1st 996 984 .5 -1 .2 
  Cal 1%  A   1st  10 15 .6 55 .9 
  Cal 1%  B   1st 10 9 .4 -6 .3 
  Cal 1%  C   1st 10 9 .2 -7 .5 
  Cal 1%  D   1st 10 9 .5 -5 .1 
  Cal 1%  E   1st 10 8 .6 -14 .2 
  Cal 100%  A 2nd 996 937 .9 -5 .8 
  Cal 100%  B 2nd 996 1001 .3 0 .5 
  Cal 100%  C 2nd 996 909 -8 .7 
  Cal 1%  A   2nd 10 21 .3 112 .7 
  Cal 1%  B   2nd 10 11 .5 15 
  Cal 1%  C   2nd 10 9 -9 .6 
  Cal 1%  D   2nd 10 9 .7 -2 .6 
  Cal 1%  E   2nd 10 9 .5 -5 
  Cal 100%  A 3rd 996 960 .6 -3 .6 
  Cal 100%  B 3rd 996 1055 .4 6 
  Cal 100%  C 3rd 996 1045 .6 5 
  Cal 1%  A   3rd 10 7 .9 -21 .1 
  Cal 1%  B   3rd 10 8 .4 -15 .7 
  Cal 1%  C   3rd 10 7 .6 -24 .5 
  Cal 1%  D   3rd 10 8 -20 .4 
  Cal 1%  E   3rd 10 7 .7 -22 .8 
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Fluoxetine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 799 .1 -19 .8 
  Cal 100%  B 1st 996 1073 .9 7 .8 
  Cal 100%  C 1st 996 937 -5 .9 
  Cal 1%  A   1st  10 13 .2 31 .8 
  Cal 1%  B   1st 10 10 .4 4 .1 
  Cal 1%  C   1st 10 10 .6 5 .8 
  Cal 1%  D   1st 10 8 .8 -11 .6 
  Cal 1%  E   1st 10 8 .8 -12 .2 
  Cal 100%  A 2nd 996 930 .4 -6 .6 
  Cal 100%  B 2nd 996 1059 .2 6 .4 
  Cal 100%  C 2nd 996 944 .7 -5 .1 
  Cal 1%  A   2nd 10 16 .1 61 
  Cal 1%  B   2nd 10 12 19 .8 
  Cal 1%  C   2nd 10 10 .2 1 .6 
  Cal 1%  D   2nd 10 9 .5 -4 .6 
  Cal 1%  E   2nd 10 7 .9 -21 .5 
  Cal 100%  A 3rd 996 977 .6 -1 .8 
  Cal 100%  B 3rd 996 1117 .3 12 .2 
  Cal 100%  C 3rd 996 1124 .2 12 .9 
  Cal 1%  A   3rd 10 8 .8 -12 .5 
  Cal 1%  B   3rd 10 7 .4 -25 .6 
  Cal 1%  C   3rd 10 9 .3 -7 .4 
  Cal 1%  D   3rd 10 8 .5 -14 .9 
  Cal 1%  E   3rd 10 9 .3 -7 .2 
 
Fluvoxamine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 1027 .9 3 .2 
  Cal 100%  B 1st 996 1047 .4 5 .2 
  Cal 100%  C 1st 996 1018 2 .2 
  Cal 1%  A   1st  10 15 50 
  Cal 1%  B   1st 10 10 -0 .3 
  Cal 1%  C   1st 10 9 .2 -7 .8 
  Cal 1%  D   1st 10 8 .5 -15 .1 
  Cal 1%  E   1st 10 8 .7 -12 .8 
  Cal 100%  A 2nd 996 881 .5 -11 .5 
  Cal 100%  B 2nd 996 924 .3 -7 .2 
  Cal 100%  C 2nd 996 892 .2 -10 .4 
  Cal 1%  A   2nd 10 16 .3 62 .9 
  Cal 1%  B   2nd 10 12 19 .6 
  Cal 1%  C   2nd 10 11 10 .2 
  Cal 1%  D   2nd 10 10 .8 7 .7 
  Cal 1%  E   2nd 10 9 .7 -2 .8 
  Cal 100%  A 3rd 996 999 .1 0 .3 
  Cal 100%  B 3rd 996 1115 .8 12 
  Cal 100%  C 3rd 996 1052 .9 5 .7 
  Cal 1%  A   3rd 10 11 .1 10 .5 
  Cal 1%  B   3rd 10 7 .5 -25 
  Cal 1%  C   3rd 10 8 .2 -17 .6 
  Cal 1%  D   3rd 10 7 .7 -22 .6 
  Cal 1%  E   3rd 10 9 .2 -8 .4 
 
 
Melitracene 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 929 .9 -6 .6 
  Cal 100%  B 1st 996 999 .1 0 .3 
  Cal 100%  C 1st 996 970 .9 -2 .5 
  Cal 1%  A   1st  10 12 .4 24 
  Cal 1%  B   1st 10 9 .5 -5 .3 
  Cal 1%  C   1st 10 10 .4 3 .9 
  Cal 1%  D   1st 10 9 .2 -7 .6 
  Cal 1%  E   1st 10 8 .9 -11 .2 
  Cal 100%  A 2nd 996 999 .1 0 .3 
  Cal 100%  B 2nd 996 1015 .3 1 .9 
  Cal 100%  C 2nd 996 998 .5 0 .3 
  Cal 1%  A   2nd 10 12 .6 26 .1 
  Cal 1%  B   2nd 10 10 .3 3 
  Cal 1%  C   2nd 10 9 .8 -1 .6 
  Cal 1%  D   2nd 10 9 .6 -4 .3 
  Cal 1%  E   2nd 10 9 .9 -0 .9 
  Cal 100%  A 3rd 996 914 .9 -8 .1 
  Cal 100%  B 3rd 996 1034 .8 3 .9 
  Cal 100%  C 3rd 996 1102 .8 10 .7 
  Cal 1%  A   3rd 10 9 .8 -2 .3 
  Cal 1%  B   3rd 10 8 .8 -12 .2 
  Cal 1%  C   3rd 10 8 .7 -13 .4 
  Cal 1%  D   3rd 10 8 .6 -14 .2 
  Cal 1%  E   3rd 10 10 .4 3 .9 
 
 
Mianserine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 917 .1 -7 .9 
  Cal 100%  B 1st 996 1052 .1 5 .6 
  Cal 100%  C 1st 996 991 .8 -0 .4 
  Cal 1%  A   1st  10 11 .6 16 .1 
  Cal 1%  B   1st 10 9 .5 -4 .6 
  Cal 1%  C   1st 10 9 .7 -3 .2 
  Cal 1%  D   1st 10 10 .2 2 .2 
  Cal 1%  E   1st 10 10 .1 0 .8 
  Cal 100%  A 2nd 996 946 .8 -4 .9 
  Cal 100%  B 2nd 996 1047 .2 5 .1 
  Cal 100%  C 2nd 996 969 .9 -2 .6 
  Cal 1%  A   2nd 10 13 .2 32 .2 
  Cal 1%  B   2nd 10 11 .9 19 .5 
  Cal 1%  C   2nd 10 9 .3 -7 .5 
  Cal 1%  D   2nd 10 9 .6 -3 .6 
  Cal 1%  E   2nd 10 8 .4 -15 .9 
  Cal 100%  A 3rd 996 953 .3 -4 .3 
  Cal 100%  B 3rd 996 1042 .4 4 .7 
  Cal 100%  C 3rd 996 1042 .5 4 .7 
  Cal 1%  A   3rd 10 10 .2 2 .4 
  Cal 1%  B   3rd 10 9 .1 -8 .6 
  Cal 1%  C   3rd 10 8 .9 -11 
  Cal 1%  D   3rd 10 10 0 .2 
  Cal 1%  E   3rd 10 9 -10 .3 
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Mirtazapine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 1008 .3 1 .2 
  Cal 100%  B 1st 996 982 .9 -1 .3 
  Cal 100%  C 1st 996 967 .6 -2 .8 
  Cal 1%  A   1st  10 10 .7 7 
  Cal 1%  B   1st 10 9 .8 -2 .1 
  Cal 1%  C   1st 10 10 .3 2 .9 
  Cal 1%  D   1st 10 10 .6 5 .8 
  Cal 1%  E   1st 10 9 .8 -2 .5 
  Cal 100%  A 2nd 996 902 .2 -9 .4 
  Cal 100%  B 2nd 996 996 .3 0 
  Cal 100%  C 2nd 996 959 .9 -3 .6 
  Cal 1%  A   2nd 10 10 .3 2 .8 
  Cal 1%  B   2nd 10 9 .5 -4 .7 
  Cal 1%  C   2nd 10 10 .9 8 .5 
  Cal 1%  D   2nd 10 8 .9 -10 .6 
  Cal 1%  E   2nd 10 10 .8 7 .9 
  Cal 100%  A 3rd 996 983 .5 -1 .3 
  Cal 100%  B 3rd 996 1148 .7 15 .3 
  Cal 100%  C 3rd 996 1013 .7 1 .8 
  Cal 1%  A   3rd 10 10 -0 .5 
  Cal 1%  B   3rd 10 9 .4 -5 .6 
  Cal 1%  C   3rd 10 10 .6 6 .2 
  Cal 1%  D   3rd 10 9 .7 -2 .6 
  Cal 1%  E   3rd 10 9 .7 -3 .3 
 
Paroxetine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 943 .6 -5 .3 
  Cal 100%  B 1st 996 1024 .2 2 .8 
  Cal 100%  C 1st 996 953 .9 -4 .2 
  Cal 1%  A   1st  10 15 .3 53 .3 
  Cal 1%  B   1st 10 11 9 .5 
  Cal 1%  C   1st 10 9 .3 -7 .4 
  Cal 1%  D   1st 10 9 .1 -9 .3 
  Cal 1%  E   1st 10 9 .1 -8 .6 
  Cal 100%  A 2nd 996 960 .8 -3 .5 
  Cal 100%  B 2nd 996 1045 .8 5 
  Cal 100%  C 2nd 996 973 .1 -2 .3 
  Cal 1%  A   2nd 10 17 .7 76 .5 
  Cal 1%  B   2nd 10 11 .9 19 .4 
  Cal 1%  C   2nd 10 9 .8 -1 .8 
  Cal 1%  D   2nd 10 10 .6 6 
  Cal 1%  E   2nd 10 9 .4 -5 .8 
  Cal 100%  A 3rd 996 919 .3 -7 .7 
  Cal 100%  B 3rd 996 1055 .5 6 
  Cal 100%  C 3rd 996 1085 .5 9 
  Cal 1%  A   3rd 10 7 .7 -22 .7 
  Cal 1%  B   3rd 10 7 .2 -28 .4 
  Cal 1%  C   3rd 10 7 .4 -26 
  Cal 1%  D   3rd 10 8 .3 -16 .7 
  Cal 1%  E   3rd 10 8 .5 -14 .9 
 
 
Reboxetine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 940 -5 .6 
  Cal 100%  B 1st 996 1067 .1 7 .1 
  Cal 100%  C 1st 996 981 .9 -1 .4 
  Cal 1%  A   1st  10 10 .9 9 .3 
  Cal 1%  B   1st 10 10 .5 4 .8 
  Cal 1%  C   1st 10 10 .4 4 .2 
  Cal 1%  D   1st 10 9 .3 -7 .1 
  Cal 1%  E   1st 10 9 .5 -4 .8 
  Cal 100%  A 2nd 996 956 .2 -4 
  Cal 100%  B 2nd 996 1042 .4 4 .7 
  Cal 100%  C 2nd 996 979 .5 -1 .7 
  Cal 1%  A   2nd 10 11 .8 18 .4 
  Cal 1%  B   2nd 10 11 10 .4 
  Cal 1%  C   2nd 10 10 .6 5 .9 
  Cal 1%  D   2nd 10 9 .4 -6 .1 
  Cal 1%  E   2nd 10 10 .1 1 .4 
  Cal 100%  A 3rd 996 938 .8 -5 .7 
  Cal 100%  B 3rd 996 1023 .7 2 .8 
  Cal 100%  C 3rd 996 1033 .2 3 .7 
  Cal 1%  A   3rd 10 9 .8 -1 .5 
  Cal 1%  B   3rd 10 9 -10 .5 
  Cal 1%  C   3rd 10 9 .2 -8 .5 
  Cal 1%  D   3rd 10 9 .7 -3 
  Cal 1%  E   3rd 10 9 .8 -2 .2 
 
 
Sertraline 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 1077 .6 8 .2 
  Cal 100%  B 1st 996 1090 .4 9 .5 
  Cal 100%  C 1st 996 1048 .2 5 .2 
  Cal 1%  A   1st  10 17 .6 76 .1 
  Cal 1%  B   1st 10 10 .3 3 .4 
  Cal 1%  C   1st 10 9 .7 -2 .8 
  Cal 1%  D   1st 10 9 .4 -6 .2 
  Cal 1%  E   1st 10 9 .3 -7 .4 
  Cal 100%  A 2nd 996 861 .8 -13 .5 
  Cal 100%  B 2nd 996 833 .1 -16 .4 
  Cal 100%  C 2nd 996 800 .8 -19 .6 
  Cal 1%  A   2nd 10 16 .1 60 .6 
  Cal 1%  B   2nd 10 11 .7 17 
  Cal 1%  C   2nd 10 9 .5 -5 .1 
  Cal 1%  D   2nd 10 8 .1 -18 .7 
  Cal 1%  E   2nd 10 10 .4 3 .9 
  Cal 100%  A 3rd 996 1049 .6 5 .4 
  Cal 100%  B 3rd 996 1115 .5 12 
  Cal 100%  C 3rd 996 1082 .1 8 .6 
  Cal 1%  A   3rd 10 8 .4 -15 .9 
  Cal 1%  B   3rd 10 7 .1 -28 .9 
  Cal 1%  C   3rd 10 9 .3 -7 
  Cal 1%  D   3rd 10 8 .4 -16 .2 
  Cal 1%  E   3rd 10 9 .5 -5 
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Tramadol 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 776 .8 -22 
  Cal 100%  B 1st 996 942 .8 -5 .3 
  Cal 100%  C 1st 996 930 .4 -6 .6 
  Cal 1%  A   1st  10 10 .8 8 .4 
  Cal 1%  B   1st 10 11 9 .9 
  Cal 1%  C   1st 10 9 .2 -8 .4 
  Cal 1%  D   1st 10 9 .3 -7 .2 
  Cal 1%  E   1st 10 9 .1 -8 .7 
  Cal 100%  A 2nd 996 930 .5 -6 .6 
  Cal 100%  B 2nd 996 1228 .1 23 .3 
  Cal 100%  C 2nd 996 1259 .2 26 .4 
  Cal 1%  A   2nd 10 10 .1 0 .7 
  Cal 1%  B   2nd 10 10 .1 0 .7 
  Cal 1%  C   2nd 10 9 .3 -7 .5 
  Cal 1%  D   2nd 10 10 .3 3 .3 
  Cal 1%  E   2nd 10 9 -10 .1 
  Cal 100%  A 3rd 996 883 .5 -11 .3 
  Cal 100%  B 3rd 996 1000 .6 0 .5 
  Cal 100%  C 3rd 996 1014 .8 1 .9 
  Cal 1%  A   3rd 10 9 .9 -1 .2 
  Cal 1%  B   3rd 10 8 .8 -12 .2 
  Cal 1%  C   3rd 10 10 .4 3 .9 
  Cal 1%  D   3rd 10 10 -0 .2 
  Cal 1%  E   3rd 10 10 .1 0 .6 
 
Trazodone 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 4267 4345 .6 1 .8 
  Cal 100%  B 1st 4267 4841 .8 13 .5 
  Cal 100%  C 1st 4267 4235 .2 -0 .7 
  Cal 1%  A   1st  43 73 .5 70 .9 
  Cal 1%  B   1st 43 49 .2 14 .3 
  Cal 1%  C   1st 43 42 .8 -0 .5 
  Cal 1%  D   1st 43 47 .3 9 .9 
  Cal 1%  E   1st 43 47 .3 9 .9 
  Cal 100%  A 2nd 4267 4193 .4 -1 .7 
  Cal 100%  B 2nd 4267 4145 .1 -2 .9 
  Cal 100%  C 2nd 4267 3933 -7 .8 
  Cal 1%  A   2nd 43 71 .7 66 .7 
  Cal 1%  B   2nd 43 47 .9 11 .5 
  Cal 1%  C   2nd 43 37 .4 -13 .1 
  Cal 1%  D   2nd 43 43 .1 0 .1 
  Cal 1%  E   2nd 43 42 .5 -1 .2 
  Cal 100%  A 3rd 4267 4105 .5 -3 .8 
  Cal 100%  B 3rd 4267 4260 .7 -0 .1 
  Cal 100%  C 3rd 4267 4288 .4 0 .5 
  Cal 1%  A   3rd 43 42 -2 .4 
  Cal 1%  B   3rd 43 39 .6 -7 .9 
  Cal 1%  C   3rd 43 35 -18 .7 
  Cal 1%  D   3rd 43 36 .6 -14 .9 
  Cal 1%  E   3rd 43 43 .7 1 .5 
 
 
Venlafaxine 
 
Name Std. Conc Conc. %Dev 
  Cal 100%  A 1st 996 972 .3 -2 .4 
  Cal 100%  B 1st 996 1032 .5 3 .7 
  Cal 100%  C 1st 996 943 .7 -5 .3 
  Cal 1%  A   1st  10 10 .8 7 .7 
  Cal 1%  B   1st 10 10 .8 8 .2 
  Cal 1%  C   1st 10 9 .3 -7 
  Cal 1%  D   1st 10 9 .5 -4 .7 
  Cal 1%  E   1st 10 10 0 .2 
  Cal 100%  A 2nd 996 939 .9 -5 .6 
  Cal 100%  B 2nd 996 1051 .3 5 .6 
  Cal 100%  C 2nd 996 1005 .3 0 .9 
  Cal 1%  A   2nd 10 11 .1 10 .5 
  Cal 1%  B   2nd 10 11 10 .1 
  Cal 1%  C   2nd 10 10 .2 2 .2 
  Cal 1%  D   2nd 10 9 .4 -6 .5 
  Cal 1%  E   2nd 10 9 .8 -2 .2 
  Cal 100%  A 3rd 996 967 .9 -2 .8 
  Cal 100%  B 3rd 996 1056 .2 6 
  Cal 100%  C 3rd 996 994 .6 -0 .1 
  Cal 1%  A   3rd 10 10 .2 1 .8 
  Cal 1%  B   3rd 10 9 .2 -8 .3 
  Cal 1%  C   3rd 10 9 .6 -4 .5 
  Cal 1%  D   3rd 10 9 .7 -2 .7 
  Cal 1%  E   3rd 10 9 .8 -1 .8 
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Appendix 6.5: Matrix Effects 
The following tables explain the results regarding to matrix effects. All the calculations were 
made with the areas of each compound. 
 
Citalopram 
Name Area IS Area 
  LOW SET A  48785 17921 
  LOW SET B Matrix A 31547 15568 
  LOW SET B Matrix B 29115 15473 
  LOW SET B Matric C 34589 17187 
  LOW SET B Matrix D 33919 16610 
  LOW SET B Matrix E 44020 15049 
  LOW SET B Matrix F 32616 14882 
  LOW SET C Matrix A 36024 11885 
  LOW SET C Matrix B 38956 13912 
  LOW SET C Matric C 42874 14178 
  LOW SET C Matrix D 43344 14328 
  LOW SET C Matrix E 40319 18653 
  LOW SET C Matrix F 39782 13466 
 
DM Citalopram  
Name Area IS Area 
  LOW SET A  50978 5607 
  LOW SET B Matrix A 27894 2008 
  LOW SET B Matrix B 29772 2163 
  LOW SET B Matric C 35653 2299 
  LOW SET B Matrix D 31715 2743 
  LOW SET B Matrix E 36145 2480 
  LOW SET B Matrix F 31883 2692 
  LOW SET C Matrix A 37444 1360 
  LOW SET C Matrix B 38363 1908 
  LOW SET C Matric C 45867 1432 
  LOW SET C Matrix D 40732 1845 
  LOW SET C Matrix E 37521 1993 
  LOW SET C Matrix F 37573 1948 
 
DM Fluoxetine 
Name Area IS Area 
  LOW SET  28085 18278 
  LOW SET B Matrix A 8174 15568 
  LOW SET B Matrix B 7710 15473 
  LOW SET B Matric C 7509 17187 
  LOW SET B Matrix D 9271 16610 
  LOW SET B Matrix E 10074 15049 
  LOW SET B Matrix F 10553 14882 
  LOW SET C Matrix A 9327 11885 
  LOW SET C Matrix B 12820 13912 
  LOW SET C Matric C 13347 14178 
  LOW SET C Matrix D 14522 14328 
  LOW SET C Matrix E 12290 18653 
  LOW SET C Matrix F 14338 13466 
 
 
 
 
 
DM Tramadol 
Name Area IS Area 
  LOW SET A  51680 26626 
  LOW SET B Matrix A 44862 25171 
  LOW SET B Matrix B 38170 26234 
  LOW SET B Matric C 41951 27077 
  LOW SET B Matrix D 43837 24033 
  LOW SET B Matrix E 67433 24914 
  LOW SET B Matrix F 45292 25400 
  LOW SET C Matrix A 48061 20281 
  LOW SET C Matrix B 53059 24073 
  LOW SET C Matric C 51525 23254 
  LOW SET C Matrix D 51809 24728 
  LOW SET C Matrix E 51674 34891 
  LOW SET C Matrix F 49921 25304 
 
 
DM Venlafaxine 
Name Area IS Area 
  LOW SET A  4924 26626 
  LOW SET B Matrix A 5096 25171 
  LOW SET B Matrix B 4585 26234 
  LOW SET B Matric C 5031 27077 
  LOW SET B Matrix D 4689 24033 
  LOW SET B Matrix E 7106 24914 
  LOW SET B Matrix F 4729 25400 
  LOW SET C Matrix A 4817 20281 
  LOW SET C Matrix B 4896 24073 
  LOW SET C Matric C 4611 23254 
  LOW SET C Matrix D 4632 24728 
  LOW SET C Matrix E 4921 34891 
  LOW SET C Matrix F 4676 25304 
 
Duloxetine 
Name Area IS Area 
  LOW SET A  65072 17921 
  LOW SET B Matrix A 13387 15568 
  LOW SET B Matrix B 15815 15473 
  LOW SET B Matric C 14433 17187 
  LOW SET B Matrix D 16894 16610 
  LOW SET B Matrix E 16696 15049 
  LOW SET B Matrix F 19024 14882 
  LOW SET C Matrix A 22094 11885 
  LOW SET C Matrix B 26784 13912 
  LOW SET C Matric C 26616 14178 
  LOW SET C Matrix D 31776 14328 
  LOW SET C Matrix E 26915 18653 
  LOW SET C Matrix F 29535 13466 
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Fluoxetine 
Name Area IS Area 
  LOW SET A  16001 17921 
  LOW SET B Matrix A 2972 15568 
  LOW SET B Matrix B 2671 15473 
  LOW SET B Matric C 2684 17187 
  LOW SET B Matrix D 4057 16610 
  LOW SET B Matrix E 4226 15049 
  LOW SET B Matrix F 4875 14882 
  LOW SET C Matrix A 6080 11885 
  LOW SET C Matrix B 7645 13912 
  LOW SET C Matric C 7310 14178 
  LOW SET C Matrix D 9313 14328 
  LOW SET C Matrix E 7619 18653 
  LOW SET C Matrix F 8647 13466 
 
Fluvoxamine 
Name Area IS Area 
  LOW SET A  57607 26626 
  LOW SET B Matrix A 29556 25171 
  LOW SET B Matrix B 27025 26234 
  LOW SET B Matric C 29343 27077 
  LOW SET B Matrix D 33536 24033 
  LOW SET B Matrix E 41081 24914 
  LOW SET B Matrix F 32241 25400 
  LOW SET C Matrix A 42733 20281 
  LOW SET C Matrix B 43798 24073 
  LOW SET C Matric C 46473 23254 
  LOW SET C Matrix D 48053 24728 
  LOW SET C Matrix E 45770 34891 
  LOW SET C Matrix F 42662 25304 
 
 Melitracene 
Name Area IS Area 
  LOW SET A  23296 5607 
  LOW SET B Matrix A 4478 2008 
  LOW SET B Matrix B 5227 2163 
  LOW SET B Matric C 4357 2296 
  LOW SET B Matrix D 6144 2743 
  LOW SET B Matrix E 4770 2480 
  LOW SET B Matrix F 6858 2692 
  LOW SET C Matrix A 6036 1360 
  LOW SET C Matrix B 8321 1908 
  LOW SET C Matric C 7691 1432 
  LOW SET C Matrix D 10290 1845 
  LOW SET C Matrix E 7024 1993 
  LOW SET C Matrix F 10792 1948 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mianserine 
Name Area IS Area 
  LOW SET A  9563 17921 
  LOW SET B Matrix A 2764 15568 
  LOW SET B Matrix B 3110 15473 
  LOW SET B Matric C 3138 17187 
  LOW SET B Matrix D 3775 16610 
  LOW SET B Matrix E 3155 15049 
  LOW SET B Matrix F 3965 14882 
  LOW SET C Matrix A 4816 11885 
  LOW SET C Matrix B 5165 13912 
  LOW SET C Matric C 5292 14178 
  LOW SET C Matrix D 5590 14328 
  LOW SET C Matrix E 4722 18653 
  LOW SET C Matrix F 5323 13466 
 
Mirtazapine 
Name Area IS Area 
  LOW SET A  15435 1966 
  LOW SET B Matrix A 13424 1679 
  LOW SET B Matrix B 12182 1532 
  LOW SET B Matric C 12599 1628 
  LOW SET B Matrix D 13534 1782 
  LOW SET B Matrix E 18210 1525 
  LOW SET B Matrix F 14263 1824 
  LOW SET C Matrix A 14656 1314 
  LOW SET C Matrix B 14757 1550 
  LOW SET C Matric C 14717 1452 
  LOW SET C Matrix D 15592 1591 
  LOW SET C Matrix E 13982 2206 
  LOW SET C Matrix F 14405 1579 
 
Paroxetine 
Name Area IS Area 
  LOW SET A  34575 5607 
  LOW SET B Matrix A 8004 2008 
  LOW SET B Matrix B 9579 2163 
  LOW SET B Matric C 8071 2296 
  LOW SET B Matrix D 10454 2743 
  LOW SET B Matrix E 10663 2480 
  LOW SET B Matrix F 11478 2692 
  LOW SET C Matrix A 12751 1360 
  LOW SET C Matrix B 15785 1908 
  LOW SET C Matric C 15839 1432 
  LOW SET C Matrix D 18342 1845 
  LOW SET C Matrix E 15197 1993 
  LOW SET C Matrix F 16442 1948 
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Reboxetine 
Name Area IS Area 
  LOW SET A  48160 17921 
  LOW SET B Matrix A 31137 15568 
  LOW SET B Matrix B 31772 15473 
  LOW SET B Matric C 39493 17187 
  LOW SET B Matrix D 35173 16610 
  LOW SET B Matrix E 48627 15049 
  LOW SET B Matrix F 34224 14882 
  LOW SET C Matrix A 41779 11885 
  LOW SET C Matrix B 40979 13912 
  LOW SET C Matric C 44871 14178 
  LOW SET C Matrix D 42420 14328 
  LOW SET C Matrix E 41902 18653 
  LOW SET C Matrix F 40210 13466 
 
 Sertraline 
Name Area IS Area 
  LOW SET A  4992 26626 
  LOW SET B Matrix A 4223 25171 
  LOW SET B Matrix B 4571 26234 
  LOW SET B Matric C 4342 27077 
  LOW SET B Matrix D 5284 24033 
  LOW SET B Matrix E 5432 24914 
  LOW SET B Matrix F 6605 25400 
  LOW SET C Matrix A 3791 20281 
  LOW SET C Matrix B 7542 24073 
  LOW SET C Matric C 6065 23254 
  LOW SET C Matrix D 7815 24728 
  LOW SET C Matrix E 5497 34891 
  LOW SET C Matrix F 7735 25304 
 
 Tramadol 
Name Area IS Area 
  LOW SET A  3965 26626 
  LOW SET B Matrix A 2768 25171 
  LOW SET B Matrix B 2296 26234 
  LOW SET B Matric C 2928 27077 
  LOW SET B Matrix D 2680 24033 
  LOW SET B Matrix E 4597 24914 
  LOW SET B Matrix F 3072 25400 
  LOW SET C Matrix A 3372 20281 
  LOW SET C Matrix B 3626 24073 
  LOW SET C Matric C 3700 23254 
  LOW SET C Matrix D 3941 24728 
  LOW SET C Matrix E 4100 34891 
  LOW SET C Matrix F 3421 25304 
 
 
 
 
 
 
 
 
Trazodone 
Name Area IS Area 
  LOW SET A  173941 17921 
  LOW SET B Matrix A 122619 15568 
  LOW SET B Matrix B 119188 15473 
  LOW SET B Matric C 124847 17187 
  LOW SET B Matrix D 125545 16610 
  LOW SET B Matrix E 149102 15049 
  LOW SET B Matrix F 125098 14882 
  LOW SET C Matrix A 154378 11885 
  LOW SET C Matrix B 152770 13912 
  LOW SET C Matric C 153811 14178 
  LOW SET C Matrix D 159494 14328 
  LOW SET C Matrix E 143182 18653 
  LOW SET C Matrix F 155665 13466 
 
 
Venlafaxine 
Name Area IS Area 
  LOW SET A  34394 26626 
  LOW SET B Matrix A 29995 25171 
  LOW SET B Matrix B 27229 26234 
  LOW SET B Matric C 30931 27077 
  LOW SET B Matrix D 29679 24033 
  LOW SET B Matrix E 47509 24914 
  LOW SET B Matrix F 33415 25400 
  LOW SET C Matrix A 35173 20281 
  LOW SET C Matrix B 34417 24073 
  LOW SET C Matric C 35149 23254 
  LOW SET C Matrix D 35020 24728 
  LOW SET C Matrix E 34218 34891 
  LOW SET C Matrix F 33213 25304 
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Appendix 6.6: Limits 
The following tables present the data to calculate LOD’s. The LOD was estimated from the 
standard deviation of the y-intercept and the average slope. 
    Slope Y-Intercept 
Citalopram Run 1 2 .8 8 .4 
  Run 2 3 .1 8 .9 
  Run 3 3 .0 7 .0 
  Run 4 2 .6 3 .6 
  Run 5 2 .7 3 .6 
  Average 2 .8 6 .3 
  SD 0 .2 2 .5 
 
    Slope Y-Intercept 
DM  Run 1 8 .8 66 .2 
 Citalopram Run 2 10 .1 72 .1 
  Run 3 10 .0 71 .7 
  Run 4 9 .0 64 .8 
  Run 5 8 .8 64 .5 
  Average 9 .3 67 .9 
  SD 0 .7 3 .7 
 
    Slope Y-Intercept 
DM  Run 1 0 .7 3 .3 
 Fluoxetine Run 2 0 .7 4 .3 
  Run 3 0 .7 3 .8 
  Run 4 0 .7 3 .9 
  Run 5 0 .7 5 .3 
  Average 0 .7 4 .1 
  SD 0 .0 0 .7 
 
  Slope Y-Intercept 
DM  Run 1 1 .6 1 .4 
 Tramadol Run 2 1 .8 4 .6 
  Run 3 1 .8 1 .1 
  Run 4 1 .8 3 .1 
  Run 5 2 .5 6 .3 
  Average 1 .9 3 .3 
  SD 0 .4 2 .2 
 
    Slope Y-Intercept 
DM  Run 1 0 .2 0 .3 
 Venlafaxine Run 2 0 .3 0 .7 
  Run 3 0 .3 0 .0 
  Run 4 0 .2 0 .4 
  Run 5 0 .3 -0 .2 
  Average 0 .3 0 .2 
  SD 0 .0 0 .4 
 
 
 
 
 
 
   Slope Y-Intercept 
Duloxetine Run 1 2 .1 5 .6 
  Run 2 2 .4 6 .4 
  Run 3 2 .3 6 .1 
  Run 4 1 .9 6 .0 
  Run 5 2 .2 9 .4 
  Average 2 .2 6 .7 
  SD 0 .2 1.5 
 
    Slope Y-Intercept 
Fluoxetine Run 1 0 .5 0 .5 
  Run 2 0 .4 1 .9 
  Run 3 0 .4 0 .6 
  Run 4 0 .4 0 .9 
  Run 5 0 .4 2 .4 
  Average 0 .4 1 .2 
  SD 0 .0 0 .9 
 
    Slope Y-Intercept 
Fluovoxamine Run 1 1 .4 3 .8 
  Run 2 1 .6 7 .1 
  Run 3 1 .5 3 .6 
  Run 4 1 .3 7 .1 
  Run 5 1 .3 7 .7 
  Average 1 .4 5 .9 
  SD 0 .1 2 .0 
 
    Slope Y-Intercept 
Melitracene Run 1 3 .5 6 .8 
  Run 2 4 .3 5 .0 
  Run 3 4 .5 5 .5 
  Run 4 3 .5 5 .1 
  Run 5 3 .8 8 .9 
  Average 3 .9 6 .2 
  SD 0 .5 1 .6 
 
    Slope Y-Intercept 
Mianserine Run 1 0 .4 1 .7 
  Run 2 0 .4 1 .5 
  Run 3 0 .4 0 .6 
  Run 4 0 .3 0 .8 
  Run 5 0 .4 1 .0 
  Average 0 .4 1 .1 
  SD 0 .0 0 .5 
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   Slope Y-Intercept 
Mirtazapine Run 1 7 .6 17 .3 
  Run 2 7 .8 18 .7 
  Run 3 8 .4 16 .0 
 Run 4 6 .8 16 .0 
 Run 5 7 .7 12 .0 
 Average 7 .6 16 .8 
  SD 0 .5 2 .7 
 
    Slope Y-Intercept 
Paroxetine Run 1 5 .4 19 .6 
  Run 2 6 .5 15 .2 
  Run 3 6 .4 17 .2 
  Run 4 5 .1 14 .5 
  Run 5 5 .5 14 .6 
  Average 5 .8 16 .2 
  SD 0 .6 2.2 
 
    Slope Y-Intercept 
Reboxetine Run 1 2 .3 4 .4 
  Run 2 2 .5 8 .3 
  Run 3 2 .4 3 .8 
  Run 4 2 .2 4 .2 
  Run 5 2 .3 5 .0 
  Average 2 .3 5 .1 
  SD 0 .1 1 .8 
 
    Slope Y-Intercept 
Sertraline Run 1 0 .5 2 .0 
  Run 2 0 .6 2 .8 
  Run 3 0 .5 2 .3 
  Run 4 0 .4 2 .0 
  Run 5 0 .5 2 .3 
 Average 0 .5 2 .3 
 SD 0 .1 0.3 
 
    Slope Y-Intercept 
Tramadol Run 1 0 .1 -0 .2 
  Run 2 0 .1 0 .4 
  Run 3 0 .1 0 .1 
  Run 4 0 .1 0 .0 
  Run 5 0 .1 0 .2 
  Average 0 .1 0 .1 
  SD 0 .0 0 .2 
 
 
 
 
 
 
 
    Slope Y-Intercept 
Trazodone Run 1 1 .8 73 .3 
  Run 2 1 .9 69 .2 
  Run 3 1 .9 65 .8 
  Run 4 1 .6 65 .8 
  Run 5 1 .7 69 .2 
  Average 1 .8 68 .7 
  SD 0 .1 3 .1 
 
    Slope Y-Intercept 
Venlafaxine Run 1 1 .3 2 .6 
  Run 2 1 .2 3 .4 
  Run 3 1 .3 2 .4 
  Run 4 1 .1 3 .8 
  Run 5 1 .0 2 .4 
  Average 1 .2 2 .9 
  SD 0 .1 0 .6 
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Appendix 6.7: Stability 
The following table shows the average peak area for processed sample stability study according time (from 0 to 66 hours). The first table shows data 
from the lowest concentration analysis (20 ng/mL) and the second for the highest (800 ng/mL).  
Table 6.7.1. Average peak areas for 20 ng/mL 
 Instability Point Average Peak Area 
  Maximum 
Area 
Minimum 
Area 
T0 T6 T12 T18 T24 T30 T36 T42 T48 T54 T60 T66 
Citalopram 26581 .72 17721 .15 22151 .43 17015 .31 11207 .38 10093 .74 8503 .517 9903 .442 12308 .82 12033 .07 11135 .23 13321 .4 13019 .36 12564 .25 
DM Citalopram 23318 .28 15545 .52 19431 .9 14982 .31 10069 .95 9014 .758 7355 .262 9142 .396 10427 .54 10004 .82 10574 .42 12511 .1 11103 .03 10992 .6 
DM Fluoxetine 9671 .708 6447 .805 8059 .757 6167 .453 4214 .056 4443 .958 2551 .667 3448 .811 4313 .845 3360 .434 3835 .355 4196 .718 5505 .451 4512 .47 
DM Tramadol 20620 .31 13746 .88 17183 .6 17497 .18 18118 .15 15654 .94 11190 .43 11118 .31 15522 .39 13823 .66 11507 .24 13820 .75 13258 .4 15313 .36 
DM Venlafaxine 1788 .165 1192 .11 1490 .137 1347 .688 979 .4463 974 .7313 736 .654 800 .8137 1090 .468 990 .1953 1050 .74 1255 .596 1160 .758 1111 .105 
Duloxetine 24744 .85 16496 .57 20620 .71 17178 .27 11887 .76 12961 .19 7821 .983 10523 .63 12842 .71 11628 .51 12590 .69 14320 .15 15041 .39 12430 .74 
Fluoxetine 4811 .413 3207 .609 4009 .511 2890 .431 2047 .681 1970 .411 1375 .511 1297 .066 1690 .061 1383 .805 1398 .568 2275 .437 1568 .476 1592 .116 
Fluvoxamine 20426 .08 13617 .38 17021 .73 13926 .27 9929 .147 10567 .51 7277 .745 7574 .871 9874 .847 8776 .682 8733 .792 9593 .114 11379 .03 11138 .66 
Melitraceen 9576 .307 6384 .205 7980 .256 6547 .51 4051 .092 3690 .521 3025 .383 3627 .657 4829 .949 4193 .54 3847 .216 4641 .773 4810 .993 4524 .52 
Mianserine 4498 .59 2999 .06 3748 .825 2919 .988 2027 .883 1685 .69 1619 .568 1617 .681 1910 .941 1987 .177 1788 .31 2068 .725 1857 .404 2036 .559 
Mirtazapine 9817 .962 6545 .308 8181 .635 6583 .567 4516 .998 4293 .145 2934 .451 3647 .245 4669 .578 4471 .055 3878 .855 4572 .269 4819 .404 5095 .087 
Paroxetine 13687 .31 9124 .87 11406 .09 8933 .501 5839 .65 5861 .918 4060 .022 5488 .861 6244 .709 5550 .716 6395 .574 7238 .818 8748 .265 6840 .202 
Reboxetine 23502 .86 15668 .57 19585 .72 15547 .99 10226 .24 11877 .56 7913 .837 9363 .115 12192 .33 10878 .16 9892 .778 12659 .57 12609 .84 11907 .22 
Sertraline 7136 .422 4757 .615 5947 .018 4866 .885 3192 .912 2993 .949 2432 .026 2836 .068 3462 .502 3139 .47 3300 .834 3947 .258 3439 .374 3196 .26 
Tramadol 1447 .51 965 .0069 1206 .259 936 .82 662 .806 559 .1203 483 .7765 327 .3823 580 .9947 439 .9947 416 .9097 625 .59 387 .362 622 .7923 
Trazodone 98784 .77 65856 .51 82320 .64 62581 .99 39445 .22 36407 .51 31806 .42 36962 .67 47205 .14 44885 .14 43181 .3 50021 .1 47909 .99 46649 .12 
Venlafaxine 13097 .98 8731 .985 10914 .98 8148 .258 5392 .862 4975 .127 4012 .354 3904 .453 5504 .347 4933 .955 4786 .216 6025 .324 5651 .772 5899 .967 
Internal Standards               
Mirtazapine-d4 5325 .092 3550 .061 4437 .577 3509 .845 2454 .214 2158 .117 1901 .066 1701 .415 2175 .915 1774 .337 2626 .525 2562 .923 2426 .374 2471 .87 
Paroxetine-d6 9877 .795 6585 .197 8231 .496 6346 .671 3909 .919 3787 .074 3617 .718 2589 .428 2562 .309 2751 .821 2458 .338 5295 .336 5321 .949 4847 .879 
Reboxetine-d5 44740 .07 29826 .72 37283 .39 30179 .06 18816 .07 17303 .52 18322 .42 14898 .57 15393 .05 14800 .66 23007 .46 22047 .87 21876 .22 21780 .33 
Venlafaxine-d6 47697 .15 31798 .1 39747 .62 32888 .44 23850 .74 20666 .26 19951 .89 16709 .58 19835 .59 18165 .49 23098 .89 23300 .84 23326 .84 25801 .33 
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Table 6.7.2. Average peak areas for 800 ng/mL 
 Instability Point Average Peak Area 
  Maximum 
Area 
Minimum 
Area 
T0 T6 T12 T18 T24 T30 T36 T42 T48 T54 T60 T66 
Citalopram 802196 .3 534797 .5 668496 .9 709569 .8 674040 .4 598895 .4 421067 .1 337809 .2 324893 .3 310085 .6 358083 343049 .4 376342 .5 375786 .6 
DM Citalopram 494933 .4 329955 .6 412444 .5 451354 .1 406515 .9 380404 .3 257870 .5 222190 .2 209240 .5 197413 216827 .2 230891 .6 242038 .2 267167 .8 
DM Fluoxetine 197892 .1 131928 164910 156980 .4 115352 .9 123846 .5 87289 .58 77976 .75 70491 .04 71005 .72 70939 .38 87957 .82 81725 .35 89929 .66 
DM Tramadol 531211 .1 354140 .7 442675 .9 446349 .6 625610 .2 459570 .0 501188 .6 395115 461060 .8 405743 .2 618951 .1 489617 .6 456114 .4 469060 .2 
DM Venlafaxine 57556 .61 38371 .07 47963 .84 54607 .88 51018 .38 46031 35908 .01 34775 .05 37372 .37 33053 .14 39525 .03 41078 .81 41115 .64 42346 .88 
Duloxetine 582047 388031 .3 485039 .1 506420 .6 392461 .2 441576 .5 319522 .6 269324 .1 252353 .4 270280 .7 268966 320263 .1 307761 .9 333652 
Fluoxetine 110078 .3 73385 .55 91731 .93 71426 .3 96500 .1 56766 .35 59635 .13 35180 .9 42479 .76 37628 .37 51509 .18 47117 .67 40551 .22 76961 .35 
Fluvoxamine 500329 .2 333552 .8 416941 409544 .5 399803 .8 399803 .8 300795 233680 .7 237111 .4 218481 .5 271331 .6 264906 .5 262445 .4 277700 .4 
Melitraceen 306980 .4 204653 .6 255817 211218 .9 167634 .2 189690 .2 127476 .1 98900 .7 100533 .6 106608 .3 103462 .5 125914 .2 117517 .8 120700 .4 
Mianserine 115643 .8 77095 .87 96369 .84 90242 .98 88617 .55 78759 .19 59192 .57 41327 .55 29819 .63 29166 .54 35181 .66 51234 .67 53494 .25 57674 .89 
Mirtazapine 321641 .7 214427 .8 268034 .7 261086 .8 301102 .6 255328 .5 180818 129797 .1 148372 .8 120612 .5 171247 .6 162747 .2 166937 .5 153986 .3 
Paroxetine 367368 .9 244912 .6 306140 .8 280492 .9 227292 .5 243799 .8 154581 133532 .2 131306 .3 138552 .9 127863 .7 152010 .6 161514 .1 160434 
Reboxetine 661897 .7 441265 .2 551581 .4 590916 .2 576283 .9 523574 .8 367714 .6 317066 .6 319393 .3 311845 .7 331628 .7 341498 .5 361686 .2 382396 .5 
Sertraline 172712 .2 115141 .5 143926 .8 130303 .3 92623 .79 113830 .5 76171 .17 66399 .38 62868 .23 65675 .68 59588 .44 81500 .58 71884 .19 85321 .49 
Tramadol 38818 .93 25879 .29 32349 .11 34235 .91 50988 .44 27853 .96 27417 .79 12967 .22 20157 .17 16167 .84 26484 .3 18615 .5 15605 .46 21294 .85 
Trazodone 1549929 1033286 1291607 1453151 1363496 1207912 807657 .1 685608 .6 640833 .3 646104 .6 707614 .1 718883 .5 776948 .6 805219 
Venlafaxine 403028 .9 268685 .9 335857 .4 380821 .9 422533 .1 304127 .7 232632 157595 .7 181265 .3 165384 .7 213337 .1 196109 .9 194945 .1 218485 .1 
Internal Standards               
Mirtazapine-d4 4758 .041 3172 .027 3965 .034 3543 .069 3324 .128 2876 .604 2196 .636 1701 .415 2175 .915 1774 .337 2467 .992 2342 .32 2313 .153 2212 .469 
Paroxetine-d6 8422 .258 5614 .838 7018 .548 5984 .946 4157 .228 4229 .972 3199 .964 2589 .428 2562 .309 2751 .821 2458 .338 2974 .04 3049 .983 3335 .985 
Reboxetine-d5 38529 .78 25686 .52 32108 .15 29893 .13 23992 .54 21740 .87 17849 .04 14898 .57 15393 .05 14800 .66 15873 .62 16908 .76 17518 .92 18906 .15 
Venlafaxine-d6 40627 .69 27085 .13 33856 .41 32890 .71 31827 .07 25614 .44 23558 .04 16709 .58 19835 .59 18165 .49 23525 .7 20122 .23 20651 .12 21110 .74 
 
Based on the values in table 6.7.1 and 6.7.2. and in the SWGTOX guideline, the following figures represent the stability for desmethylcitalopram, 
desmethylfluoxetine, desmethylvenlafaxine, duloxetine, fluoxetine, fluvoxamine, melitracene, mianserin, mirtazapine, reboxetine, sertraline, trazodone and 
venlafaxine. Again, the red line corresponds to an increase of 20% in signal, compared to T0, and a green one which correspond to a 20% decrease in signal.
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